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Abstract 
 
 
Chromosome One Amplified Sequence 2 (COAS2) is a member of the cyclophilin family of 
proteins (Meza Zepeda et al., 2002). It has 84% amino acid homology to H. sapiens 
cyclophilin A, also known as Peptidylprolyl Isomerase A or PPIA. COAS2 is localised in 
1q21, and frequently amplified and over-expressed in a specific subset of mesenchymal 
cancers (sarcomas). We have used the 293 Flp-In system to establish stably transfected cell 
lines with constitutive and tetracycline-inducible expression of COAS2. The different cell 
lines have been used for microarray-based expression profiling experiments, as well as 
various phenotypic analyses, such as growth in soft agar, chemotherapy sensitivity and 
tumourigenicity in immunodeficient mice. Several expression constructs have been made for 
production of recombinant protein in bacteria and insect cells. In addition, attempts to localise 
the protein and confirm putative interaction partners using MYC-His6-and EGFP fusion 
proteins and confocal fluorescence microscopy were performed. 
 
Through collaboration with Dr. Schiene-Fischer’s group at The Max Planck Institute in Halle, 
Germany, the enzymatic activity and possible substrate of COAS2 will be evaluated.  
We are now establishing different Flp-In systems in a set of mesenchymal cell lines to make 
an improved model system, and we seek to express COAS2 in a yeast cell model system for 
monoclonal antibody production.  
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Human genes should be presented in uppercase ITALIC, while proteins should be presented by the same letters 
in PLAIN uppercase (McAlpine, 1995). These guidelines have been followed for all H. sapiens genes and 
proteins in this work. Genes from other organisms and their gene products have been referred to in lowercase 
italic and lowercase plain, respectively. Some terms, words and methods are presented in italics, indicating their 
description in the glossary found in the appendix section A.  
 1
1 Introduction 
 
1.1 Cancer in general 
 
Developmental aspects of cancer 
 
The embryo is sectioned into three primary germ layers at the transition between the blastula 
and gastrula stage of mammalian embryogenesis. From only 150 cells, all future defined 
organs and tissues will emerge, leaving a powerful mass of stem cells behind as backup for 
tissue renewal and repair. The blastula consists of an outermost layer of cells, or 
trophectoderm, a fluid-filled cavity called blastocoel and a cluster of cells called the inner cell 
mass. Following blastocyst growth and invasion of the uterus epithelium, the inner mass will 
further be layered into the ecto-, endo-, and mesoderm layers of cells, respectively. Ectoderm 
is the precursor of skin, nerves and brain. The endodermal cells will differentiate into lungs 
and digestive organs (kidneys, gut etc), whilst the mesoderm layer of the inner cell mass will 
be the starting material for connective tissue that support and surround other structures, such 
as tendons, bone and muscle.   
 
 
 
Figure 1.1: Model illustrating the development of cell types from respective embryonal tissues. 
 
This thesis focuses on benign and malignant tumours in tissue of mesenchymal origin. 
Mesenchymal stem cells (MSCs) originate from the mesenchyme, a loose network of cells 
within the mesoderm. MSCs can be obtained from bone marrow and cultivated in vitro. 
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Currently, attempts to establish a mesenchymal stem cell line model from bone marrow are 
made by members of the Myklebost group. Such a model would prove great worth in future 
cancer research. 
The following model modified from (Meltzer, 2001b) depicts the evolution of MSCs and their 
derivated normal cell types and cancer subtypes: 
 
 
 
Figure 1.2: Pathways of sarcoma development from tissue of mesenchymal origin (Meltzer, 2001b).  
 
Cancer, as a genetic disease, is driven by mutations in an organism’s DNA (Cavenee and 
White, 1995). There are, however, two key differences between cancer and other genetic 
diseases. First, cancer is caused mainly by mutations in somatic cells, whereas traditional 
diseases are caused solely by mutations in the germ line. However, some individuals do have 
inherited mutations that predispose them to develop specific types of cancer. Second, an 
individual cancer does not result from a single mutation, but rather from the accumulation of 
as few as three to perhaps as many as 20 mutations, depending on the type of cancer, in genes 
that normally regulate cell multiplication. Processes that affect cellular homeostasis may 
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create a rapidly dividing cell, which may grow to form a cell clone. Whether benign or 
malign, this cell clone resembles the normal tissue from where it came. Based upon this fact, 
pathologists generally classify malignant tissues (i.e tumours) as follows: The epithelial 
tumours from the ectoderm and endoderm are named carcinomas, and malignant tumours of 
mesodermal origin are called sarcomas (Enzinger, 1995). There are 300 types of cells or so in 
the human body, giving more than 200 different types of cancer. With the exclusive exception 
of leukemias, which grow in the blood as individual cells, most other tumours are solid 
masses. It is generally agreed that the malignant neoplastic cell is less differentiated than the 
normal adult cell in the organ from which the cancer originates. However, for a long time, 
there has been a controversy among cancer biologists on the question of whether neoplastic 
transformation results from de-differentiation of normal adult type cells or from the abnormal 
differentiation of committed, but not yet mature, stem cells in tissues. It can be concluded, 
however, that malignant neoplastic transformation occurs only in cells that are capable of 
dividing (Varmus, 1993; Weinberg, 1996). Currently, the hypothesized existence of cancer 
stem cells holds great promise. Such cells may arise by acquisition of self renewal potential in 
postmitotic differentiated cells, or mutations in “normal” stem cells. By January 2004, their 
existence was devised in three cancer subtypes (Pardal et al., 2003). Another peculiar subtype 
is the teratomas, tumours harbouring tissues from three embryonic germ layers. These 
tumours are most often found in ovary and testis cancer (http://www.kreft.no). 
 
1.2 Cancer and the cell cycle 
 
Most eukaryotic cells live according to an internal program; that is, they go through a series of 
phases that constitute the cell cycle. The processes of cell growth, rest or necessary arrest and 
possible apoptosis (i.e. programmed cell death) are being tightly regulated at key checkpoints. 
Monitoring the status of a cell requires the cooperation of many proteins. Nobel Prize 
Laureate Leland Hartwell illustrated this in the work on the budding yeast Saccharomyces 
cerevisae. The isolation of yeast cell-division cycle (cdc) mutants led to the identification of 
genes that regulate the yeast cell cycle through phosphorylation and protein degradation 
(Hartwell, 1991). Later, the discovery of yeast protein homologues in Homo sapiens affirmed 
their important role in the eukaryotic cell cycle. In both organisms, the cycle has a mitotic 
phase (M) where cells divide, and an interphase consisting of a gap phase 1 (G1), a synthesis 
phase (S) (where the nuclear genomic DNA is duplicated) and a gap phase 2 (G2). In addition 
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to this, cells can enter a paused, non-dividing, so-called quiescent state (G0) during G1. 
Examples of cells maintained in the G0 state are nerve and striated muscle cells, which do not 
divide at all (Ford and Pardee, 1999). The complex regulatory events that guide eukaryotic 
cells from phase to phase will not be fully described here, but some essential proteins should 
be mentioned: The conserved enzyme family of cyclin-dependent kinases (the CDKs), are 
activated by binding regulatory proteins called cyclins (Ford and Pardee, 1999). Following 
activation, the CDKs phosporylate target proteins, acting chiefly on the amino acids serine 
and threonine (Pardee, 1994);(Pardee, 2003). The CDKs and cyclins A-E with subclasses act 
in partnership with external growth factors, cytokines and tumour suppressor proteins (Pardee, 
1994);(Pardee, 2003). Examples of the latter are E2F, Retinoblastoma (RB) and p53. 
Together, they survey the cells’ condition through tight checkpoint control. Large protein 
complexes (such as the anaphase promoting complex, or APC) in the G2, M and G1 phase 
also mark specific inhibitors of cell-cycle events (e.g. p16 and p21), for proteolytic 
degradation by proteasomes, thus driving the cycle in one direction because of the 
irreversibility of protein degradation (Ford and Pardee, 1999). As the amount of growth 
factors and cyclins vary throughout the cell cycle, the cell goes from G1 to S to G2 via M (see 
figure 1.3). Proteasomal breakdown, cell size and the mentioned external growth factor 
signals participate in the regulation of cyclin levels (Pardee, 1994). At the restriction point in 
G1, the cell can proceed to S phase, rest in G1, or go into G0. Under favourable conditions (if 
the G1-S checkpoint is passed), cells will enter the S phase. Unfavourable conditions will 
block or pause the cells in G0, or hold the cell at the G1-S checkpoint until cyclin D-CDK4 
and cyclin D-CDK6 couples have phosphorylated pRB and thereby released the E2F protein, 
(Nevins, 2001). The transcription of genes needed during S phase was undertaken during G1, 
as for the G2 genes in mid S phase. Passing through S phase, cyclin A and the respective 
CDK regulate the active replication complexes that effectively ensure the duplication of 
DNA. If the genome wide replication is incomplete or if the DNA has been damaged, cyclin 
A and B with respective CDKs pause the cell at the G2-S checkpoint until necessary steps 
have been taken. In the M phase, the mitotic spindle separates through a complex regulatory 
mechanism. The cell cycle maintains the cell number in a living organism, keeping growth 
and differentation in check. 
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Figure 1.3: CDK-cyclin levels throughout the cell cycle (Lodish, 2000). See text for further 
information. 
 
1.3 Oncogenes, DNA repair-genes and tumour suppressor genes 
 
Several types of proteins participate in the controlling of cell growth: (Vogelstein and Kinzler, 
1993) Growth factors and their receptors, signal-transduction proteins, transcription factors, 
pro- or anti-apoptotic proteins, cell cycle control proteins and DNA-repair proteins. Of these, 
mutations in pro- or anti-apoptotic proteins greatly enhance the probability of mutations in 
other classes (Vogelstein and Kinzler, 1993), whilst mutations in the cell cycle control 
proteins increase the probability that the mutant cells will become tumour cells (Ford and 
Pardee, 1999), (Pardee, 1994). In cancer, three main classes of genes are frequently found 
altered. Proto-oncogenes give rise to oncogenes through dominant gain of function-mutations, 
translocations (chimeric gene products or deranged regulation), rearrangements (truncated 
products) and amplifications (Hayward, 1981; Reddy, 1982; Alitalo and Schwab, 1986; 
Haluska, 1987). Most proto-oncogene gene products have functions in cell growth or division. 
The term “oncogenic” essentially means, “will lead to cancer development”, and accounts for 
the ability to transform either cells in culture or in inducing cancer in animal models. Tumor-
suppressor genes encode proteins that directly or indirectly perform negative regulation of the 
cell cycle, e.g. TP53 (Knudson, 1971). These genes are inactivated through recessive loss of 
function-mutations. Inheritance of a single mutant allele of many tumour-suppressor genes, 
greatly increases the risk for developing certain types of cancer, e.g. RB1 (retinoblastoma), 
TP53 (Li-Fraumeni syndrome) and APC (colon cancer) (Li et al., 1969; Knudson, 1971; 
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Lindahl, 1996). The third class of genes is involved in DNA repair, the genes belong to one of 
four subgroups that function either during (mismatch repair, MMR or direct repair) or after 
synthesis of new DNA (nucleotide excision repair, NER or base-excision repair, BER). 
Germline mutations in one of these genes may confer an enhanced predisposition to cancer 
(Berwick and Vineis, 2000; Kohno and Yokota, 2002). Examples of DNA-repair genes linked 
to cancer in H. sapiens include BRCA1 (breast cancer) and BRCA2 (breast and ovary cancer) 
(Smith et al., 2003).  
A landmark observation in the search to identify a genetic basis for cancer was reported by 
Rous in 1911, when he showed that sarcomas could be reproducibly induced in chickens by 
cell-free filtrates of a sarcoma which had previously arisen in another chicken (Rous, 1911). 
Sixty years later, the oncogenic region of the Rous sarcoma virus was identified. Further 
characterization and cloning of the transforming sequences demonstrated that the 
oncogenicity of the virus was dependent on v-src, later found to be a transduced and mutated 
copy of the c-src cellular proto-oncogene (Varmus et al., 1977). (V = viral whilst the prefix C 
= cellular in this context.) Subsequently, all oncogenes of acutely transforming RNA tumour 
viruses have, in fact, been found to be transduced cellular genes, the proto-oncogenes. 
Although the biochemical mechanisms by which most viral oncogenes cause neoplastic 
transformation are still not fully defined, the viral oncogenes appear to cause transformation, 
in general terms, because they are activated versions of cellular proto-oncogenes and/or are 
expressed aberrantly. In the majority of human cancers, somatic mutations generate oncogenic 
alleles from proto-oncogenes. The first human oncogene to be identified encodes a 
constitutively active form of Ras, a signal-transduction protein first isolated from a human 
bladder carcinoma (Boriack-Sjodin et al., 1998). Activation of a proto-oncogene into an 
oncogene can occur by point mutation, gene amplification leading to overexpression of the 
gene product, or gene translocation (Vogelstein and Kinzler, 1993). Examples of common 
oncogenes in mammalian cancers would be MYC (which retroviral gene is called MC29), 
MYB (frequently found in myeloblastic leukaemia), RAF and RAS (Alitalo et al., 1984; 
Vogelstein and Kinzler, 1993; Hesketh, 1997; Dang, 1999; Pinson et al., 2001). All four are 
among the most frequently altered proto-oncogenes in human cancers (Cavenee and White, 
1995; Lengauer et al., 1998). Interestingly, a 2001 review of the findings made by nine groups 
working in the cell cycle field of research concludes that all oncogenes can deregulate cell 
growth, but they cannot and will not all lead to cancer if their downstream target proteins are 
missing (Bartek and Lukas, 2001). In 2001, Yu et al suggested a model of breast cancer 
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resistance development in cyclin D1 deficient mice, depending on oncogene identity, where 
the lack of one mutated proto-oncogene conferred resistance to certain types of cancer (Yu et 
al., 2001). This field of interest is highly promising, and equally enlightening for all types of 
cancer. Despite the significance of oncogenes in the genesis of many different human tumour 
types, many of the altered properties of cancer cells appear to be attributable to the 
inactivation of tumour-suppressor genes (Hesketh, 1997). They encode proteins that delay or 
inhibit progression through a specific stage of the cell cycle; so called “checkpoint-control” 
proteins that arrest the cell cycle if DNA is damaged or chromosomes are abnormal. Inherited 
mutations causing retinoblastoma, an embryonic neoplasm of retinal origin, led to the 
identification of RB1, the first tumour-suppressor gene to be recognized (Knudson, 1971). The 
G1-S transition in the cell cycle depends upon RB and the E2F protein. RB negatively 
regulates the transcription factor E2F, but upon RB phosporylation by the CDK2/cyclinE 
complex, E2F is released. E2F-1 is thus free to activate transcription of important genes 
needed in the S phase of the cell cycle, (Nevins, 2001). A model of this pathway can be found 
at: http://www.biocarta.com/pathfiles/h_skp2e2fPathway.asp 
The p53 tumour suppressor stands alone as the most extensively studied gene because of its 
involvement in the genesis of various types of cancer. Bearers of the Li-Fraumeni syndrome 
hold more than 50 % probability for cancer development in their lifetime, this due to a loss of 
one allele in the p53 gene (Li et al., 1969). Chromosomal alterations and genomic imbalance 
activate p53, thus putting the cell cycle on hold until the DNA has been mended. Severe 
DNA-damage activates p53, which leads the cell to apoptosis (programmed cell death) 
(Szymanska and Hainaut, 2003). This illustrates the need to inhibit p53 protein for the 
development of most cancers. 
 
1.4 Genetic basis of cancer 
 
Six necessary steps for neoplastic growth 
 
While researchers have long known cancer to be a genetic disease, it is only recently that they 
have been able to begin explaining the mechanisms that lead to neoplastic growth. At first, the 
immense phenotypic and genotypic differences between different types of cancer lead many 
researchers to treat them as completely distinct diseases. However, persistent research has 
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slowly revealed an underlying pattern common to all types of cancer. It seems that for a 
tumour to progress it must overcome a certain number of biological defence mechanisms 
(Vogelstein and Kinzler, 1993; Cavenee and White, 1995). Cancer thus appears as a multi-
step process, where different cancers having different ways of achieving each of these steps. 
They can be suggested as six major alterations in cell physiology, each of them corresponding 
to an essential acquired trait: (1) self-sufficiency in growth factors, (2) insensitivity to anti-
growth factors, (3) the ability to evade apoptosis and attacks of the immune system, (4) 
infinite replication potential, (5) sustained angiogenesis and (6) the necessary changes needed 
to allow metastasis (Cavenee and White, 1995; Klein, 1998). Most often, each of these steps 
must be successfully taken before a tumour can become truly malignant. This again explains 
the relatively low occurrence and late onset of cancer during an average lifetime. Turning a 
normal cell into a malignant cancer cell requires perhaps six specific mutations in the one cell. 
The chance of a single cell undergoing six independent mutations is negligible, suggesting 
that cancer should be vanishingly rare. Cancer nevertheless happens because of a combination 
of two mechanisms: 
• Mutations in oncogenes and/or tumour suppressor genes enhance cell proliferation, 
creating an expanded target population of cells for the next mutation.  
• Some alterations affect the stability of the entire genome, at either the DNA or the 
chromosomal level, increasing the overall mutation rate, (namely translocations, 
amplifications, deletions and insertions). 
 
 
 
Figure 1.4: Multistage evolution of cancer (Read, 1999). Each successive mutation gives the cell a 
growth advantage as mentioned in the text.  
 
Accumulating all these mutations nevertheless takes time, so that cancer is mainly a disease of 
post-reproductive life, when there is little selective pressure to improve the defenses still 
further. Because cancers depend on some of these mechanisms, they develop in stages, 
starting with tissue hyperplasia or benign growths, while malignant tumour cells have the 
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ability to invade surrounding tissues or metastasise. Studies suggest that it is not simply the 
accumulation of mutations, but rather it is their order which determines the propensity for 
neoplasia, and that only a subset of the genes which can affect cell growth can actually initiate 
the neoplastic process (Kinzler and Vogelstein, 1996). Recently, the existence of cancer stem 
cells (CSCs) (Pardal et al., 2003), has been given much interest. Their self-renewal potential 
might largely benefit a tumour’s ability to establish and grow from tissue at several stages of 
development. It is known that the asymmetrical division of normal stem cells give rise to a 
new stem cell and a progenitor cell (www.nih.gov/news/stemcell/scireport). Hypotheses are 
that both descendants of a normal stem cell may become a cancer stem cell (Pardal et al., 
2003). This may happen either through mutations in normal stem cells, or acquisition of self 
renewal potential for the partially differentiated progenitor cell. Please address (Pardal, Clarke 
et al., 2003), for further reading on the subject of CSCs. 
 
1.4.1 Self-sufficiency in growth factors 
 
The ability to produce its own growth factors is the most intuitive of the traits that a 
developing tumour must acquire, and was therefore the first to be clearly defined. Under 
normal conditions the cell division cycle is triggered by exogenous growth factors (GFs), thus 
enabling the cell to pass from its quiescent state (G0) into an active proliferative phase (G1). 
However, tumour cells tend to show a very reduced dependence on external factors, and must 
therefore somehow be able to generate their own growth signals (GS). There are three main 
ways of achieving this independence: Many neoplastic cells acquire the ability to produce 
GFs to which they are responsive (autocrine stimulation). Others modify their external 
receptors to react to different GFs or over-express them so much that they become hyper-
responsive to normal GF levels (Cavenee and White, 1995). The third possibility is to alter the 
complex molecular cascades that process the signals from the external ligands (Varmus, 1993; 
Lengauer et al., 1998). The most important of these is the SOS-RAS-RAF-MAP kinase 
pathway, and structurally altered RAS proteins are found in approximately 25% of human 
cancers (Enzinger, 1995). They continuously release a flux of mitogenic signals into the cell, 
even in the absence of stimulation from their normal upstream regulators.  
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1.4.2 Insensitivity to anti-growth factors 
 
In normal tissue, a multitude of anti-GFs help to maintain homeostasis. They operate in two 
ways, either by forcing the cell out of its proliferative state into a quiescent state (G0), or by 
further inducing them to enter differentiated postmitotic (following cell division) states. 
Tumor cells acquire insensitivity to these exogenous factors either by altering their external 
anti-GF-receptors or by modifying the intracellular processing cascades, but these 
mechanisms remain not well understood (Varmus, 1993). 
 
1.4.3 Evading apoptosis 
 
Once triggered, apoptosis (programmed cell death) completely destroys the cell within a span 
of 30-120 minutes. Apoptotic marker genes and signal cascades have been given much 
attention over the past two decades, and especially the proapoptotic regulator genes. One of 
the most important of the latter is the p53 tumour suppressor gene, which is deactivated in 
over 50% of human cancers (Hesketh, 1997).  
 
1.4.4 Infinite replication potential 
 
The three acquired capabilities that have been described till now should, in theory, enable a 
cell to replicate without limit. However, all mammalian cells except the germ cells seem to 
carry an autonomous multiplication limit. After a certain number of doublings, a cell enters a 
final relaxed state named senescence and stop growing. However, any extrapolation from cell 
senescence to aging of the organism is fraught with difficulties (Faragher and Kipling, 1998; 
Kipling and Faragher, 1999). This can be circumvented through disabling of p53, although the 
effect has been linked to accumulation of the cyclin-dependent kinase inhibitors p16INK4a and 
p27 in mice (Malumbres et al., 2000). The cell may then go through several more division 
cycles before it reaches another state named crisis, due to the progressive decay and ultimate 
loss of the chromosomal telomere caps (Zakian, 1997). This state is characterised by end-to-
end fusion of chromosomes, leading to massive karyotypic disarray and cell death (Zakian, 
1997). At this stage one occasionally observes the emergence of a cell with the ability to 
maintain telomeres at a length beyond the critical limit, thus acquiring the ability to multiply 
without limit (immortalisation) (Zakian, 1997).  
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1.4.5 Sustained angiogenesis 
 
A growing tumour needs oxygen, and therefore blood vessels, to be able to survive. The 
tumour cells must co-opt neighbouring endothelial cells into expanding and creating new 
blood vessels. p53 once again plays an important role. It is known to positively regulate 
thrombospondin-1, an angiogenesis inhibitor (Yu et al., 1999). The loss of p53 amongst 
others thus allows the endothelial cells to replicate. Several oncogenes are known to drive 
angiogenesis, e.g. MYC and hypoxia-inducible factor-1, HIFα (Brizel et al., 1996; Maxwell et 
al., 1997). Though co-operation between different cell types is also observed at other points in 
cancer development, the need for angiogenesis most clearly illustrates the fact that neoplastic 
cells must be studied in their physiological environment. 
 
1.4.6 Metastasis 
 
The final, and generally lethal step of cancer development is metastasis, the ability to invade 
foreign tissues. Successful colonisation of new sites, whether local or distant, requires a 
capability to adapt to changing tissue environment, and is most regularly achieved through 
modification of external receptors. However, the tumours of certain cancers become 
anaplastic, which enables them to colonise new tissues with great ease. 
 12
 
 
Figure 1.5: Illustration of the spread of a tumour from an organ such as the lung or bladder to the liver 
(Alberts, 1994). Tumor cells may enter the bloodstream directly by crossing the wall of a blood vessel, 
as depicted here, or, more commonly, by crossing the wall of a lymphatic vessel that ultimately 
discharges its contents (lymph) into the bloodstream. Tumor cells that have entered a lymphatic vessel 
often become trapped in lymph nodes along the way, giving rise to lymph-node metastases.. 
 
1.4.7 Genomic instability 
 
A cell must acquire a large proportion of mutations before it becomes truly neoplastic. Cancer 
is said to be the disease of the old, but the high number of single and “independent” mutations 
are actually highly unlikely to occur at normal rates during a normal human life span. Thus, 
genomic instability becomes an important enabling characteristic. This is usually achieved 
through disablement of monitoring systems that normally supervise the genome and repair 
errors. The most important of these is the p53 signalling pathway, a fact that helps explain 
why inactivation or mutation of p53 is such an important step in many cancers. Alterations 
may occur through translocations, deletions, insertions and amplifications. Tumor-type-
specific shromosomal rearrangements are thought to be involved in early tumour development 
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(Rabbitts, 1994), and the unscheduled gene amplification reported to be involved in 
tumourigenesis (Alitalo and Schwab, 1986). 
 
 
Figure 1.6: Controls on cell cycle progression and genomic integrity mediated by the RB1, TP53, 
MDM2 and CDK4/6 gene products(Read, 1999). (RB = retinoblastoma, MDM2 = mouse double 
minute 2, CDK = cycline dependent kinase.) 
 
Cancer cells possess traits that make them distinguishable from normal cells by microscopic 
examination. They are usually less well differentitated (a common feature of tumour cells is 
their failure to differentiate terminally under appropriate conditions either in vivo or in 
culture), have a high nucleus-to-cytoplasm ratio, prominent nucleoli, many mitoses and 
relatively little specialized structure (Vogelstein and Kinzler, 1993). However, all kinds of 
degrees exist, making detection at early stages of cancer development difficult.  
 
1.5 Sarcomas in Homo sapiens 
 
Introduction 
 
Sarcomas in general are rare malignant tumours, accounting for 1 % of adult neoplasms and 
less than 10% of pediatric malignancies (Slominski et al., 1999). The word sarcoma is derived 
from the Greek sarcos = fleshy and oma = tumour. This huge class of histologically diverse 
cancers have their origin in mesodermal or ectodermal germ layers, and the tumours harbour 
traits from muscle, bone, cartilage and other connective tissues of mesenchymal origin. In 
contrast to carcinomas, which are derived from the endoderm, the sarcomas are not so much 
defined by their organ of origin as for their molecular pathology, very unlike most epithelial 
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tumours. The many types of sarcomas do have some common traits, and four familiar cancer 
syndromes have been associated with sarcomas: Patients with retinoblastoma (RB) germline 
mutations (Abramson et al., 1984), Li-Fraumeni syndrome including germline mutations of 
the p53 gene (Li et al., 1969; Malkin et al., 1990), germline loss of the NF1 gene in a 
malignant peripheral nerve sheath tumour (MPNST) (King et al., 2000), and finally a recently 
characterised familial gastrointestinal stromal tumour (GIST), associated with germline 
mutations of the c-kit gene (Nishida et al., 1998). These cancers can be arranged genetically 
into two broad main categories, although there are traditional classifications in use by both 
researchers and clinicians (Helman and Meltzer, 2003). According to the pathologists, 
sarcomas can be described as either soft tissue sarcomas or sarcomas of the bone (Enzinger, 
1995). In 2003, Meltzer and Helman suggested a primary category that encompasses tumours 
with specific translocations seemingly central to their pathogenesis. The second is 
characterised by complex, chaotic karyotypes displaying severe genetic and chromosomal 
instability.  
 
In addition, pathologists and clinicians often grade sarcomas according to metastatic potential. 
The histological grade of malignancy, where well-differentiated sarcomas show good 
prognosis in contrast to the aggressive less differentiated sarcomas, adds to the clinical point 
of view in terms of classification. Regardless of the classification method in use, the amount 
of annual sarcoma detections in humans remains relatively stable at 1% of all human cancers. 
Of these cases, 0,8 % were soft tissue sarcomas, developed from muscle, blood vessels, fat, 
nerves, deep skin and synovial tissues (Slominski et al., 1999). The remaining 0,2 % evolved 
from bone and cartilage. 156 patients were diagnosed with malignant soft tissue sarcomas and 
36 with malignant sarcomas of the bone at the Radium Hospital in Norway during 2000. 
(22185 Norwegian inhabitants were diagnosed with cancer in 2000, according to the 
Norwegian institute of population-based cancer research, http://www.kreftregisteret.no). 
Surgery has so far been the primary approach to treating most sarcomas, assisted by radiation- 
and chemotherapy in many cases (http://www.kreftregisteret.no). Most sarcomas have 
abnormalities in signal transduction pathways, exemplified by insulin-like growth factor 1 
(IGF-1), retinoblastoma (RB) and p53 signal routes (Helman and Meltzer, 2003). Aside from 
the translocations and signal transduction pathways mentioned, few initiating events in 
sarcomas have been described. Amplification of the cell cycle-related genes MDM2 and 
CDK4, both localised on chromosome 12, occurs sporadically in various sarcomas (Forus et 
al., 2001a; Helman and Meltzer, 2003). The establishment of xenografts has been proven 
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difficult in some cases, because of the complexing tumour-specific translocations linked to 
aggressive growth in vivo. Not all grafts have the ability to grow, and there is a minor 
selection of malignant tumour transplants that grow very slowly as nude mice xenografts, 
making their use in experiments rather difficult (S. Bruheim, personal communication). 
Diagnostic procedures may be a field where more research should be made, since as many as 
10% of all sarcomas cannot be classified, harbouring very complex karyotypes (Myklebost, 
1998). But most importantly, the characterisation of benign growth in lipomas holds potential. 
The existence of benign mesenchymal tumours, e.g. lipomas, may help researchers understand 
the transition to the aggressive phenotype held by the malignant counterpart, the 
liposarcomas. 
 
Table 1.1: Sarcoma subtypes.  
 
Type of sarcoma Subtype Tissue/cell of origin 
Sarcoma of the bone Ewing’s sarcoma Bone 
 Chondrosarcoma Cartilage 
 Osteosarcoma (OS) Bone 
Soft tissue sarcoma Fibrosarcoma Fibroblasts 
 Leiomyosarcoma Smooth muscle 
 Liposarcoma (LS) Fat 
 Malignant fibrous histiocytoma Histocytes/Fibroblasts 
 Malignant schwannoma Peripheral nerves 
 Rhabdomyosarcoma Striated muscle 
 Synovial sarcoma Primitive mesenchyme
 
1.5.1 Sarcomas of the bone 
 
Bone sarcomas are very infrequent, with osteosarcoma as the most common, followed by 
chondro- and Ewing’s sarcoma, a third variant which occurs mostly in the shafts of long 
bones. OS appears more often in the bone growth plates, as well as the long bones. Ewing’s 
and OS are found in patients of all ages, although more common in youth, and Ewing’s is 
predominant among the male Caucasian population (Sæter, 1996). Tumors from cartilage-
forming chondrocytes appear as chondrosarcomas, a disease with predominance in patients of 
50+, affecting the axial skeleton and proximal bones. Metastases often occur early with 
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deadly outcome as a result of spread to the lung, and the five year overall relative survival rate 
is approximately 55-70 % for OS and Ewing’s and 70 % for chondrosarcoma (Saeter et al., 
1997).  
1.5.2 Gene amplification and over-expression 
 
Occurring quite commonly in cancer, gene amplification increases dosage of proto-oncogenes 
that give tumour cells a selective advantage (Schwab, 1999). There are several ways of 
accomplishing this kind of activation: Coding sequences of the given genes can be found as 
either direct or inverted repeats, either in situ on the original chromosome or dispersed to 
extra chromosomal markers like homogenously staining regions (HSRs), double minutes, 
supernumerary rings or giant rod chromosomes (Biedler and Spengler, 1976; Kaufman et al., 
1979). The latter are characteristic of well-differentiated liposarcomas and some borderline 
tumour types, often found to be the sole cytogenetic abnormality in these tumours (Dal Cin et 
al., 1993). In addition to other genetic alterations connected to cancer, such as translocations, 
deletions or aneuploidy (uneven chromosome number), the increased gene copy number 
phenomenon is found in a large fraction of human sarcomas. Detection of amplified material 
has been possible by various molecular and cytogenetic methods; Southern blotting, 
fluorescent in situ hybridisation (FISH), real time-PCR, comparative genomic hybridisation 
(CGH) and array CGH. Nils Mandahl’s group at the University of Lund (Sweden) described 
the COAS2 gene using FISH with cosmid probes (Nilsson et al., 2004). COAS2 was found 
amplified in lipomatous tumours, with the extra copies located to ring or giant marker 
chromosomes, as expected for this type of tumours. 
 
          
 
Figure 1.7: Metaphase spread showing additional (red) signals of COAS2 in ring and marker 
chromosomes, pictures courtesy of Malin Nilsson. 
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1.5.3 The 1q21-23 and 12q13-15 amplicons 
 
Some regions are highly amplified in a major percentage of human sarcomas, with the 1q21-
22 and 12q13-15 amplicons frequently seen in tumours of both soft tissue and bone. Forus et 
al. were the first to identify the important chromosome 1 amplicon in sarcomas (1998), and it 
has also been observed in breast and ovarian cancer (Kudoh et al., 1999; Tarkkanen et al., 
1999). 
 
 
 
 
 
Å1q21-q22 
 
 
 
 
Figure 1.8: CGH studies of chromosome 1 in soft tissue sarcomas. Each vertical line represents 
amplification in one tumour sample. The arrow indicates the main amplified region, 1q21-q22. The p 
and q represent the short and the long arm of chromosome 1, respectively. Figure modified after 
(Forus et al., 1995a). 
 
Amplification in the 1q region is associated with an aggressive phenotype with high 
metastatic potential, short overall patient survival and poor chemotherapy response (Hirai et 
al., 1999; Tarkkanen et al., 1999). The APOA2 gene, and the COAS genes are known target 
genes in this region. Further studies in progress, using a complete tiling path array throughout 
the region, will give a high-resolution picture of the DNA copy number changes in this 
amplicon. Other common amplicons in osteosarcomas include the 6p, 8q, 17p11-p12 and the 
frequent 12q amplicon with amplified MDM2, CDK4 and HMGIC. The architectural 
transcription factor HMGIC is frequently rearranged during the process, and thus probably 
oncogenically activated (Forus et al., 1993); (Maelandsmo et al., 1995); (Meza-Zepeda et al., 
2001). Several other proto-oncogenes are over-expressed in sarcomas. The rapidly increasing 
identification of marker genes is made possible with microarray techniques. The array 
technology will be described in further detail in the methods section.  
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1.6 The immunophilins 
 
Cyclophilin A (Cyp A) was first identified and purified from bovine spleen in 1984 on the 
basis of its high affinity (Kd =10-8-10-9) for the immunosuppressive drug Cyclosporin A, 
(CsA) (Walsh et al., 1992). Other groups found similar proteins that catalyzed the 
interconversion of cis- and trans-amide bonds adjacent to proline residues in peptide 
substrates, and termed these enzymes peptidylprolyl isomerases (PPIase) (Fischer et al., 
1984). Subsequent studies demonstrated that the found PPIase and cyclophilin A were the 
same molecular entity, and that CsA inhibited its PPIase activity (Fischer et al., 1989; 
Takahashi et al., 1989). However, the 18 kDa cytosolic protein had an abundant overall 
distribution which dit not correlate with the selective immunosuppressive action of CsA, and 
a search for additional members of the immunosuppressive drug binding cyclophilin protein 
family commenced. Today, the peptidyl-prolyl isomerase (also known as rotamase) family 
consists of three subclasses based upon drug specificity: The cyclophilins (Cyps), that take 
CsA, the FK-binding proteins (FKBPs), binding the peptide FK506, and the parvulins, that do 
not bind immunosuppressants. Ubiquitously expressed, the immunophilins also appear to 
function as accessory helper enzymes of folding chaperones that provide functional stability 
to multiprotein macromolecules. Links to axonal transport, synaptic vesicle assembly and the 
possible role in neuroprotection against normal protein aggregation enhance the image of 
immunophilins as multitasking proteins (Avramut and Achim, 2003). They are found in 
various compartments of the cell: the endoplasmatic reticulum: CypB and FKBP13; the 
nucleus: FKBP25 and 52; and in CypD in mitochondria. CypA and FKBP12 are both 
cytosolic proteins. The C. elegans isoform of CypB has been associated to the gut (Picken et 
al., 2002). All members share the ability to catalyze the cis-trans isomerisation of peptide 
bonds N-terminal to proline residues in polypeptide chains; a rate-limiting step in protein 
folding and regulation of ligand selection (Brazin et al., 2002; Shaw, 2002). The PPIase 
activity is also essential for skeletal and muscular differentiation (Hong et al., 2002). Parvulin 
activity is directed by the prior phosphorylation of target proteins in both yeast and 
mammalian cells (this is also the case for some cyclophilins), and they are structurally distinct 
from FKBPs and cyclophilins. Cyclophilins have an eight-stranded β-barrel that forms a large 
hydrophobic pocket located at the surface of the central core in which CsA binds (Carpentier 
et al., 2002), whereas FKBPs consist of an amphiphatic (i.e. both hydrophilic and 
hydrophobic) five-stranded β-sheet that wraps around a single, short α-helix (Michnick et al., 
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1991). Parvulin family members possess a PPI domain of a half β-barrel, its four antiparallel 
strands surrounded by four α-helices.  
 
 
 
 
 
   
Figure 1.9: Peptidyl-prolyl isomerization of the amide bond preceding Proline. This bond has partial 
double bond character and can exist as both cis and trans isomers. For all amino acids except proline, 
the trans isomer is the preferred conformer because of steric hindrance in the cis form, whereas the 
peptide bond preceding proline residues are equally stable as both cis and trans isomers. PPIases have 
the ability to catalyze the interconversion between the cis and the trans isomers. See text for further 
information. 
 
A peptide bond has partial double bond character and can exist as either cis or trans isomers. 
For all amino acids except proline, the trans isomer is the preferred conformer because of 
steric clashes in the cis form. In contrast to this, the peptide bonds preceding proline residues 
are equally stable in both isomeric states (Arevalo-Rodriguez et al., 2000). In the living 
organism, cis-trans forms of peptidyl-proline bonds exist in a 5% - 95% equilibrium (Reimer 
et al., 1998). In the cell, these bonds are thought to be catalyzed by the ribosomes as trans-
isomers, and spontaneous OR assisted (by either protein disulfide isomerases or PPIases), 
isomerisation yields the cis form (Fischer and Schmid, 1990). 
The phenomenon of peptidyl-prolyl isomerisation of Xaa-Pro amide bonds (where Xaa is any 
amino acid) has been extensively studied. The parvulins have high specificity for 
phosphorylated pSer/Thr(PO3H2)-Pro motifs, and a few Cyps use this well-studied substrate 
(Ryo et al., 2001; Messenger et al., 2002). Concerning the immunosuppressant-binding PPIs, 
X-ray and NMR structures of the CypA/CsA and FKBp/FK506 complexes suggest that these 
proteins promote the cis-trans isomerisation of an Xaa-Pro bond by preferentially binding it in 
a twisted (nonplanar) conformation. They thus follow a transition state binding type of 
catalysis, whereof some substrates may be phosporylated as an initiating signal. The early step 
of conversion from cis- to trans-X-Pro bonds is thought to release the substrate from the 
enzyme for further processing or post-folding modification. The phosphorylation dependent 
PP isomerisation has also been suggested to act as a signal enhancer for kinase activity, where 
 
CIS TRANS 
PPIases
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phosphorylation followed by cis-trans conversion tags target proteins for ubiquitin-mediated 
proteasomal degradation (Hsu et al., 2001). A model for PPI inhibition has been suggested 
where the immunosuppressant drugs act as substrates where this cis-trans conversion does 
happen, but not to its full extent. This resulting in a permanently bound substrate with both 
cis-and trans-structures accomodated in the same active site with minimal changes in the path 
of the polypeptide, resulting in occupancy of the pocket and full inhibition of the PPI activity 
(Howard et al., 2003). Various amino acids are responsible for the PPI activity in the 
respective enzymes, which again helps explain the difference in drug specificity. As an 
example, steric hindrances in the natural state of many X-Pro bonds and Proline side chain 
oxygen binding to Arg55 in CypA add up to give this particular cyclophilin a preference for 
Gly-Pro-bonds (Howard et al., 2003). However, the preference is but that, and Cyp catalysis 
of cis-trans conversion does not depend on the identity of the preceding residue X, (in 
XC(=0)-Npro bond rotation), but that of FKBP does (Hur and Bruice, 2002). Surrounding 
domains account for interfamiliar differences and specificities of the respective proteins. 
WW-domains in parvulins connect them to transcription factors, protein kinases (Messenger 
et al., 2002; Shaw, 2002), and Tetratricopeptide repeat domain (TPR) immunophilins are 
linked to steroid receptor signalling through binding to heat-shock chaperone Hsp90; 
FKBP51,FKBP52 and Cyp40 (Ratajczak et al., 2003). There are glycosaminoglycan (GAG)-
binding domains in CypA and B, organelle-signaling sequences (in CypB+D), and RNA 
Recognition Motifs, with 1 RRM in hCyp33 and in the D. melanogaster orthologue 
(Anderson et al., 2002). Through these domains, the rotamases attach to interaction partners 
and possible substrate(s). Some have secretory signals, such as CypD. These peptides enable 
the sorting of proteins from the endoplasmatic reticulum (ER) to the cell membrane. CypB 
has such a 25-amino acid signal at the N-terminus, and is secreted during immunogenic 
responses to a final concentration of <5nM, whilst amino acids 1-29 of CypD is a 
mitochondrial target sequence, cleaved after import into mitochondria. CypD is specifically 
up-regulated in human tumours of the breast, ovary and uterus, and has been identified as a 
component of the permeability transition pore in mitochondria (Schubert and Grimm, 2004). 
Both Cyp A and B bind to T cells via binding to the glycosaminoglycan (GAG) chains of 
heparins (Allain et al., 2002; Yurchenko et al., 2002). In addition, CD147/EMMPRIN, a 
highly glycosylated cell surface protein of the immunoglobulin superfamily, has been shown 
to act as a costimulatory molecule in cyclophilin-mediated signalling events, in addition to its 
role as signaling receptor for CypA (Carpentier et al., 2002; Yurchenko et al., 2002).  
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The work presented by Carpentier et al., (2002), suggested a scenario where CypB is 
immobilized on the T-lymphocyte surface bound to proteoglycans, then isomerises an 
exposed X-Pro bond in a functional receptor and thereby induces the biological response and 
ultimately the T cell’s adhesion to the extracellular matrix via fibronectin. Importantly, this 
effect appears to be targeted predominantly to memory CD4+ cells, suggesting a role for 
CypB, recruiting T cells to infected tissue in vivo (Carpentier et al., 2002). De Ceuninck 
elucidated the Cyclophilin-GAG-interaction further in 2003, by connecting CypB to 
chondrocytic heparan sulfate proteoglycans (HSPGs) and matrix metalloproteinases, MMPs. 
Earlier studies have shown that the attachment of HIV-1 to target cells is a multi-step process 
that requires an initial CypA-heparin interaction (Sherry et al., 1998; Saphire et al., 1999). 
Other immunophilins have been linked to cancer, such as the parvulin Pin1, a cell cycle 
regulator (Basu et al., 2002; Wulf et al., 2002). Over the last decade, several studies on 
immunophilins in yeast have found that all but one parvulin null mutation are not lethal, 
indicating that the remaining yeast immunophilins are not essential to neither growth nor cell 
survival. Intriguing, however, were studies where the Pin1 yeast homologue ess1 null mutants 
were shown to have an increased sensitivity to CsA. This was supported by equally interesting 
crosstalk and complementation studies of ess1/cypa across subfamiliar boundaries in yeast 
(Arevalo-Rodriguez et al., 2000; Fujimori et al., 2001). The authors concluded that cypa 
becomes essential when ess1 function is compromised. Complementation as a cancer 
development/progression inhibitory mechanism illustrates fully the potential for 
immunophilins in cancer research. 
 
1.6.1 Natural substrates of immunophilins 
 
Little is known about immunophilins and their substrates in vivo. Receptor kinases, calcium 
release channels and steroid receptor complexes have been linked to FKBP12, FKBP12, 
Cyp40, FKBP51 and FLBP52, respectively. The Cyclophilin H interacts specifically and 
stably with the U4/U6-specific protein 60K involved in splicing. This through a second 
protein-protein interaction site, named a “CypH like cleft” formed by the α1-β3 loop 
(Ingelfinger et al., 2003; Reidt et al., 2003). Otherwise, most of the interactions described here 
are transient only, except when the cyclophilins posess a TPR domain or a Ran-binding 
domain (Ferreira et al., 1996). Transitional interaction is a keyword for immunophilins in 
general, as they perform their rotamase activity without being permanently coupled to the 
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substrate. Murine Cyclophilin C has an alleged 77 kDa membrane protein substrate named 
Cyclophilin C associated protein (CyCAP) (Friedman and Weissman, 1991). CypA and 
FKBP12 interacts with YY1, a zinc finger transcription factor (Yang et al., 1995). The 
nonreceptor protein tyrosine kinase Itk alternates between the CypA bound monomer and the 
phospholigand bound mono- or dimeric state. CypA effectively regulates Itk through 
transition state binding, switching the kinase from an inactive cis-state to the active trans-
isomer. More importantly, the interaction of the retinoblastoma gene product RB and Itk links 
CypA closer to T-cell activation and regulation (Cui et al., 2002).  
 
1.6.2 The pseudosubstrates of immunophilins 
 
As for CypA, given the NMR evidence indicating that CypA-bound CsA undergoes a cis to 
trans-isomerization, the drug can be thought to be a slow binding pseudosubstrate (Fesik et 
al., 1990). A parallel occurs in FK506 bound to FKBP (Van Duyne et al., 1991). The 
difference of bound and soluble CsA is most notable around the 9-10 amide bond, which is cis 
in solution but trans when bound to the protein. Therefore, each immunosuppressant drug may 
inhibit its respective immunophilin by selective accumulation as a trans product analog, 
selectively stabilized in the active site and slowly released (Walsh et al., 1992). Several CsA 
analogues lacking the immunosuppressiveactivity have been developed. These are of interest 
in the field of anti-HIV therapy, where the prevention of CypA binding to the HIV1 gag 
protein may prevent replication of the HIV virion (Franke and Luban, 1996). 
 
1.6.3 The cyclophilin class of Peptidylprolyl Isomerases 
 
Cyclophilins are highly conserved genes from prokaryotes to eukaryotes and archaea, and 
they all share a 109 amino acid-domain surrounded by unique domains involved in organelle 
and domain targeting (Walsh et al., 1992). Several subgroups are known: at least 12 unique 
proteins are found in humans (Galat, 2003). Of these, crystal structures of 11 isoforms can be 
found in structure databases in July 2003 (Galat, 2003). The most common types have all a 
high extent of amino acid similarity to the family prototype CypA (an example: COAS2: 84%, 
CYPB: 65%). The proteins have multiple roles in vivo, targeted to pre-mRNA splicing 
(Horowitz et al., 2002), transcription factor regulation (Leverson and Ness, 1998) and 
peroxiredoxin activation (Lee et al., 2001). The cyclophilin family includes CypA, B and C-
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like proteins, divergent loop cyclophilins and multidomain proteins (Dornan et al., 2003). 
CypA has several pseudogenes (www.pseudogene.org). Regardless of amount or false 
positives, they have a central core composed of eight antiparallel β-strands that form a right-
handed β-barrel. The barrel is overlayed by connecting loops and α-helices with additional β-
sheets at the termini. The 11 residues responsible for PPIA activity and substrate/CsA binding 
lie in close vicinity within a large hydrophobic pocket at the surface of the central core 
(Dornan et al., 2003). In line with differential interaction with calcineurin, different residues 
present in two loops and in the 310 helix residing near the CsA binding site are involved and 
altered from cyclophilin to cyclophilin (Etzkorn et al., 1994). Studies of cyclophilin-ligand 
complexes show that the substrate proline always adopts a cis-conformation, binding via 
Arg55 and Asn102.   
 
 
Figure 1.10: The proposed structure of COAS2 with bound cyclosporin A, as wieved with the Cn3D 
software (NCBI). Blue = amino acids differing from CypA, Red = amino acids identical to CypA, 
Grey = N- and C-termini. The colors are kept in the sequence aligment of human cyclophilin A and 
the translated COAS2 mRNA, as shown below. Figure courtesy of Ms B. Lygren. 
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The basic C-terminal 148RRKE155 domain in CypA and the respective 3KKK5 plus 
14YFD16 N-terminal domains in CypB have been assigned to mediate GAG-binding through 
an ionic, temperature-dependent interaction (Carpentier et al., 2002). The interaction is very 
likely to be of transient nature, since most cyclophilins bind to ubiquitously expressed ligands 
except for the stably interacting CypH-orthologues and perhaps some of the RNA-b binding 
cyclophilins (Shaw, 2002). Recent publications have reported a degree of cis-trans 
isomerisation in HIV-virions during interactions between CypA and the HIV Vpr N-terminus 
(Bruns et al., 2003). Figure 1.11 illustrates a possible model for this CypB-GAG/ CypA-Vpr 
protein interaction.  
 
 
 
 
Figure 1.11: Possible model for transient cyclophilin B-binding to GAGs followed by cis-trans 
isomerisation on a third molecule. In a second model proposed by Carpentier et al., (2002), the third 
molecule could be a cell surface receptor. 
 
With a huge number of CypA-paralogues seemingly non-essential for life in the host 
organism, one can hypothesise about the targets and functional aspects of small cyclophilins 
in vivo. In this work, COAS2, a H. sapiens class A cyclophilin with 84 % amino acid identity 
to CypA has been studied at the DNA, RNA and protein level. 
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1.6.4 Immunosuppressive agents bind immunophilins 
 
Cyclosporin A, FK506 and rapamycin 
 
Cyclosporin A, or CsA, is a cyclic undecapeptide derived from a Norwegian soil fungus; 
Tolypocladium inflatum. CsA has revolutionized the field of transplantation medicine since its 
discovery at Hardangervidda, and was characterised in the mid-1970s (Borel et al., 1976). 
Another immunosuppressant is FK506 or tacrolimus; a macrolide compound from the 
filamentous Japanese bacterium Streptomyces tsukabaensis. A third example and 
Streptomyces macrolide is rapamycin or sirolimus from S. hygroscopicus. Rapamycin was 
found at the Easter Island in the early 1970s and evaluated initially for antifungal activity 
(Sehgal et al., 1975). All three exert their pharmacological effects through the binding of 
immunophilins: CsA to CypA, FK506 to the FK506 binding protein (FK506P), and 
rapamycin to other FKBPs. The binding blocks the intrinsic PPI-activity of the 
immunophilins, but blocked immunophilins do not directly inhibit the immune response (see 
next paragraph). Recently, another immunosuppressant drug that shares its intracellular target 
with CsA was discovered. Named sanglifehrin A, it exerts its activity in yeast cyclophilins via 
the same specific tryptophan; number 128 (Pemberton and Kay, 2003).Both the 
immunophilins and their molecular targets are found in many cell types, and therefore have 
effects on many types of tissues. CsA is also linked to muscle differentational arrest: In a 
FASEB Journal express article (Hong et al., 2002), the authors showed that CsA blocks 
muscle differentation by inducing oxidative stress and by inhibiting the PPI activity of CypA. 
The PPI-activity is necessary for muscle cell differentiation and thus protects myoblasts from 
CsA-induced cytotoxicity. In addition, CsA has higher affinity for Cyclophilin B and C than 
for CypA (Carpentier et al., 2002), and it may be likely that CsA mediates the above effect by 
binding to more than one type of cyclophilin. Both CsA and FK506 are efficacious for the 
treatment of autoimmune and inflammatory diseases, such as psoriasis, Behcet’s disease and 
insulin-dependent type-1 diabetes (Matsuda and Koyasu, 2003). 
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1.6.5 Immunosuppressive agents exert their effect through a third molecule 
 
Calcineurin (CN), or protein phosphatase 2B, was originally identified as a novel protein in 
neural tissue which bound Ca2+ and inhibited the cAMP phosphodiesterase activator 
calmodulin (Klee et al., 1979). Subsequently, it was found to be a calcium- and calmodulin-
binding protein serine/threonine phosphatase (Aramburu et al., 2000). Conserved in all 
eukaryotes from yeast to humans, it is in the inactive state composed of two subunits (Fox and 
Heitman, 2002). One catalytic subunit, calcineurin A, and a regulatory subunit, calcineurin B, 
with molecular weigths of about 58 to 69 kDa and 16 to 19 kDa, respectively. Upon binding 
of T-cells to T-cell receptors on damaged cells, CN is activated as the intracellular calcium 
ion levels rise. Ca2+ -calmodulin will free the active site upon binding of the catalytic subunit 
A. Two Calcineurin B-binding proteins have been identified, namely tubulin and heat shock 
protein 60 (Li and Handschumacher, 2002). Calcineurin exerts biological functions in higher 
eucaryotes, inlcuding sperm motility, ion channel regulation, muscle glycogen metabolism, 
cardiac hypertrophy T-lymphocyte activation and neurite extension (Li and Handschumacher, 
2002). It has also been found to dephosporylate a number of phosphoproteins including 
histones, myosin light chain (gene symbol MYL) and the regulatory subunit of cAMP-
dependent protein kinase (Aramburu et al., 2000). In their paper from 2002, Neal and 
Clipstone show that CN mediates the Ca-dependent inhibition of adipocyte differentiation in 
3T3-L1 cells. Describing calcineurin’s role as a regulator of adipogenesis, the link to CsA has 
been given proper attention. Their data suggest that CsA and FK506 treatment leads to 
obesity, and this may partly explain why increased obesity, hyperlipidemia and type II-
diabetes have been reported in patients treated with these drugs (Neal and Clipstone, 2002). 
Lymphocyte activation requires the dephosphorylation and revealing of a nuclear transport 
signal of the Nuclear Factors of Activated T cells (NFATs). This important checkpoint is 
regulated by calcineurin. Upon addition of CsA or FK506, the drug-immunophilin complex, 
and not the immunophilin alone will bind to and sequester CN and thus the activation of an 
immunogenic response. As a result of the drug-immunophilin-blockade, the NFAT class of 
transcription factors will not be able to translocate into the cell nucleus, and the necessary 
lymphokines and activating mediators of the immune reaction will not be transcribed. 
(Interleukin 2 (IL-2), whose synthesis by T lymphocytes is an important growth signal for T 
cells, Interleukin 4 (IL-4), Interpheron alpha (IFNγ), the CD40 ligand etc.) Calcineurin exists 
at lower levels in T cells compared to other types of cells, and is therefore more sensitive to 
drug inhibition (Aramburu et al., 2000). 
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Recently, Cyclosporin’s mechanism of action have been thoroughly discussed, something 
which led Satoshi Matsuda and Shigeo Koyasu in 2003 to suggest that CsA and FK506 exert 
their immunosuppressive activity not only through binding immunophilins and Calcineurin, 
but also by the suppression of Jun Kinase (JNK) and p38 pathways. However, the potential 
role of immunophilins in this process has not yet been fully elucidated. Unlike CsA and 
FK506, Rapamycin inhibits by blocking downstream proteins in the signal transduction 
pathway triggered by ligation of the IL-2 receptor (IL2R). A rapamycin-FKBP12 complex 
binds to the protein kinase Mammalian target of rapamycin (mTOR), and effectively inhibits 
further phosphorylation of intracellular targets. mTOR is a member of the PI3K kinase family 
based on its homology within its catalytic domain. Because rapamycin has different 
pharmacological activities from CsA and tacrolimus, trials are being undertaken to see if a 
combination of the drugs might provide more effective and safer treatment with less side 
effects. For additional information, please see Nature Insight reviews Vol 411 May 2001. 
 
1.6.6 CN inhibition by immunosuppressive drugs 
 
The X-ray structures of the ternary CN-FK506-FKBP and CN-CsA-CYPA complexes 
revealed in molecular detail how these natural products achieve specific inhibition of 
calcineurin. First, both inhibitor complexes form extensive drug-protein and protein-protein 
contacts with CN. Residues 3-9 of CsA, the presumed ”effector domain”, create a 
hydrophobic interface with Cn, containing two buried hydrogen bonds (Jin and Harrison, 
2002). Second, both inhibitor complexes bind to the hydrophobic interface between the 
subunits in site that is unique to CN. Third, the active site of CN is not occupied in either 
complex, but one assumes that the inhibition occurs by occlusion of large protein substrates 
by the inhibitor complexes. Most importantly, the sites at which the two drug-immunophilin 
complexes bind to CN are overlapping but distinct, providing a molecular explanation of how 
two completely dissimilar complexes can both inhibit the same target in a competitive fashion 
(Fox and Heitman, 2002). In their excellent JBC paper, Yukun Cui et al. (2002) investigated 
the interaction of the retinoblastoma gene product with CypA. According to the authors, RB 
can possibly prevent CsA-inhibited NFAT-signalling (Cui et al., 2002). 
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1.7 Background 
 
The highly amplified 1q21-22 region was characterised in a YAC-based sarcoma panel by 
Forus, Meza-Zepeda and colleagues at the Norwegian Radium Hospital using comparative 
genome hybridisation (CGH), and fluorescent in situ hybridisation (FISH) (Forus et al., 
1995b; Forus et al., 1998). Early CGH results were confirmed by FISH, where the yeast 
artificial chromosome (YAC) CEPH789f2 was chosen to select cDNAs corresponding to 
target genes (see Figure 1.12). A linked cDNA library from an osteosarcoma cell line with 
high-level amplification of the designated area was constructed and hybridised to biotinylated 
YAC sequences. 
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Figure 1.12: YACs covering the 1q21-23 region. The different YACs containing segments of human 
1q21-23 DNA used to find the amplification status of 1q21 in a panel of sarcomas are shown in green, 
and the YAC 789f2 most frequently detecting 1q21 high level amplification, shown in red, was chosen 
to select cDNAs corresponding to genes in this YAC. The two YACs at the right cover the 1q23 
region. Red circles represent different markers in the region of interest. Figure kindly provided by Dr.  
Meza-Zepeda.  
 
After collection of biotinylated cDNAs with streptavidin-coated magnetic beads and testing 
for false positives, three novel coding sequences remained as positive hits. They were named 
Chromosome One Amplified Sequence 1, 2 and 3, (COAS1, -2 and -3) (Meza-Zepeda et al., 
2002). 
• COAS1 shows no homology to any known protein families. The 10 kb transcript 
apparently consists of numerous repeats, yielding a pattern of repeats within repeats, 
and the function of COAS1 is not known. 
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• COAS3 had some sequence resemblance to the Profilin 1 gene, but the eventual 
COAS3 gene product has not been submitted to any further investigation, because it is 
less amplified than the others. 
COAS2, however, was stated a novel member of the cyclophilin family of proteins, with 84% 
amino acid identity to CypA. It has been reported to be over-expressed in liver cancer by S. 
Tanaka, (directly submitted to the NCBI database in May 2002, not published), and exists as 
cyclophilin-LC with NCBI accession number AB084917. The gene has multiple allelic 
versions. The one exon (495 bp) mRNA allegedly codes for a protein of 164 amino acids. The 
overview article by A. Galat (2003) points out the major problem concerning the 
characterisation of this gene. Para- and orthologues are very similar, and numerous allelic 
versions exist, as well as non-translated mRNAs of cyclophilin pseudogenes. COAS2 was 
given the LocusLink-number 164022, it bears all signs of a protein-encoding gene, but has 
until now only been identified as mRNA in vivo (Meza-Zepeda et al., 2002). 
Earlier work on COAS2 using transient transfection of egfp fusion constructs gave egfp-
COAS2 a speckled distribution pattern within the transfected fibroblast cell, but only very few 
cells showed fluorescence compared to egfp controls, suggesting some kind of experimental 
artifact (Lygren, 2002). Interaction partners were searched for by yeast two-hybrid analysis, 
where the Filamin A and C genes plus the proteasome subunit 7 alpha gene were identified as 
positives. Localization studies attempting to assay the filamin-COAS2 link did not come to 
any final conclusion, since the commercial anti-chicken filamin antibody used still has not 
been fully tested for human filamin specificity. This work set out to confirm and complete 
some of the early findings. 
 
1.8 Aims of this study: Functional studies of COAS2 
 
Ms Birgitte Lygren performed several experiments with COAS2 during her time as a MSc-
student; some have been referred to and even reprinted here after kind permission.  
Dr. Leonardo A. Meza-Zepeda is also a major contributor, and their collaborate work have 
been of great importance to this study. Without the aid of Mr. David J. Warren and Mr. Jørn 
Henriksen, the protein analysis would never have been made possible. 
Initially, the aims were clearly defined, encircling the expression analysis of COAS2 using 
cell line material, northern hybridisations and cDNA microarrays, in addition to protein 
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expression for monoclonal antibody production. The primary goal was nevertheless to 
establish stably transfected mammalian cell lines as the starting material for the entire 
microarray-study. We also hoped for the microarray-based transcription profile to link 
COAS2 to gene regulatory pathways. Characterisation of the mammalian cell clones, 
confirming the proper insertion, expression and cell cycle regulatory effect of the gene and its 
product was thus prioritised. Later, the project evolved to include confocal microscopy-based 
localisation studies using Flp-In 293 cell lines stably transfected with MYC-HIS6-tagged 
COAS2. We finally transfected both egfp-COAS2 and COAS2-egfp constructs into the Flp-In 
system to localize the recombinant proteins with confocal microscopy, aiming to confirm 
Birgitte Lygren’s results achieved with transient transfection systems.  
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2 Methods, short protocols and related theory 
 
Each topic and some related basic theory is presented in brief, followed by the protocol. In 
some cases, the protocol included from the supplier was used, and eventual minor changes to 
the commercially available protocols are indicated. Plasmid maps, list of reagents, solution 
recipes and a list of equipment used in this work can be found in the appendix, whilst flow 
charts for the cloning procedures are located in the results section. 
 
2.1 Some standard methods used in molecular biology 
 
 
2.1.1 Growth and transformation of bacteria 
 
Escherichia coli strains used in this work were all grown in Luria-Bertani (LB) medium 
supplemented with the appropriate antibiotic (Sambrook, 2001). After 12-18 hours of growth, 
a freezer stock was prepared with 1 ml of the total culture volume to 25-30% (v/v) of 
glycerol, and stored at -80°C (Sambrook, 2001). The remaining culture volume was harvested 
by a centrifugal spin and the pellet was stored at -20°C, awaiting plasmid isolation. A plasmid 
is a small, circular double stranded fragment of DNA, harbouring an antibiotic resistance 
marker gene. In vivo, plasmids are located in bacterial cells, where their natural role is not 
well defined. But plasmids do express proteins conferring antibiotic resistance to the host cell, 
and its autonomic replication in bacteria inspired researchers to isolate and use plasmids as 
DNA transfer vectors. This technology is well established, and commercially available 
vectors of many types and sizes are available. Using restriction enzyme techniques (see 2.1.4) 
the user can insert a gene of interest into the polylinker of a chosen plasmid. Engineered 
bacterial strains are often preferred hosts, into which the constructs are inserted by 
transformation (see further on). When grown in a shaker for 12-18 hours, a bacterial culture 
thus creates a large amount of plasmid DNA, which can be purified using standardized 
methods. Commercial bacterial strains were all transformed using SOC-medium and modified 
heat-shock methods, as described in (Sambrook, 2001). Basically, 30-50 µl of a chosen 
competent bacterial suspension, (e.g. JM109, DH5α or DH10α, as used in this work), is 
thawed on ice, quickly mixed with 1-50 ng of the plasmid to be transferred, and the mix is 
submitted to a cycle of cooling on ice, heating at 42°C for 30-45 seconds followed by re-
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cooling on ice. This heat-shock method will permeabilize the bacterial cell membrane and 
hence permit the constructs to enter. After 2-3 minutes on ice, different dilutions were plated 
on LB plates with selection marker antibiotic, and incubated at 37°C overnight. Positive 
clones were picked using a sterile pipette tip, and grown in LB for 12-15 hours in a shaker at 
37°C to enable harvest, storage and further isolation of the plasmid. A modified strain-
specific heat shock transformation protocol can be found at the website of the supplier. 
 
2.1.2 Isolation of plasmid DNA from bacterial cultures 
 
1-5 ml of bacterial culture is the starting point for a plasmid “miniprep”, whereas the amount 
increases to 100-250 ml for a “midiprep” and approximately 500 ml for a “maxiprep”.  
The plasmid miniprep protocol used in this study is based upon alkaline lysozyme/detergent 
lysis of cells as described by H.C.Birnboim in 1983. After a lysis period of 5 minutes 
maximum, a swift gentle neutralisation will prevent bacterial genomic DNA from being 
sheared. Now, the high salt concentration causes cell debris, genomic DNA, total RNA and 
proteins to aggregate and be pelleted by the following centrifugation. The small plasmids will 
quickly renaturate and remain in the supernatant. In the commercial miniprep kits used in this 
work, the supernatant is loaded onto a spin column having a plasmid-binding silica 
membrane. Repeated ethanol washes remove most contaminants, and following elution steps 
with alkaline 10 mM Tris solutions yields relatively pure plasmid DNA. Along with 
increasing starting material comes the need for larger columns, which makes spin columns 
unsuitable for large preps. For midis and maxis, the use of gravity flow columns and 
isopropanol precipitation of plasmid DNA is followed by centrifugal spins and washes and 
elution as above. In this work, the JetQuick mini- and midiprep kits from Genomed, and the 
WizardSV plasmid miniprep kit from Promega were used. All maxipreps were made using the 
EndoFree Maxi kit from Qiagen, giving endotoxin-free preps of high purity. For detailed 
experimental descriptions, please see http://www.qiagen.com. For most centrifugation steps in 
the above protocols, the Sorvall RC5C Plus centrifuge was used, with either SS-34 (maximum 
30 ml tubes) or HS-5 rotors (maximum 250 ml tubes). 
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2.1.3 Spectrophotometric quantitation of nucleic acids 
 
A spectrophotometer reads the intensity of both incident and transmitted monochromatic light 
of a sample compared to a blank control, enabling quantitation of the content when the 
sample’s extinction coefficient, the size of the container/cuvette and sample dilution is 
known. (According to the Lambert-Beer law, relating path length, incident and transmitted 
light in a closed sample volume.) Using a fixed path length, the optical density or absorbance 
A is directly proportional to the concentration of the absorbing solute. DNA and RNA have 
absorbance maxima at 260 and 280 nm, respectively, caused by the purine and pyrimidine 
rings’ ability to absorb UV light. (At 260 nm, an absorbance value of 1 equals 50 µg/ml 
dsDNA and 40 µg/ml RNA and ssDNA in the sample, respectively). Contaminating protein in 
a nucleic acid sample has a maximum at 280 nm, (caused by the tryptophane and threonine 
side chains in the proteins), making the A260/A280 ratio a measure of DNA/RNA sample purity. 
Pure DNA/RNA preparations have a A260/A280 ratio of 1.8 and 2.0 respectively, depending 
upon pH and ionic strength of the liquid used for sample dilution and reference (usually H2O 
or Tris-EDTA pH7.5, (TE)). Lower pH results in a lower ratio and reduced sensitivity to 
protein contamination. It should be mentioned, however, that determination of the RNA 
concentration in a sample demands a buffer with neutral pH, since the relationship between 
absorbance and concentration (see above) is based on an extinction coefficient calculated at 
neutral pH (Wilfinger et al., 1997); (Sambrook, 2001). In this work, the Pharmacia Gene 
Quant apparatus with quartz cuvettes was used for all measurements. 2 µl of the sample was 
diluted 1:35 or more in 1x TE, pH 7.5, or sterile water. 
 
2.1.4 Restriction enzyme analysis of DNA  
 
Class II-restriction enzymes recognize palindromic sequences in dsDNA, and exert their 
function as an enzymatic defence towards viral DNA in prokaryotes, from where they have 
been isolated in general. The bacterial DNA itself is well protected towards these 
endonucleases (cuts within), by DNA-methyltransferases that protect the cell’s own DNA 
from cleavage by the restriction enzyme. Methyltransferases recognize the same DNA 
sequence as the restriction enzyme that they accompany, but instead of cleaving the sequence, 
they methylate one of the bases in each of the DNA strands (often adenine (A) or cytosine 
(C)). The methyl groups protrude into the major groove of DNA at the binding site and 
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prevent the restriction enzyme from acting upon it. Of the three restriction enzyme classes 
known, number II is the most important and most frequently used in molecular cloning. In 
addition to the endonucleases, an enzyme class named exonucleases (cuts from ends) is of 
much use. Some class II-endonucleases leave blunt ends (see Figure 2.1), whilst the majority 
of the commercially available enzymes leave protruding, staggered ends behind.  
It is well known that enzyme-catalyzed ligation of single stranded complementary overhangs, 
or “cohesive ends” is easier than for the blunt. As a standard measure, 1 unit (U) of a given 
enzyme is per definition the necessary amount of enzyme needed to cut 1 µg of phage λ DNA 
in a 1 hour reaction at the ideal temperature for the actual enzyme. Every procedure needs 
optimization, with adjustments of carrier protein and salts and temperature as the most 
important aspects. Performing multiple restrictions is possible, depending on internal distance 
between sites of digestion and buffer preferences for both enzymes in addition to the above.  
 
 
 
 
Figure 2.1: Restriction endonucleases can generate blunt-ended fragments or “sticky” fragments with 
5 - or 3 -overhanging ends (Read, 1999).  
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2.1.5 Restriction analysis of plasmid DNA  
 
Standard protocol 
 
A typical reaction mix would consist of restriction buffer, carrier protein, (most often BSA to 
a final 0,1 mg/ml, necessary for some enzymes), 0,1-5 µg of DNA, 3 Units of enzyme(s) per 
µg of DNA and distilled or sterile H2O to the total volume. The DNA fragments can be 
double stranded PCR products, cloned cDNA or vector DNA. Regarding incubation time and 
temperature, all enzymes were used according to the supplier’s descriptions. Please see the 
detailed illustration for each cloning procedure further on. 
  
2.1.6 Ligation of DNA fragments using T4 DNA ligase 
 
The bacterial virus T4 harbours a DNA ligase, an enzyme which links juxtaposed 3’-hydroxyl 
and 5’-phosphate termini of fragmented nucleic acids to form one continous strand, in 
addition to repairing single stranded nicks in duplex DNA, RNA and RNA/DNA hybrids 
(Engler, 1982). In this work, T4 DNA ligase was used to ligate pre-digested DNA fragments, 
i.e. plasmids and PCR products pre-cut with the same enzymes. After incubation, agarose gel 
analysis of both sample and negative control (plasmid without added ligase), was performed. 
 
Standard protocol 
 
Mix T4 ligase buffer1, 2-400 Units T4 DNA ligase, 50-300 ng insert DNA and 100-300 ng 
plasmid DNA plus distilled or sterile H2O to 15µl. The blend is gently mixed in an eppendorf 
tube and incubated over night (14-18 hours), at 14-16°C or 1-2 hours at room temperature. If 
room temperature is preferred for convenience reasons, this may negatively influence the 
reaction’s rate of accuracy, although the T4 ligase enzyme is relatively tolerant when buffer 
composition is otherwise correct. The recommended DNA concentration for ligation of sticky 
ends is 0,1-1µM (5’termini). For blunt-end ligation, over night incubation is recommended. 
When all buffer conditions are correct, the DNA purity and concentration, more so than 
volume is important. Heat inactivation of the ligase is often recommended, but was not used 
in this work since the recombinant vectors always were transformed immediately after 
 36
ligation. Typically 2-3 µl of the ligase mix was mixed with loading buffer and loaded on a 1 
% agarose gel for verification of expected migration lengths. After confirmation, 
transformation was performed according to section 2.1.1, using 5-10 µl of ligation mix.   
 
2.2 Electrophoresis 
 
Electrophoresis is movement of charged biomolecules in an applied external electric field. 
There are several suitable media, of which gels are the most commonly used for nucleic acids. 
Four types of gels have been used in this work, of which two have been used for RNA- and 
DNA-fragment-separation. 
 
2.2.1 Agarose gel electrophoresis 
 
Agarose is a linear polysaccharide made up of the basic repeat unit agarobiose, which 
comprises alternating units of galactose and 3,6-anhydrogalactose. It forms gels with pores 
ranging from 100-300 nm in diameter; ideally suited for low-resolution separation of 
relatively large molecules. When mixed with an appropriate buffer and heated until the 
powder has dissolved, the pore size mirrors the agarose content, which varies from 0,2-5% in 
general, with 1% as the most common, separating fragments from 300 bp-12 kb with ease, see 
table 2.1.  
 
Table 2.1: The range of separation of linear DNA molecules in 0,3-2,0% agarose gels. 
Amount of agarose in gel (% [w/v]) Effective range of separation of linear DNA molecules (kb) 
0.3 5-60 
0.6 1-20 
0.7 0.8-10 
0.9 0.5-7 
1.2 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
Data adapted from (Sambrook, 2001).  
 
Charged biomolecules will migrate through the pores towards the oppositely charged 
electrode, their rate of migration through the electric field depends largely on the strength of 
the field, size and shape of the molecules, relative hydrophobicity of the samples, and on the 
                                                                                                                                                                                     
1 1 x T4 DNA ligase-buffer: 50 mM Tris-HCl pH 7,5, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 µg/ml BSA 
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ionic strength and temperature of the buffer in which the molecules are moving.  
(Nucleic acids have a net negative charge, and will therefore migrate towards the positive 
electrode.) In all forms of electrophoresis, the force moving the macromolecule (nucleic acids 
or proteins), is the electrical potential, E. The electrophoretic mobility (E.M) of an ion is 
known as the ratio of the velocity of the particle, v, to the electrical potential: E.M = v / E. 
Electrophoretic mobility is also equal to the net charge of the molecule, Z, divided by the 
frictional coefficient, f: E.M = Z / f. The current in the solution between the electrodes is 
conducted mainly by the buffer ions with a small proportion being conducted by the sample 
ions. Ohm's law expresses the relationship between current (I), voltage (V), and resistance (R): 
R = V / I. This equation demonstrates that it is possible to accelerate an electrophoretic 
separation by increasing the applied voltage V, which would result in a corresponding 
increase in the current flow. The distance migrated will be proportional to both current and 
time. However, increasing the voltage would ignore one of the major problems for most forms 
of electrophoresis, namely the generation of heat. During electrophoresis the power (W, watts) 
generated in the supporting medium is given by W = R x I2. Most of this power generated is 
dissipated as heat. Heating of the electrophoretic medium can have the following effects: An 
broadening of the separated samples; mixing of separated samples caused by formation of 
convection currents, and thermal instability of heat-sensitive samples which may include 
denaturation of proteins or loss of activity of enzymes. Finally, a decrease of buffer viscosity 
and hence a reduction in the resistance of the medium may occur. The evident conclusion 
must therefore be to follow the golden middle path of low voltage and physiological pH for 
optimal agarose electrophoresis-assisted separation of nucleic acids. There are, of course, 
exceptions from the rule.  
The intercalating agent Ethidium bromide, EtBr, was used for visualisation purposes. EtBr 
binds between DNA base pairs and fluoresces when activated by UV radiation. To ease the 
sample loading procedure, the samples are mixed with an appropriate dye-containing loading 
buffer. The dye serves two purposes; it visualizes of the migration front and facilitates sample 
loading. (The buffer dye migrates faster than all samples, creating a colour front in the 
transparent gel, making it possible to estimate when the electrophoresis should be stopped). 
The loading buffer contains glycerol, making the blend heavier and thus easier to load into the 
wells of a gel that has been immersed in running buffer. Sample size (base pairs) is assessed 
using standards. In this work, the phage lambda DNA was cut with the HindIII or BstEII 
restriction enzymes, to give two useful broad range size standards. We also used two 
commercial standards; the 1kb and the 100 bp ladders from New England Biolabs. 
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Protocol (1 % TAE- gel) 
 
1 g of 99,9% pure agarose powder is boiled in 100 ml of 1x Tris-acetate-Ethylene Diamine 
Tetra-acetic Acid (EDTA) buffer until the powder is completely dissolved, typically 2-3 
minutes. The liquid is thereafter cooled until it holds ≈ 60°C, then EtBr may be added to 0,1-
0,2 µg/ml, and the liquid poured into a plastic casting tray with pre-inserted comb. The comb 
once removed, samples are mixed with an appropriate loading buffer and loaded into the wells 
of a gel that previously has been immersed in running buffer. Gels are run in 1x TAE buffer at 
60-100 V until the coloured dye has migrated three quarters of the gel, and then photographed 
using UV illumination. In this work, the bands were photographed using the BIO RAD 
GelDoc 1000.  
 
2.2.2 Polyacrylamide gel electrophoresis 
 
Raymond and Weintraub introduced the polyacrylamide gel electrophoresis (PAGE) 
technique in 1959. This high-resolution electrophoresis method is able to separate single-
stranded DNA molecules that differ in length by just one nucleotide, making it amenable to 
nucleic acid sequence determination as well as separation of nucleic acids and proteins. 
A polyacrylamide gel consists of chains of acrylamide monomers, cross-linked with 
N’N’methylenebisacrylamide, or “bis” units. Pore size depends both upon the total 
concentration of monomers, (including bis), and the ratio of acrylamide to bis, typically 19:1 
for a sequencing gel. The separation of proteins and peptides takes place in gels typically 
ranging from 8-15% PA content, whilst nucleic acids are electrophoresed in gels with 5-
12,5% [w/v] acrylamide, see table 2.2. The cross-linking reaction is oxygen-sensitive and 
polymerisation needs Ammonium Persulfate (APS), and TEMED (N’,N’,N’,N-
tetramethylethylenediamine), as initiator and catalyst, respectively. When nucleic acids are 
separated in PA gels, different MW-sizes are used due to the narrower resolution range of the 
PA-gels. The ϕX174 DNA cut with HindIII was used as MW-standard upon electrophoresis 
of nucleic acids in this work. (Protein gel electrophoresis is discussed in more detail in section 
2.2.3.) Various additives serve alternative purposes, as the addition of urea denaturates duplex 
DNA in a sequencing gel, and the addition of the detergent Sodium Dodecyl Sulphate, (SDS), 
in protein PA-gels where we wish to focus on protein size; not charge. (SDS binds to and 
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unfolds the protein, creating an overall negative charge independent of native dimensions, but 
largely proportional to peptide length.) For protein separation, we often wish to optimize the 
resolution of the separating gel. This can be achieved with a glycine/Cl-stacking gel, making 
all samples enter the separating gel at the same time point. When the electric field is 
established, chloride, protein, bromophenol and glycinate ions all begin to move toward the 
anode. Due to the low pH, glycinate ions (weak acids with pKa below the pH of the stacking 
gel buffer) will be present as their equivalent non-ionic zwitterions that are immobile. Failure 
of glycine zwitterions to move into the stacking gel creates a deficiency of mobile ions. 
However, a constant current must be maintained throughout the entire electrical system. This 
is accomplished in the area between the leading chloride ions and the trailing glycinate ions 
by an increase in voltage. The result is a very high voltage gradient occurring between the 
chloride ions and the glycinate ions. In this condition the relative ion mobilities are 
glycinate<protein<bromophenol blue<Cl-. In this strong local electric field the anionic 
proteins all migrate rapidly through the large pores of the stacking gel which do not impede 
their progress. If any of the proteins overtake the chloride ions, they slow down because 
wherever there are chloride ions there is no ion deficiency. Thus all samples enter the 
separating gel at the same time, and the higher pH reforms glycinate ions. This balances the 
ion deficiency. Additional details and protocols for SDS-PAGE on protein samples can be 
found in section 2.2.3. 
 
Table 2.2: The range of separation of linear DNA molecules in 3,5-20,0 %[w/v] acrylamide gels. 
Acrylamide  
(% [w/v])a 
Effective range of separation (bp) Xylene cyanol FFb Bromophenol blueb 
3.5 1000-2000 460 100 
5.0 80-500 260 65 
8.0 60-400 160 45 
12.0 40-200 70 20 
15.0 25-150 60 15 
20.0 6-100 45 12 
a    N,N’-methylenebisacrylamide is included at 1/30th the concentration of acrylamide.  
b    The numbers given are the approximate sizes (in nucleotide pairs) of fragments of double-stranded DNA with 
which the dye co-migrates.  
Data adapted from (Sambrook, 2001). 
Standard Protocol for 7,5% Polyacrylamide gel 
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Work in a ventilated hood, and always clean the glass plates with isopropanol before 
assembly. Mix the reagents from table 2.3 adding TEMED as the final ingredient. 
 
Table 2.3: Standard recipe for a 7,5% PA gel. 
Acrylamide 40% 1,125 ml 
1 x Tris-Acetate-EDTA (TAE) 4,8 ml 
APS 20% 45 µl 
TEMED 10 µl 
 
Swirl container to mix contents and pour into the premade plastic or glassware form. Finish 
by inserting a clean comb of choice. The gels were run at 200 V at room temperature in 1 x 
TAE buffer in electrophoresis equipment from BIO-RAD. DNA and RNA-fragments were 
visualized using 3-6 µl of the intercalating dye SYBR Gold (Molecular Probes). This dye is 
comparable to Ethidium bromide, intercalating between base pairs in the nucleotide sequence. 
It is however less toxic and more sensitive to light. It is most often added to 5-10 ml running 
buffer containing the gel after the run, in contrast to EtBr. 
 
2.2.3 Electrophoresis of proteins 
 
The percentage of acrylamide in a PA gel determines its resolution range (table 2.4). 
 
Table 2.4: Relation between acrylamide percentage and range of protein separation for a PA gel. 
Acrylamide percentage Range of separation 
8% 36-94 kDa (7,5%) 
12% 15-50 kDa 
15% 12-43 kDa 
Data adapted from (Sambrook, 2001). 
 
We chose 12 and 15% gels since our expression products had molecular weights of 21-28 
kDa. The gels were cast as described for a 7,5 % PA gel, using the recipe from table 2.5. 
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Table 2.5: Recipe for 12% SDS PA gel with 5% concentrating gel. 
12% separating SDS PA-gel: 
 
Acrylamide 30% 2,0 ml 
1M Tris pH 8,8 1,9 ml 
SDS 10% 50 µl 
APS 20% 25 µl 
H2O 1,1 ml 
TEMED 2 µl 
 
5% concentrating gel: 
 
Acrylamide 30% 0,5 ml 
1 Mtris pH 6,8 0,67 ml 
SDS 10% 40 µl 
APS 20% 20 µl 
H2O 2,7 ml 
TEMED 4 µl 
 
10 µl of supernatant was mixed with an equal amount of 2x loading buffer, while pellets were 
dissolved in 20 µl loading buffer. All samples were boiled at 95°C for 5 minutes, spun briefly 
in a benchtop centrifuge and loaded onto a 12% SDS-PA gel with slim pipette tips. Protein 
molecular weight standards are often pre-stained for ease of detection. In this work, two such 
commercially available standards were used; the broad range (6,7-208 kDa), and the dual 
color ‘Precision Plus’ (10-250 kDa), both from BIO-RAD. The gels were run at 15mA for 30 
minutes, then 30 mA to end at room temperature. Proteins were fixed for 15 minutes in a 
Coomassie fixing solution, stained with Coomassie Brilliant Blue staining solution for 60 
minutes, and destained over night using the fixing solution. (Please see the appendix for all 
recipes.) Coomassie Brilliant Blue has a downward resolution of 0,1 µg or 2 pmol protein for 
visualization in a gel, making this a crude visualisation method applicable to bacterial lysates. 
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2.2.4 Purification of DNA from agarose gel slices 
 
Isolation of DNA fragments from agarose gel slices was performed using the QiaQuick Gel 
Extraction Kit from Qiagen. The slice of gel containing the band of interest is resuspended in 
a saline buffer at 50-60°C. The buffer in question contains a pH-sensitive dye in addition to 
guanidine thiocyanate (a strong protein denaturant) and chaotropic salts. The solution is 
loaded onto a spin column with a DNA-binding silica-membrane, which eases further EtOH-
wash and elution using 10mM Tris-Cl or Tris-EDTA (TE) pH 7,5-8,5. For a detailed protocol, 
please see the Qiaquick handbook at http://www.qiagen.com. 
 
2.3 Polymerase Chain Reaction 
 
The PCR method enables amplification of nucleic acid sequence fragments in vitro by primer 
extension (Mullis et al., 1986). Briefly, a pure DNA fragment or equivalent material from 
other non-purified sources such as bacterial colonies or phage plaques can be amplified in 
vitro, by mimicking the in vivo DNA polymerase replication machinery. The cyclic process 
includes three repeated temperature-regulated levels plus pre- and post-preparation steps. 
First, the samples containing the double strand fragment of interest is denatured at 95°C or 
higher for 15-240 seconds, permitting 18-24 bp sequence-specific oligomers called primers to 
attach to the single stranded template at the lower annealing temperature at step two, lasting 
for 30-60 seconds. (The latter temperature can be estimated by various methods, but often 
equals the template-primer melting temperature (Tm) -5 degrees, ranging from 40 to 60°C, and 
needs to be optimized in most cases.) An included DNA polymerase attaches at the primer 
site where DNA is double stranded, and completes the remaining sequence in the elongation 
step. This temperature is the optimal for the chosen enzyme, and usually lies around 72°C. 
Deoxynucleotide trisphosphates, specific salts needed for enzymatic activity (MgCl2 or 
MgSO4), and necessary additives ensure proper PCR product formation. The cycle is repeated 
typically 15-40 times in a thermal cycler. Since amplified products from the previous cycle 
serve as templates for the next cycle of amplification, PCR is an exponential process, 
following an exponential curve from cycle #2. At each step, 2n new copies of the template are 
produced, where n is the number of cycles. PCR can be illustrated with the formula N= N0 x 
2n, where N is the number of amplified molecules; N0 represents the original molecule 
number and n the number of cycles. In a typical reaction, 104-106 copies of the initial DNA 
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template will be produced. PCR is a sensitive and potent tool used in all sorts of biological 
research, and has been utilised extensively in the DNA work of this study. A number of 
factors can improve the reaction, typically primer- and template design and template amount 
as well as magnesium concentration. Adding formamide, betaine, DMSO and/or glycerol 
have been successful. (Their proposed mechanism is to lower the DNA melting temperature, 
thereby enabling improved elongation and accuracy. Fully melted DNA hinders elongational 
arrest or enzyme throw-off caused by difficult secondary structures.) The magnesium 
concentration directly affects the polymerase activity, making metal complexing salt buffers 
with high EDTA content unwanted as DNA dilution liquid. The MgCl2 or MgSO4 
concentrations should be optimized for each individual reaction. Generally, excess Mg2+ will 
result in the accumulation of non-specific amplification products and insufficient Mg2+ will 
reduce the yield of wanted PCR product. Adding Bovine Serum Albumine (BSA) and non-
ionic detergents such as Tween20 may stabilise the enzyme. The identity of the latter is often 
critical, and temperature-activated, or so-called thermostable polymerases, are preferred. 
Some, like the PfU polymerases (derived from the thermophilic archae Pyrococcus furiosus), 
have 3’Æ 5’ proofreading activity in addition to the 5’Æ 3’ activity provided by the Taq 
polymerases, derived from the thermophilic bacterium Thermus aquaticus. Most commercial 
heat-stable polymerases may be combined with an antibody that binds to the enzyme at lower 
temperatures, thus inhibiting the polymerase activity until the tubes have been put into the 
thermal cycler. This hot start-method is the most common, minimizing the risks and amount 
of labour needed. Throughout this work, both heat-stable Taq and PfU polymerases have been 
provided by Dr. David J. Warren, The Norwegian Radium Hospital. 
A standard PCR reaction mix:  
(All concentrations are final. MgCl2, primers and buffer were vortexed prior to use.)  
1-50 ng of template DNA 
1 x PCR buffer (10 mM Tris-HCl, pH 8.8, 50mM KCl (or NaCl), 0,08% (v/v) NP-40) 
2,5 mM MgCl2 
0,1-0,5 µM of each primer 
0,2mM dNTP 
1-2 Units of thermostable polymerase 
Volumes usually range from 20-100 µl. If the MgCl2 stock solution has been through many 
freeze/thaw-cycles, it may be heated to 90°C for 10 minutes to restore the homogeneity of the 
solution, (Hu et al., 1992). All PCRs in this work were done using the GeneAmpR PCR 
System 2400/9700 with 0,2 ml tubes (both from Perkin Elmer). 
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2.3.1 Handling of PCR products 
 
PCR reactions should be set up in a designated area, preferably an isolated room where the 
products will be stored later. Volatile PCR products (aerosols) can contaminate reactions and 
laboratory equipment, and sample tubes should therefore be kept closed or opened only in 
“secure” areas (hoods, clean benchtops etc), and separate pipettes should be used for products. 
 
2.3.2 Primer design 
 
The choice of primers for plasmid constructs depends on the identity of the template. 
Precautions ought to be taken to avoid primer-dimer formation and hence poor performance, 
for instance a high GC-content at the 5’end, and neither non-complementary sequences nor 
high GC content at the 3’-ends. Restriction enzyme-sites can be added to the template using 
5’ overhanging primer ends, which will be used for later cloning purposes. It is common to 
use overhangs with such sites and subsequently cut the PCR product with appropriate 
restriction enzymes before inserting the readily cut PCR product into a vector of choice. This 
method was used several times in this work. Estimation of the melting temperature Tm is 
crucial, and various computational methods exist. (At Tm, 50% of the primer and its 
complementary single strand sequence are present in a DNA duplex.) Most important; cycling 
conditions and buffer concentrations should be optimized for each primer pair. 
 
2.3.3 Purification and analysis of PCR products 
 
PCR products were purified using DNA-binding spin column-based kits from Qiagen. 
A guanidine hydrochloride/isopropanol-buffer is mixed with the PCR reaction, and the blend 
loaded onto a spin column. Basically, denaturated impurities pass through the DNA-binding 
silica membrane, whereas the amplified DNA does not. EtOH-wash and elution in a 10 mM 
Tris or TE pH 8,5-solution follows to give a reasonably pure preparation. This method is not 
as thorough as purification from gel (because other DNA fragments are not removed during 
the spin column purification), and should be avoided when further high purity-applications 
(sequencing, blunt end cloning) are considered. Amplified PCR products were analysed using 
1,5-2% agarose gels or polyacrylamide electrophoresis (PAGE) as described earlier. The 
products were always stored at 4°C. 
 45
2.3.4 Colony PCR for transcription/translation analysis  
 
A quick and easy way of screening a large number of bacterial colonies is by direct PCR, 
evading the purification prep and further agarose gel electrophoresis of a good number of 
possibly negative samples. The template for each reaction is simply a minuscule amount of 
each colony to be tested. A pipette tip or a sterile toothpick may be used to touch a colony of 
choice, and the tip is left in sH2O for the template to dissolve. The tip is removed, and the 
template-containing water mixed with remaining PCR reaction ingredients. Insert-specific 
primers should be used in a standard PCR as described in previous sections. For optimal 
results, it is common to denaturate the bacterial template at 94-99°C for 4 minutes before the 
premier PCR cycle. An important point is the amount of template loaded, as too much 
bacteria will easily inhibit the PCR. 0,7-2% agarose- or PAGE electrophoresis can be applied 
to 2-5 µl of the PCR reaction. 
 
2.3.5 End phosphorylation of a PCR product with T4 polynucleotide kinase  
 
The polynucleotide kinase (PNK) from the bacteriophage T4 catalyzes the transfer and 
exchange of Pi (inorganic phosphate), from the γ position of ATP to the 5´ hydroxyl terminus 
of polynucleotides (duplex and single-stranded DNA and RNA), and nucleoside 3´-
monophosphates. PNK also catalyzes the removal of 3´- phosphoryl groups from 3´-
phosphoryl polynucleotides, deoxynucleoside 3´-monophosphates and deoxynucleoside 3´-
diphosphates (Engler, 1982). T4 PNK was used for radioactive labelling in this work, please 
refer to section 2.6.6. For non-radioactive phosphorylation, up to 300 pmol of 5´ termini in a 
50 µl reaction containing 1 x T4 PNK Reaction Buffer2, 1 mM ATP and 10 units of T4 PNK 
is recommended. The efficiencies of blunt and recessed 5´-end phosphorylation can be 
improved by heating to 70°C for 5 minutes, then chilling on ice prior to kinase addition and 
by adding PEG-8 to 5% (w/v) (Sambrook, 2001). Since PNK is inhibited by ammonium ions, 
DNA was not precipitated in the presence of ammonium ions prior to phosphorylation. The 
following protocol was used for the creation of the pFastBacHTa/COAS2 vector, but the 
method is applicable in general to all kinds of blunt-end PCR products. 
                                                          
2 (70 mM Tris-HCl, 10mM MgCl2, 5 mM DTT) 
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Standard protocol 
 
2 µg in a total of 71 µl of H2O was heated to 70 °C for 5 minutes and then chilled on ice. 10 
µl of (700 mM Tris, 100 mM MgCl2) pH 7.6 was added and resuspended before the addition 
of fresh 5 µl 100 mM DTT and 10 µl 10 mM AdenosineTriPhosphate, (ATP). 4 µl (40 U) of 
T4 PNK was added. After gentle mixing, the reaction mix was incubated for 30 minutes at 37 
°C. The products were purified according to sections 2.3.3 and 2.2.4. 
 
2.4 Sequencing 
 
The dideoxy, or chain termination method from Sanger (Sanger et al., 1977) was used along 
with automated MEGA BACE 500 sequencing kits and DYEnamicTM ET dye reagents from 
Amersham to determine nucleotide sequences. In the dideoxy method, the fluorophore-tagged 
2’3’dideoxy analogues of the 3’deoxy nucleoside trisphosphates act as specific chain-
terminating inhibitors for the included DNA polymerase. Each NTP has an individual tag, 
(e.g. red fluorochrome for ATP, blue for GTP), improving the assay accuracy and enabling all 
reactions to take place in a single tube. As mentioned, a commercial sequencing kit was used, 
but the producer has not published the composition of the DYEnamic mastermix. 
The reaction is mainly a single 30-cycle PCR where primer and template is mixed with the 
mentioned mastermix containing ddNTPs, Mg2+, a saline buffer (probably Tris-HCl and 
alkaline salts), and polymerase. The product is precipitated with 7,5 M ammonium acetate and 
70% EtOH, centrifuged, washed and air-dried. The pellet is resuspended in 10 µl loading 
solution before the run (70% formamide, 1mM EDTA). The MEGA BACE instrument 
performs capillary electrophoresis, where the sample electrophoretically migrates through 
tubes with separation matrix, (3% linear polyacrylamide in 1x Tris-Borate-EDTA (TBE)). 
The laser beam scans the capillaries continuously, exciting the fluorochrome tags. The 
emitted photons are filtered through six beamsplitters, leading to their respective 
photomultiplier tubes (PMTs). The light is converted to electrical pulses, that again are 
digitized to give an electropherogram (raw data), for each capillary. Taken together, the raw 
data gives us the readthrough sequence for the user to analyze with the Sequence Analyzer 
software v3.0 from Molecular Dynamics. In a typical plasmid sequencing reaction, vector 
primers flanking both ends of the gene of interest were used along with 400 ng of template, 
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generating products of 5-800 bases in each reaction. For a more detailed sequencing PCR 
procedure,please see http://www5.amershambiosciences.com. 
 
2.5 Sequence analysis 
 
All database searches for either nucleotide- or amino acid sequences including homology 
searches were performed using variants of the Basic Local Aligment Search Tool (BLAST) at 
the National Center for Biotechnology Information (NCBI) website (Altschul et al., 1990). 
Aligning a pair of nucleotide sequences was done using the Blast2 tool, which finds multiple 
local alignments between the two sequences (Tatusova and Madden, 1999). The primers used 
in this work were created with the Informax Vector NTI suite 8. Additional protein and 
mRNA knowledge was extracted with various online services; please refer to the appendix 
section. All online services used in this work are accessable through URLs listed in the 
appendix. 
 
2.6 Expression analysis 
 
Working with RNA 
 
Ribonucleic acids are widespread molecules with multiple and dynamic functions. Working 
with and purifying RNA demands that some precautions should be made. First, all samples 
and RNA equipment should be shielded from RNAses, the latter existing e.g. on glassware 
and fingers. Second, the RNA should be kept on ice when possible, and stored at -80°C. 
Water was treated with diethylpyrocarbonate (DEPC) before autoclaving. DEPC reacts with 
histidine residues in the enzymes, thereby inhibiting their harmful activity. After autoclaving, 
DEPC is hydrolyzed to form CO2 and EtOH. All of the equipment, except glass, was treated 
with RNAseZAP before use to remove all traces of RNAse. This is a solution from Sigma of 
unknown exact composition, but its material safety data sheet states the existence of three 
different agents, of which some have oxidizing effects, with known inhibitory effects on 
RNAses. Electrophoresis trays were treated with SDS and DEPC-water between runs. 
Compounds with primary amine groups, e.g. Tris, may not, however, be DEPC-treated as they 
react with and thus inhibit DEPC. (See further details on RNAses and DEPC-treatment at 
http://www.ambion.com/techlib/tb/tb_178.html.) Most importantly, preferentially non 
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powdered gloves were always used and changed often when handling RNA. 
 
2.6.1 Isolation of total RNA 
 
For all applications, the biochemical Trizol from Invitrogen was used to isolate Total RNA 
from cell material. As described by Chomczynski and Sacchi (1987), the monophasic reagent 
contains the carcinogenic phenol in mixture with guanidinum thiocyanate, (GTC), a toxic, 
protein-denaturating compound. Trichloromethane (chloroform) is added to create two phases 
after agitation. The organic phase holds denaturated proteins and DNA, whilst RNA and some 
contaminating DNA are present in the aqueous phase. (DNA levels are kept low if the amount 
of Trizol is increased. Here, 1,2 ml Trizol was used for 107 cells). After centrifugation, total 
RNA is precipitated with isopropanol, followed by washes with 75% ethanol, air-drying of the 
pellet and resuspension in a proper solvent. At the time of harvest of the cell flask, the cell 
pellets were most often resuspended in Trizol and the container immediately snap-frozen in 
liquid N2. Working in a ventilated hood, the cell pellets in Trizol reagent were thawed on ice 
and then homogenised with a pipette. Because the RNA would be used for micro array 
analysis after a short pause in the freezer, sterile water was always used to dissolve the pellet, 
even though TE or sarcosyl may be preferable to limit the extent of degradation and RNA 
loss. It is important to register that TE may not be garanteed to be free of RNAses (please see 
previous paragraph). All RNA samples were quantified with the Pharmacia Gene Quant 
apparatus, or the NanoDrop apparatus (Nano Drop Technologies). The latter has a detection 
range from 2 ng/µl-3,7 µg/µl, and needs merely 1 µl for quantification. 10 million cells would 
give 350-400 µg of RNA, typically. For detailed and updated protocols, please refer to the 
suppliers’ homepage at http://www.nanodrop.com. All RNA samples were assayed for quality 
with the Agilent BioAnalyzer. This advanced miniature gel electrophoresis system also holds 
quantitation functions. Solutions between 0,05 and 0,4 µg/µl RNA may be used, requiring 
merely 1 µl for a run in the predyed gel system. The protocol from the supplier for the RNA 
6000 Nano Chip was followed. Please see http://www.agilent.com for further information 
regarding the BioAnalyzer and its applications. 
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Figure 2.2: Picture from the BioAnalyzer software showing a pure eukaryotic total RNA preparation  
(upper case) and a degraded sample (lower case). The peaks at 24, 44 and 49 seconds represent 5S, 
18S and 28S RNA, respectively. 
 
2.6.2 Introduction to the northern blotting method 
 
Expression analysis at the RNA level is mainly focused on detection of post-transcriptionally 
modified mRNAs in a sample. In the northern blotting technique, negatively charged, 
separated RNA preparations are transferred from an agarose gel to a positive nylon membrane 
by capillary forces (see figure 2.3). After transfer, the nucleic acids can be fixed to the 
membrane using either brief ultraviolet (UV) irradiation or heating at 80°C for about half an 
hour. The RNA filter can now be hybridized to a radioactive-labelled RNA/DNA probe in a 
strong saline solution at a fixed pH and temperature. Autoradiography gives hybridised bands 
corresponding to the specific mRNA in each sample. 
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2.6.3 Agarose gel electrophoresis of RNA 
 
Messenger RNA (mRNA) is much smaller than genomic DNA, so it can be analyzed by 
agarose gel electrophoresis without the enzymatic digestion steps that are necessary for the 
analysis of high molecular weight DNA applied in the Southern blot method. 1% agarose gels 
containing the denaturant formaldehyde are used to separate RNA electrophoretically. 
Formaldehyde forms unstable Schiff bases with the single imino group of guanine residues, 
thereby preventing intrastrand base pairing. The binding of RNA to formaldehyde is strongly 
affected by changes in pH (Sambrook, 2001). During electrophoresis, a pH-gradient is 
established in the buffer system, making formaldehyde-assisted denaturation of RNA 
difficult. This negative effect may be prevented by recirculation of the buffer through the 
formaldehyde gel during electrophoresis. For a 300 ml gel, 3 g agarose, 6 ml 1M sodium 
dihydrogenphospate (NaH2PO4) pH 6.6, and 240 ml DEPC-treated H2O are mixed and heated 
in a microwave oven to dissolve the agarose. After cooling to ≈ 60°C, 54 ml formaldehyde 
and 4,5 µl of 10 mg/ml EtBr are added in a secure ventilated hood to avoid the inhalation of 
harmful vapours. In general 2-10 µg of total RNA is loaded onto each lane of the agarose gel 
(after denaturation at 65-70°C for 10 minutes), using a loading buffer containing formamide. 
The running buffer (20 mM NaH2PO4 pH6.6) is recirculated in the formaldehyde gel during 
the 10 V run, thus maintaining a stable pH throughout the gel over night. The gel is run at 30-
35 V until the samples have entered the gel, and then at 10 V until the next morning. At this 
point, the electric pump was switched on for buffer recirculation and the jet properly adjusted. 
In this work, the gel was visualized with the GelDoc instrument (BIO-RAD) after 
electrophoresis, followed by a 30 minute-wash in 10 x Standard Saline Citrate (SSC).  
 
2.6.4 Blotting from gel to filter 
 
Transfer of RNA from the gel and onto the nylon membrane over night was performed as 
illustrated, placing the gel upside down on a buffer-soaked pad of Whatman filter paper. On 
top of the gel, we put a Hybond N+ nylon filter (Amersham Pharmacia Biotech), and another 
Whatman paper again followed by large amounts of dry absorbing paper with a small weight 
to ensure tight transfer. The RNA is carried along through the gel and onto the nylon filter as 
the mobile phase, (10 x SSC buffer), migrates upwards, towards the weight, see illustration 
below. 
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Figure 2.3: Schematic representation of a capillary blotting apparatus. Capillary forces mediate 
transfer of the nucleic acids from a formaldehyde-agarose gel to a filter paper. The mobile phase 
(saline solution) is drawn towards a weight placed on top of a stack of dry paper towels. Passing 
slowly through the gel, the solution solubilizes the nucleic acids and transfers the latter to the above 
filter paper.  
 
2.6.5 Preparation of RNA membranes for hybridisation 
 
After gel visualisation, the wells’ positions were indicated on the filter using a soft pencil. 
(The picture ideally should indicate that no RNA is left in the gel, but this is made difficult 
because of both the 30’ SSC wash and the background caused by remaining formaldehyde.)  
Fixation of the RNA to the nylon filter was performed using 70 mJ UV light for 45 seconds. 
The filter was then soaked in 50 mM NaH2PO4 pH 7.2, and pre-hybridised in a glass container 
containing Church hybridisation buffer3 at the given temperature. The filter is “polar”, having 
most of its RNA on one side. This has to be facing away from the glass to obtain optimal 
hybridisation results. The container is kept in a rolling incubator at a set temperature.  
 
2.6.6 Probe synthesis and purification 
 
cDNA probes intended for use with the Church hybridisation method should ideally have a 
final undiluted concentration of 25-50 ng/µl. In this work, 25-50 ng was used for all 
hybridisations where [α-32P]-dCTP was the radioactive reactant. Accession numbers for all 
the probes are located in the appendix section. 
 
cDNA clones for the Homo sapiens sex determining region Y (SRY)-box transcription factors 
L-SOX5, SOX6 and SOX9 were ordered from the Ressourcenzentrum für Genomforschung 
                                                          
3 (0,5M Na2HPO4 pH7.2, 7% SDS, 1mM EDTA) 
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(RZPD), Germany, and shipped in LB-agar containing bacteria which harboured the 
recombinant plasmids. (Unigene accession numbers are located in the appendix section.) 
Some of the shipped LB-agar was diluted in warm LB-medium, grown over night and 100 µl 
dispensed on LB-plates containing 50 µg/µl ampicillin. (SOX5 and -6 were present in the 
pOTB7 and pCMVsport6 plasmids, respectively, that both harbour an ampicillin-resistance 
gene.) The SOX9 gene was shipped as a cDNA clone in the T7T3PacI plasmid, necessitating 
25 µg/µl chloramphenicol for selective growth in LB-medium. All three SOX-factors each 
gave rise to several clones that were picked on the following day with a sterile pipette tip, 
dissolved in LB-medium and grown over night to create culture stocks for miniprepping and 
restriction enzyme analysis. Subsequently, maxipreps were made as described in section 
2.1.2. Sequencing confirmed the identities of SOX5, -6 and -9 at both mini- and maxiprep 
stages of purification. Probes were made for northern blotting using restriction enzyme 
digestion of 6 µg plasmid DNA with two appropriate enzymes in each case (35-40 units of 
each enzyme). 2 hours of incubation at 37°C was promptly followed by gel purification 
according to section 2.2.4. After quantification, the probes were diluted to a duplex DNA 
content of 25-50 ng/µl. 
 
A purified COAS2 495 bp cDNA of 32 ng/µl was used for all blots. Another probe used for 
hybridisation held 1000 bp of the collagen type two alpha one (COL2A1), of 25 ng/ µl.  
 
2.6.7 Probe labelling (Modified from Feinberg and Vogelstein, 1983) 
 
25-50 ng DNA or cDNA fragment was mixed with 1 µl (25 µg/µl) dN6 primer and sterile 
water to 10 µl. The blend was boiled for 4 minutes to denature the fragment, and cooled on 
ice, thereby annealing the primer to the single stranded fragments. Subsequently, 4,5 µl 5 x 
OLB buffer4, 1 µl 3mM dNTPs-C, 3 µl “Redivue” [α-32P]-dCTP 3000Ci/mmol solution 
(Amersham Biosciences, containing a red dye and β-mercapthoethanol), and finally 1 µl of 
(5U/µl) Klenow polymerase were added before incubation took place at either room 
temperature for 2-5 hours or at 37°C for 0,5-2 hours. A cleanup after the probe synthesis was 
performed with Sephadex G50 gel separation columns. 5 µl of NT stop solution (600 µl 25 
mg/ml blue dextran, 50 µl 10% SDS, 50 µl 0,5M EDTA) was added before the probe was 
applied onto the homemade column. The blue fraction, containing the dextran and probe, will 
                                                          
4 250 mM Tris-HCl pH 7.6, 25 mM MgCl2, 1 M HEPES 
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be excluded from the gel pores due to the large MW, and will therefore migrate fast through 
the column, in contrast to the small molecules in the red fraction. Elution was halted after 
collection of the blue fraction, followed by a Geiger counter control of the probe. Good 
incorporation should give 2 times the signal when the column containing non-incorporated 
[α-32P]-dCTP and the collected probe are measured from the same distance with the Geiger 
counter, (e.g. 100 cps for the probe, and 50 for the red column, containing non-incorporated 
[α-32P]-dCTP). After pre-incubation (10-15 minutes), the Church solution (0,5M Na2HPO4 
pH7.2, 7% SDS, 1mM EDTA) was changed. The probe was heat-denaturated for 4 minutes in 
boiling water, and immediately added to the warm Church solution. The main hybridisation 
period typically lasted 12-20 hours. 
 
2.6.8 Wash 
 
The following morning, the buffer was changed for pre-heated Church wash solution, 
(1%SDS, 40mM Na2HPO4 pH7.2). Two 10 minute-washes at 65°C followed by a final 15’ 
wash at RT with gentle shaking were used in general. This could however vary from probe to 
probe. The remaining radiation was measured with a Geiger counter, and the filter prepared 
for autoradiography. 
 
2.6.9 18 S rRNA hybridisation 
 
To assay RNA sample loading and enable quantification of the band intensities, an 18S rRNA 
oligonucleotide was hybridised to the chosen filter, as performed by (Maelandsmo et al., 
1996)). All hybridisations and washes were performed exactly as the above, but at 55°C, with 
shorter incubation times (2-4 hours). A synthetic single strand-oligonucleotide without a 
5’PO4 group was phosphorylated using [γ-32P]-dATP. Labelling with the polynucleotide 
kinase (PNK) from the bacterial virus T4 takes place at 37°C, and no clean up or heat 
inactivation of the enzyme is needed. 1 µl (50 ng/µl) 18 S oligo, 1 µl 10 x PNK buffer (recipe 
found in the appendix), 2-3 µl “Redivue” [γ-32P]-dATP (3000 Ci/mmol, Amersham 
Biosciences), 1 µl (10 U/µl) T4 PNK and sH2O to 10 µl was gently mixed and incubated at 
37°C for 30-45 minutes. 90 µl of 1 x TE was added to halt the reaction before the 
incorporation of [γ-32P]-dATP was measured using two Diethylaminoethyl (DEAE) cellulose 
membranes (NA 45, Schleicher & Schuell). One µl was applied onto each DEAE-filter. Only 
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filter #1 was washed three times in 5 ml 0,5 M Na2HPO4 pH7.2, before both filters were 
measured using a Geiger counter. The difference between these two will ideally give a ratio of 
70-80 % under optimal conditions. Unincorporated nucleotides do not have to be removed 
prior to incubation. The probe was added to the filter-containing glass tube, and hybridised to 
the filter as described in this paragraph. 
 
2.6.10 Strip of radioactivelly labelled filters 
 
Removal of radioactive probes before new hybridisations was done regularly in this work. 
The filter was washed in a rocker for 10 minutes in 80-90°C RNA strip solution (0,1 x SSC, 
0,1% SDS), before measurement of radiation and further use or storage at -20°C.  
 
2.6.11 Autoradiography and quantification 
 
The membranes were wrapped in plastic and put with a sheet of sensitive film (X-OMAT UV-
film, KODAK), into film cassettes with intensifying screens. After exposure at -80°C, the 
films were developed in the automated 3M Xp515 developer and bands quantified using the 
18S signals. In this work, the Molecular Dynamics Personal Densitometer SI connected to a 
PC with the GeneQuant software was used for the quantification. The northern blot 
procedure has its weaknesses; only moderately abundant mRNAs can be detected. Total RNA 
was used for all downstream applications in this work, even though verification of candidate 
genes after microarray analysis using the northern blot method would benefit from increased 
sensitivity. To obtain optimal sensitivity, the RNA preparation can be enriched for mRNA, a 
fraction that ordinarily makes up less than 10% of the total RNA content of a cell or tissue. By 
removing all RNA molecules that lack the 3´polyadenine tail, the sensitivity will be highly 
increased (Aviv and Leder, 1972).  
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2.7 Microarray analysis 
 
There are many types of arrays, from tissue and protein microarrays via carbohydrate and 
genomic to cDNA and oligonucleotide arrays. Only two-channel cDNA spotted microarrays 
were used in this work. A cDNA-microarray slide has several thousand spots (Ø < 300 µm) 
printed in a grid on a coated surface. Each spot contains PCR products or synthetically 
generated nucleotide sequences, double or single stranded. The cDNA to be probed is made 
from mRNA in a reverse transcriptase reaction. It consists of test and reference total RNA 
(e.g. cell line or tumour material). Visualisation of the results is made possible through 
incorporation of fluorescent dyes (fluorochromes with known excitation and emission 
spectra), typically Cy3 and Cy5 (in this work from Amersham Biosciences containing NHS-
ester leaving groups). When the single strand Cy-dye tagged nucleotide sequence is 
hybridised to the array, the fluorochrome-tagged cDNA will bind in a stoichiometric fashion 
to the cDNA in each spot. After wash and scan of the slide, the picture gives a ratio in each 
spot between the Cy5-and Cy3 channels. This ratio indicates the relative abundance of 
specific mRNAs in each sample. A Cy3-tagged sample will emit in the green spectrum, whilst 
Cy5-tagged material will seem red on the computer screen. (The colours have been artificially 
created, as each raw picture has no colour, i.e. is grey.) A raw image is seldom completely 
trustworthy due to spot variation, uneven incorporation of dyes and perhaps different cDNA 
masses in reference and sample. One must therefore filter bad spots and normalize the ratios 
in order to quantify and analyze the sample’s mRNA profile correctly. It is common to apply 
log2-transformed ratios, because this creates a model of up- and down-regulated mRNAs in 
the sample versus the reference that is more easily interpreted. To illustrate an array image, 
we could imagine a sample where the tumour suppressor gene coding for the p53 protein was 
deleted, compared to a p53-containing reference. If the sample has been tagged with Cy5-dye, 
then the lack of p53 mRNA will cause a green spot to occur, because there is only p53 in the 
Cy3-tagged reference. This example fully illustrates the necessity of p53 (or any other gene of 
interest for that matter) to be printed on the actual array, and to be expressed in the reference 
to give a reliable measurement. Otherwise, we would never detect a lack or excess of our gene 
of interest. 
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Figure 2.4: An overview of the DNA microarray procedure. Picture courtesy of Amersham  
 
 
 
 
 
 
 
 
Figure 2.4: The process of microarray hybridisation. The cDNAs are printed in a regular array onto 
glass slides. The test and reference RNA samples are labeled with different fluorochromes and 
combined before they are hybridised to the processed microarray. After stringent washes, the 
microarray is scanned in a laser-scanner device, and the image processed to generate numerical data. 
Figure from (Meltzer, 2001a). 
 
2.7.1 Probe preparation, hybridisation and wash 
 
Twenty micrograms of test- and reference total RNA was labelled with the indirect aminoallyl 
labelling technique, which couples the Cy-dyes to the generated cDNA in a two-step 
procedure. This method ensures less dye-dependent internal variability compared to the direct 
labelling methods where dye incorporation is done during cDNA synthesis in one single and 
sequence dependent reaction. Artefacts may be a problem due to steric effects of the large 
fluorochromes. First, aminoally-linked cDNA is generated from mRNA with the aid from a 
dT oligo primer, aminoallyl-dUTP, remaining dNTPs and a reverse transcriptase, before the 
dyes are coupled to the aminoallyl-linked cDNA in the second step. During this work, we 
have used the FairPlay labelling kit from Stratagene, where a longer centrifugation time at 
the cDNA purification step was the only alteration to the instructions form the manufacturer. 
All reagents and columns in this kit were otherwise used without exceptions. For additional 
information, please refer to the instruction manual from the supplier or (Schena et al., 1995). 
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Figure 2.5: Illustration of the indirect aminolabelling technique. Figure courtesy of Ms. Signe Indahl, 
the Microarray Core Facility, DNR. 
 
Additional reagents:  
• Human Cot-1 DNA (placental DNA enriched for repetitive Alu/Kpn sequences) used 
to suppress repetitive Alu/Kpn sequence cross-hybridisation. 
•  PolydA used to bind the polydT tails of the generated sample/reference cDNA and 
probes (Invitrogen), to suppress polydT-hybridisation to A-rich sequences. 
 Total or mRNA 
Reverse transcription with 
Aminoallyl dUTP 
Hydrolyze RNA, 
Neutralize reaction 
Purification and 
concentration of Aminoallyl 
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• Hybridisation buffer #3 from Ambion, containing 20% formamide, SSC and t-RNA.  
 
Additional solutions, buffers and reagents were made according to the Fairplay protocol. 
 
2.7.2 cDNA hybridisations with the GeneTac hybridisation station 
 
After spin column purification, the labelled reference and sample were mixed before addition 
of Cot-1. Following SpeedVac-assisted up-concentration of the labelled probes, (vacuum 
centrifugation), they were mixed with polydA and hybridisation buffer to a final volume of 
112 µl. 3 minutes at 100 °C and a 15 minute incubation at 42 °C enables Cot-1 to bind to 
repetitive sequences and thereby prevent cross hybridisation. During this time, the slides and 
equipment had been washed and prepared for loading. Samples were loaded and hybridized in 
a stepdown procedure from 65 to 50 °C over night. The cDNA microarrays have cDNA 
fragments from the IMAGE consortium deposited onto the surface of a GAPS (gamma amino 
propyl silane) coated glass slide, 15000 spots in total. All slides were printed at the Radium 
Hospital Micro Array Core Facility (uio.mikromatrise.no). All hybridisations took place at 
the Core Facility. 
 
2.7.3 cDNA Wash 
 
Stepdown from 50 to 42 °C, using three solutions of increasing stringency. 
[Wash1 = 2 x SSC, 0,1% SDS, Wash2 = 0,1 x SSC, 0,05% SDS, Wash 3 = 0,1x SSC] 
The slides were finally washed by vigorous shaking in 0,05 x SSC (2 x 2 min) before they 
were spun dry for 3 minutes at 1000 rpm in a swingout centrifuge (Eppendorf 5810 R). 
 
2.7.4 Generation of image and raw data 
 
In this work, a high resolution-scanner from Agilent enabled early visualisation and creation 
of a result file from each array slide. After scans at 635 (Cy5) and 532 (Cy3) nm, the GenePix 
software version 4.0 (www.axon.com) was applied in this work to give result files and TIFF 
pictures that were uploaded to and further treated in the BASE software platform.  
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A “GenePix Array List” file, (GAL-file), further links spot pictures to their respective 
reporter (i.e. gene) ID through the gridding procedure. When combined, the merged TIFF 
image together with the GAL-file permits positioning of the spots before ratio analysis. In 
GenePix, the user can “flag”, i.e. manually tag and hence either remove poor quality spots, 
or keep those that have not been detected when TIFF and GAL were combined. A spot 
affected by dust and fingerprints et cetera may thus be removed. A GenePix Result file (gpr 
file) will further be generated. The gpr file and TIFF images constitute the raw microarray 
data set. In this work, the raw data was uploaded to the BASE-environment for filtering and 
normalisation. 
 
2.7.5 Analysis of microarray data in the BASE-environment 
 
BASE (at http://alba.uio.no/base) is an open network created by Saal et al., the University of 
Lund, Sweden (Saal et al., 2002). The software enables uploading of scanned pictures and 
their respective result files, to create data sets and gather experiments. BASE has several 
algorithms, enabling filtering and various methods for computer data normalisation, clustering 
and plotting of data.  
Microarray data acquired in this work was processed in BASE following a series of steps. 
First, both sample and reference TIFF images plus the adherent result data file were combined 
in a single hybridisation experiment. In general for each spot, the sample signal divided by 
reference signal creates a signal ratio representing the direct amount of mRNA found in the 
sample. For representation purposes, this ratio is often log2-transformed. The raw data can be 
used in several experiments, and the experiments may be divided into so-called bioassays. 
During this correlation process, the background intensities are subtracted from the spot 
intensities: mean intensity in the spot foreground, and median intensity in the background for 
lowered bias. (Median background gives contamination and dust particles less significance.) 
Further on, when discussing BASE, the term “channel” refers to either reference or sample 
data. 
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Filtering raw data 
 
Signal to noise 
So-called doughnut (a spot lacking signal in its centre), may be negatively affected by the 
signal to noise (SNR)-filtration step, where spots with a signal-to-noise ratio of less than a 
fixed value (SNR mean or median in both channels lower than a fixed value), are removed. 
This step may be avoided if the array has a number of doughnuts, because the software may 
incorrectly remove such spots.    
 
Ratio controls 
Commercially available ratio controls consisting of DNA from various organisms give the 
user the possibility to control Cy-dye incorporation, non-specific hybridisation and the signal 
dynamics of each experiment. Scaled amounts may be printed on the microarray slides so that 
fixed ratios of e.g. 10, 3 and 1 may be obtained for each channel. In addition, negative 
controls (e.g. water or probe print buffer only) may be added to the microarrays to adress any 
non-specific hybridisation. These ratio- and negative controls are printed on the array, and 
RNA that will hybridise to these spots may be included at the cDNA target preparation stage. 
Naturally, the amount of added RNA at the cDNA target preparation step depends on 
pipetting accuracy, thus perhaps giving a false impression upon examination in the scanner 
software. Pictures may indicate that signal ratios are evenly spread, even though this may be 
caused by too much added control RNA to the sample RNA at the cDNA preparation stage. 
Taken together, these ratios may be used to assay dye incorporation, unspecific binding and 
the dynamics of the hybridisation (i.e. diversity of signal intensity from 0 to the maximum of 
65000), but they should be used with care. In this work, the Lucidea scorecard ratio controls 
from Amersham Biosciences were used, and negative controls were applied for non-specific 
hybridisation control. They were not, however, used for normalisation purposes. In BASE, the 
scorecard spots, i.e. ratio-, dynamic range- and negative controls were excluded from the data 
set before normalisation. In addition, irregular spots with a small diameter may be removed. 
In this work, spots with a diameter of less than 60 µm were excluded. 
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Figure 2.6: Illustration of the Lucidea scorecard ratio control used in this work. Red spots are 
upregulated, and green signifies downregulated spots, whilst yellow spots have unaltered expression 
values when compared to the reference. 
 
Removal of spots that cannot be log2-transformed 
A second filter, here the “DNR-filter”, may be applied to remove all spots with intensities 
below a set threshold. This filtration is performed because spots with intensities close to zero 
in one channel (and high values in channel 2) may obtain huge and inaccurate ratios after 
transformation, and may thus be efficiently replaced with low value to “stabilise” the ratios. 
The filter prepares the data for normalisation by removing intensity values that cannot be 
log2-transformed (e.g. intensities ≤0), i.e. spots that may not be correctly normalized. The 
“DNR-filter” can be adjusted, but the standard setting filters out a spot that has intensity lower 
than 2 times its standard deviation (SD) in either of the two channels from the data set. The 
standard filter keeps spots that fail in one channel, replacing the failed with the value 0.  
 
Normalisation of raw data 
 
After filtering, the data must be normalised, i.e. adjusted to adjust the Σintensities in channel 1 
equal to the Σintensitites in channel 2. Normalisation corrects the data set for uneven amounts 
of RNA in each channel and uneven incorporation of the two Cy-dyes. Most normalisation 
methods assume that without any experimental variability, the majority of the genes in the 
data set have an average expression ratio of 1. In general, a normalisation factor is calculated 
and applied to the entire data set. One such normalisation method is the “global normalisation 
method”, where all spots are taken equally into account. The intensities are scaled in such a 
way that their geometric mean (square root (intensity1 * intensity2)) is kept constant but the 
median of their ratios (i1/i2) is shifted to 1. More precisely described by Yang et al. (2002), 
one assumes that the red and green intensities are related by a constant factor;  
i.e. Red= k*Green. The center of the distribution of log ratios is shifted towards zero:  
log2 [Red/Green] Ælog2 [Red/Green]-constant = log2 [Red/(k*Green)]  
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The constant = log2 [k] is most often chosen as the mean or median of the intensity log ratios 
M for a data set. However, if the scanned arrays harbour non-linearity (banana shape) due to 
e.g.unequal background in the two channels, or if the signals are outside the linear range of 
the scanner, this calls for the ‘locally weighted regression’ (lowess) normalisation method. 
However, before a normalisation method is chosen, is is common to plot the M (log2 ratio) 
values versus the A log10 [sqrt (Ch1xCh2)] values for each experiment. This plot depicts 
filtered raw signals and their symmetry around the horizontal x-axis, telling the user whether 
1) the ratios are intensity-independent, and 2) the mean ratio is on average 1 (0 on a log scale) 
and 3) the number of up-and down-regulated genes are equal. It provides segment by segment 
intensity-based normalization based upon an MA plot (figure 2.7). A user defined factor f 
describes the fraction of data that should be used to smoothe the plot at each segment; the 
larger the value, the smoother the fit. The above formula for global normalisation is altered as 
follows: log2 [Red/Green] Æ log2 [Red/Green]-constant(A) = log2 [Red/(k*(A)*Green)] 
The constant(A) is the Lowess fit to the MA plot.  
The major difference between the two methods can be said to be the indifference of lowess to 
a small group of differentially expressed genes that would have a large impact in the global 
method, where all points are valued as a whole. Depending on the width of the segment used 
for lowess normalisation, it is important to delimit the use of lowess on an otherwise 
“healthy” data set, as this method may “repair” a good spot (Yang et al., 2002). After 
normalisation, the data may be exported for cluster analysis, pathway mapping and statistical 
analyses, options not used in this work. For additional information, please refer to the results 
and appendix sections. 
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Figure 2.7: MA plot depicting the relationship between gene expression ratio and intensity on a log-
log scale for the 25 hour sample taken from the time series used in this work. Data have been plotted 
before (left) and after normalisation (right). This positions the mean ratios around 0 (log scale). 
 
2.8 Southern Blotting 
 
Southern blotting is comparable to northern and western blotting techniques, but used to 
identify and detect specific deoxyribonucleotide sequences in genomic DNA. 
Through this method, information regarding whole genes and gene fragments may be 
gathered for DNA profiling and comparison to expression data, e.g. tumour profiling at the 
genomic, transcribed and translated stages (Southern, 1975). 
 
2.8.1 Isolation of genomic DNA with the DNAZol reagent 
 
The samples were all submitted to genomic DNA purification using the DNAZol reagent, 
(Invitrogen). The reagent contains mostly Guanidine hydrochloride, a strong protein 
denaturant, comparable to the phenol-based Trizol used for total RNA isolation. The cells are 
lysed in DNAZol, removing proteins and cell constituents, and total genomic DNA will then 
be precipitated along with total RNA using 100 % ethanol. After a brief 75 %-ethanol wash, 
the pellet is “fished” out of the solution with a pipette tip, and briefly air-dried before it is 
resuspended in 8 mM NaOH, pH 12. The alkaline NaOH serves two purposes; both increasing 
the rate of DNA dissociation compared to that at lower pH, as well as hydrolysing the 
remnants of total RNA still present in the sample. Quantification of the genomic DNA is 
performed after removal of total RNA in the sample (for quicker removal of RNA, RNAse A 
may be applied after ethanol-mediated precipitation). The pH is subsequently adjusted using 
Log
2 (R
atio) 
Log10(sqrt(Ch1*Ch2) 
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0,1 M HEPES-buffer. In this work, DNA was at first quantified as described in section 2.1.3, 
and secondly verified by 0,8% agarose gel electrophoresis with EtBr for visual control. 
(Genomic DNA often dissolves slowly, and is hence difficult to quantify properly.) 
 
2.8.2 Enzymatic digestion of genomic DNA and electrophoresis of digested products 
 
The genomic DNA can be digested with restriction enzymes, creating a smear on an agarose 
gel after overnight digestion, due to the complexity of the fragments. The DNA may further 
be blotted onto a positively charged nylon filter, which subsequently can be hybridised to 
radioactively labelled probes. In this work, Church hybridisation was used equally for 
northern and Southern hybridisation. A standard enzymatic digestion with λDNA was used as 
positive control: 
 
Genomic DNA and STD genomic normal DNA 7 µg 
10 x restriction enzyme buffer 6,5 µl 
Spermidine (carrier protein) final 4 mM 2,5 µl 
BSA if necessary, final 0,1 mg/ml 6,5 µl 
Enzyme (20 U/µl) 2,5 µl 
Sterile water to: 65 µl 
   
• Remove 1/10 of the total volume, then add 200 ng of λ DNA. Incubate separately. 
• Make a positive control digest with the enzyme, 200 ng λ DNA to 8 units of enzyme. 
• Incubate over night at the enzyme’s indicated working temperature. 
• The next day, cast two 0,8% TAE agarose gels with 10 µg/ml final EtBr. 
 
The digest controls will give feedback on the reaction’s rate of completion. If the controls 
show that λ DNA has been fully digested, one can proceed by adjusting sample volume upon 
visual comparison to the intensity of normal DNA of known concentration. The remaining 60 
µl should be loaded onto the second 0,8% gel, and samples should be run at 40 V for 3-5 
hours. A molecular weight standard marker may be included at this point. 
 
In this work, HindIII was used in parallel with a set of 6 samples, plus control digests as 
outlined above.  
 
 65
2.8.3 Blotting from gel to filter membrane 
 
At the visualization step, the gel may be left under UV illumination for 1-2 minutes for further 
nicking of the DNA and thus optimization of transfer from gel to membrane. The gel is 
further denatured for 30-45 minutes in an alkaline buffer with gentle shaking (0,4 M NaOH, 
1,5 M NaCl), and the blotting apparatus is mounted as illustrated in figure 2.7, using a 
standard Southern blot transfer buffer (0,4 M NaOH, 1,5 M NaCl). After incubation over 
night, the gel is removed from the blotting apparatus, and the positions of the wells are 
located with a soft pencil on the nylon filter. A soak in 50 mM NaH2PO4 pH 7.2 for 30-45 
minutes will neutralise the alkaline transfer buffer. The filter may further be treated as 
described for a northern blot (although all Church solutions intended for DNA use are made 
with regular ddH2O, and not DEPC-treated water).  
 
2.8.4 Probe preparation 
 
Hygromycin ORF 
 
Specific primers were designed in silico towards a subsection of the hygromycin open reading 
frame. With the pcDNA5FRT plasmid as template, a standard PCR was performed (annealing 
at 53°C), using a Pfu polymerase in four 100 µl reactions. Of the total 400 µl, 200 µl were 
submitted to PCR and gel purification according to 2.3.3 and 2.2.4. 
 
lacZ-Zeo fusion gene 
 
6 µg of the pFRTlacZeo vector was submitted to enzymatic digestion with 35 units EcoRV 
and 40 units SacI for two hours at 37°C to yield a short 807 bp lacZ-Zeo fragment, which was 
visualised after electrophoresis, and later gel purified as described in section 2.2.4. 
 
The Southern technique was applied to various DNA samples from the Flp-In system, please 
see the results section for further information.  
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2.9 Working with mammalian cells 
 
All cell work was performed under sterile conditions in a laminar air flow (LAF) bench. 
Most of the work was done on adherent Flp-In 293 cells (the parental 293 cell line has the 
ATCC-number CRL 1573), although other cell lines were cultured during shorter periods of 
time. Cells were kept in humidified incubators (water vapour), where the CO2 and O2-levels 
were fixed at 5%. For medium recipes, please refer to the appendix section. 
 
2.9.1 The Flp-In system  
 
The Flp-In system allows integration of a gene of interest in eukaryotic cells at a specific 
genomic location (Craig, 1988); (Sauer, 1994). A cell line harbouring a single 34 base pair 
Flp Recombination Target (FRT) site enables the creation of stably transfected cells. Two 
plasmid vectors are co-transfected into the FRT-containing cells to generate isogenic, but non 
clonal cell lines expressing the inserted gene of interest from the FRT locus, as initially 
described by O’Gorman et al. (1991). The “Flp” recombination system has been derived from 
the budding yeast Saccharomyces cerevisae, and selection of positive clones is based upon 
addition of the antibiotic Hygromycin to the cell growth medium. Two 293 cell lines (with 
only one FRT site each) were used: The Flp-In 293 cells offer constitutive expression of the 
inserted gene, whereas the Flp-In T-Rex 293 cells carry a TetOn promoter which blocks 
transcription in the absence of tetracycline. In each parental cell line, the lacZ-Zeocin-
resistance fusion gene is expressed, making them resistant to the antibiotic Zeocin. The T-Rex 
cell line harbours a second resistance trait, having the pTR6© plasmid which codes for both 
Blasticidin resistance and the essential TetRepressor protein.  
 
 
 
Figure 2.8: Illustration of a Flp-In expression cell line depicting the integration site after Flp-
recombinase assisted insertion of the pcDNA5FRT plasmid. GOI = gene of interest. 
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Two plasmids were co-transfected to create each of our transfected cell lines: 
-The pOG44 vector constitutively expresses the Flp recombinase (Broach et al., 1982), under 
the control of a human CMV promoter. The remaining FRT or FRT/To vector, (one for each 
cell line), contains the gene of interest in frame with the coding sequence for the antibiotic 
hygromycin and the unique 34 bp FRT site, all under CMV promoter control. Upon Flp 
recombinase-mediated integration of the second plasmid into the genomic FRT site, 
hygromycin resistance and Zeocin sensitivity is conferred to the cell line as the lacZ-Zeocin 
reading frame is disrupted by the pcDNA5FRT/pcDNA5FRT/To plasmid. Upon transfection 
of these cells, the isogenic nature of the transfected cells, i.e. proper insertion of the gene-
containing plasmid, can be verified through assays for Zeocin sensitivity and/or β-
galactosidase staining. In this work, we chose to verify Zeocin sensitivity, learning more 
about the Flp-In system (for additional information, please see the results section).  
Eight kinds of cell lines were generated and used during this work. The pcDNA5FRT plasmid 
harbouring the gene of interest was transfected into the Flp-In 293 cell lines for constitutive 
expression, as the pcDNA5FRT/To with inserted gene into the Flp-In T-Rex 293 cells for 
tetracycline-inducable expression. 
 
Table 2.6: Constructs created for use with the Flp-in system. 
Constitutive expression Tet-inducable expression Produced by 
pcDNA5FRT/COAS2 pcDNA5FRT/To/COAS2 Mr Magne Skårn 
pcDNA5FRT/COAS2MycHis pcDNA5FRT/To/COAS2MycHis Mr Erik B.Paulsen 
pcDNA5FRT/egfp  Mr Jørn Henriksen  
 pcDNA5FRT/To/egfp Mr Magne Skårn 
 pcDNA5FRT/egfp/COAS2 
pcDNA5FRT/COAS2/egfp 
Mr Magne Skårn 
Mr Magne Skårn 
 
The egfp coding sequence was subcloned from the pEGFP-N1 vector (Clontech).  
COAS2-vectors created in this work all harbour the COAS2 492 nucleotide ORF, courtesy of 
Dr. Leonardo A. Meza-Zepeda and Professor Dr. philos Ola Myklebost. 
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Creation of COAS2MYC-His plasmids 
 
The C-terminal 9E10Myc-His6 tag was subcloned from the pcDNAMYCHis B(+) plasmid 
(Invitrogen), using two different primer pairs. First, COAS2 was amplified from the 
pcDNA5FRT/To/COAS2 plasmid using the COAS2XbaIUpper and COAS2SfUILower 
primers in a standard 20-cycle PCR, followed by gel purification. Both the 
pcDNA3.1MYCHis B (+) plasmid and the purified COAS2 was digested in a single reaction 
with XbaI and SfUI. The fragments were ligated, bacteria were transformed with the 
recombinant plasmids and PCR screening applied to identiy positive clones. After plasmid 
purification and verification by enzymatic digestion and MEGA BACE sequencing, the 
second PCR with HisTagCOAS2StopXhoI and COAS2BamHI primers produced a COAS2-
MYC-His duplex DNA which was gel purified and treated exactly as the above PCR product 
for creation of the pcDNA5FRT/COAS2MYCHis and pcDNA5FRT/To/COAS2MYC-His 
plasmids. A flow chart for the entire procedure is shown in the appendix section. Proper 
induction of four of the COAS2 cell lines was confirmed in a northern blot with a COAS2 
cDNA restriction digest as probe. The Myc-His tag was not selectively confirmed; please see 
the result section for data and thoughts on the subject. Both the egfp-transfected and the 
egfp/COAS2 fusion construct-transfected cells were examined for egfp expression at 488 nm 
with a Zeiss inverted fluorescence microscope. Please refer to the results and appendix 
sections for illustrations of the cloning strategies and characterisation of the Flp-In 
transformants. 
 
2.9.2 Growth and harvest of mammalian cells 
 
Cells frozen in liquid nitrogen were quickly thawed and transferred to a 75 cm2 cell flask. 
Gentle resuspension in 12 ml antibiotic-free medium was followed by incubation at 37°C over 
night. The following day, cell line-specific (i.e. with all necessary additives) medium was 
added after a brief wash with 37°C PBS. When the cells were approximately 80% confluent, 
they were washed 1 x with PBS and harvested using trypsin/EDTA. The trypsin is more 
efficient at 37°C, so some cell types were incubated for short periods, typically 2-3 minutes in 
at this temperature. Cells attach to the plastic flask through membrane glycopeptides. Trypsin 
breaks a polypeptide chain at the C-terminal end of the amino acids arginine and lysine, and 
thus cleaves glycopeptidic bonds, detaching the cells from the flask. Serum protease inhibitors 
plus Ca2+/Mg2+ inhibit trypsin, explaining partly why a PBS-wash is necessary when trypsin 
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is to be used. The chaotrophic EDTA is used to strengthen the effect of trypsin as it binds free 
calcium ions in solution (Kielberg, 1993). 
 
If downstream purposes such as cell counting or freezing requested so, the cells were 
transferred to a 10 ml polystyrene tube, sealed in the sterile bench and centrifuged for 5-6 
minutes at 200 x g = 1000 rpm in a centrifuge at room temperature (Heraeus Megafuge 1.0 or 
Labofuge 400R). The excess liquid was removed, and the pellet was either washed once in 
PBS, or resuspended in fresh medium before an eventual count of the cells was performed. 
All cells were subcultured differently, according to cell type and growth rate. 
 
2.9.3 Counting cells 
 
The cells were all counted using a hemacytometer, or cell counting chamber (Bürker, 0,1 mm 
x 0,0025 mm2). This unit contains two rectangular cavities, made up by nine major squares 
each one again divided into sixteen squares. To count, the cells are trypsinated as in 2.9.2, 
transferred to a polypropylene tube and centrifuged at 1000 rpm for 5 minutes. The pellet is 
further resuspended in a known amount of fresh medium. A small aliquot is extracted with a 
pipette, and 10 µl are applied to the cavity between a 10 mm2 cover glass and the 
hemacytometer. The amount of cells per ml is thereafter determined in a light microscope by 
counting several squares of known volume and extracting the mean value, which is multiplied 
by a chamber-dependent size factor, in this case 10000. The result is given as # cells per ml. 
For an illustration, please see (Kielberg, 1993). 
 
2.9.4 Freezing cells 
 
Cells were harvested as described in section 2.9.2, and the pellet resuspended directly into ice 
cold DMEM with 20% FCS, 10% dimethylsulphoxide (DMSO), 2 mM Glutamax and 
aliquoted into 1,5 ml cryovials (Sarstedt). The tubes were transferred to a plastic container 
with isopropanol and left at -70°C for 24 hours before they were frozen and stored in liquid 
nitrogen. The container mentioned above permits a one-degree per hour steady decrease from 
0 to –70 degrees, which minimizes the loss of cells. 
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2.9.5 Screening for mycoplasma contamination in cultured cells 
 
The contamination of cells in culture by mycoplasma and other members of the class 
Mollicutes is a common occurrence. The metabolism of the attacked cells changes towards the 
non-predictable, making experiments unreliable and non-reproducable. A simple kit from 
ATCC has been used for the detection of mycoplasma in cell cultures during this work. It is 
based on nested PCR, running 2 PCRs sequentially and finally visualising eventual bands 
with 2% agarose electrophoresis. Please refer to the supplier’s homepage at 
http://www.atcc.org for a detailed protocol (Cat.nr 90-1001K, version 2.0). 
 
2.9.6 Transient and stable transfection of mammalian cells 
 
There are several ways to transfect a eukaryotic cell, of which the author has used two 
techniques. The transfer of biomolecules across the cell membrane demands transient 
permeabilization or assisted transport across the hydrophobic region. Electroporation 
exemplifies the first method, where the cell membrane is perforated after an electric pulse has 
been submitted to the sample for some milliseconds, permitting exogenous DNA to enter. In 
this study, electroporation was used for transient transfection only, i.e. introduction of the 
recombinant DNA into the recipient cell line without its integration in the cell line’s genome.  
 
Standard protocol for electroporation of mammalian cells   
 
This protocol can be found as protocol # 304 at the BTX Division of Genetronics homepage. 
The BTX Electro Cell Manipulator electroporation device with 4 mm gap cuvettes was 
used. A cell suspension of 2,5-4,0 x 106 cells/ml growth medium (total volume: 400 µl), was 
transferred to the cold P/N 640 disposable cuvettes before addition of the plasmid DNA to be 
transfected. After the 26-45 ms pulse, the cuvettes were kept on ice until transfer of the cells 
to 75 cm2 cell flasks supplied with fresh growth medium (Baum et al., 1994); (Sambrook, 
2001). Transfection efficiency is influenced by a number of factors; as the length of the pulse, 
the capacitance value, DNA concentration as well as the strength of the applied electric field 
and ionic composition of the medium. The apparatus has only one adjustable variable, namely 
the voltage. We therefore kept the amount of DNA and medium composition fixed, and rather 
adjusted the voltage and thereby the pulse length to optimise the transfections. Samples were 
kept on ice at all times, even though some favour room temperature after the electroporation. 
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Ideally, protocol # 151 from BTX with an apparatus such as the ECM 600/630 or equivalent 
should be used for the transfection of human 293 cells. A more gentle way to transfect 
eukaryotic cells is by liposome- or non-liposome based transfection. A liposome will surround 
the hydrophilic sample to be transfected, and helps it transfer across the cell membrane and 
into the cytoplasm. Non-liposomal reagents will in similar manners assist the translocation 
across the phospholipid bilayer. This class of transfection reagents is less harmful to the cells, 
and their potency maximizes the odds for further transport into the nucleus, a matter of 
importance when stable transfection assays are performed. 
 
Transfection of mammalian cells with FuGene6 
 
The FuGene6 high efficiency transfection reagent is a non-liposomal, proprietary blend of 
lipids with low or no sign of cytotoxic behaviour. It was used for all transfections in this 
work. After optimisation of the conditions (see table 2.7), we performed all transfection 
experiments according to the standard protocol using serum-free DMEM cell growth medium 
mixed with (1-2,5) µg of DNA and (3-12) µl of FuGene6 in a sterile eppendorf tube at room 
temperature. After 15-45 minutes of incubation, the mix was added dropwise to the adherent 
cells, which had been seeded out 24 hours earlier in a 35 mm dish using 1-3 x 105 cells in 
total. The amount of FuGene was always kept higher than the amount of DNA, and egfp-
expressing plasmids were used as controls in all types of transfections. The cells were grown 
in antibiotic-free medium until selection, a timespace of 24-48 hours. For a more detailed and 
updated protocol, please see http://www.roche-applied-science.com. As indicated further on, 
optimisation was performed using transient transfection and flow cytometry measurements, 
indicating an ideal ratio of 6:1 for µl FuGene6 vs µg plasmid DNA, although 3:0,5 also has 
been found to be well suited. This was transient, however, and transfections very much 
depend on the purity of the molecules to be transfected. Co-transfection increases the 
complexity, and for stable transfections in the Flp-In system, we always co-transfected the 
pOG44/pcDNA5-plasmids in a minimum ratio of 9:1.  After some experiments, we found that 
the amount of DNA is to be kept low to avoid non-specific stable integration using the Flp-In 
system. Please see the results and discussion sections for further information regarding the 
Flp-In system performance. 
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Induction of 293 Flp-In transfectants with tetracycline 
 
Tetracycline was added to the growth medium to a final 1 µg/ml for induction. Tetracycline 
will bind to the Tet-Repressor protein, which causes a change of protein conformation and 
thus liberation of the CMV promoter (please see the next section for additional information). 
When assaying for COAS2 expression with northern blotting, we seeded out 2-3 x 106 cells in 
75 cm2 flasks the day before induction. For microarray experiments, we used 175 cm2 flasks 
and seeded out 3,75x106 cells in these the day before induction, yielding 110-360 µg of RNA, 
respectively. 
 
Testing 293 transformants for Zeocin and Blasticidin sensitivity 
 
To assay the function of both Zeocin and Blasticidin, we performed experiments throughout 
the work period. Zeocin was given at 5-1000 µg/ml for clone verification experiments, and 10 
µg/ml Blasticidin was fed parental cells to assay for homogenicity in the cell population. 
Zeocin has also been given to LOX cells (kindly provided by Mrs. H. Høifødt of the Dept. of 
Tumor Biology), to verify drug function efficacy. 
 
2.9.7 Creation of COAS2-xenografts  
 
The FRT/To/COAS2 clone#3, FRT/COAS2 clone#1, and the parental Flp-In 293 cell line were 
all grown without antibiotics for 2 passages, and harvested and counted according to sections 
2.9.2-3. Cell densities: FRT clone#1= 3,2 x 106/ml; FRT/TO clone#3=6 x 106/ml; Flp-In 
293=8,5 x 106/ml. 2 x 0,2 ml was injected subcutaneously into immunodeficient nude mice by 
staff at the Animal Research Section at the Norwegian Radium Hospital. When tumours had 
reached roughly 6 mm in diameter, they were split and pieces of Ø = 2mm transferred to new 
mice. After 2 passages, the inducible FRT/To/COAS2 clone#3 was submitted to an induction 
experiment initially described by (Kistner et al., 1996), where the tetracycline analogue 
doxycycline (which has a t1/2 two times the one of tetracycline), was fed at 200 µg/ml to the 
mice in drinking water with 2% sucrose to mask the bitter taste. Mr. Christoph Müller 
performed the experiments. Tumors from early passages were stored for total RNA 
purification, immunohistochemistry and other downstream applications. 
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2.10 The SRB protein assay 
 
The SulphoRhodamine B dye binds proteins and is used for in vitro chemosensitivity testing 
of cell lines. The assay is rapid, inexpensive and sensitive, permitting at its most primitive the 
measurement of doubling time for cell lines. Under mildly acidic conditions, SRB binds to 
basic amio acid residues, providing a sensitive index of cellular protein content that is linear 
over a cell density range of at least 2 orders of magnitude. The assay was performed 
essentially according to (Skehan et al., 1990). Dilutions of cells are seeded out in four 96-well 
plates and grown over night, ranging from 1-5000 cells per well (6 parallels for each dilution). 
At t0, cytotoxins may be added. For measurement of doubling times, the cells are merely 
fixed, washed and air-dried after 24, 48, 72 and 96 hours, respectively. 50% (w/v) trichloric 
acid (TCA) was applied to fix the adherent cells in the SRB assay, but several agents are 
currently in use5. When MeOH is used, permeabilisation of the cell membrane may cause a 
leakage of internal soluble proteins towards the medium. After fixation, the cells are rinsed in 
lukewarm tap water, shaken and left to dry at room temperature. When all plates have been 
collected, they are submitted to SRB staining6, washed in 1% CH3CO2H (w/v), shaken and 
air-dried, and finally resuspended in 10 mM Tris pH 7.5. A plate-reading spectrophotometer 
reads the intensities at 540 or 490 nm (absorbance maximum and half of the latter, 
respectively). There are numerous downstream applications of this assay. In this work, it was 
used to create growth curves plus estimating cell culture division time and also for 
preliminary chemosensitivity trials. The above experiments were made possible with the help 
of Mr. Paul Noordhuis. Mr. Christoph Müller performed cytostatica-sensitivity assays using 
the COAS2-transfected cells.  
 
Calculating doubling time 
 
The doubling time was calculated using the following formula, where A represents the 
absorbance at 540 nm:  
ratiogrowth 
)2(log
  (hours)  time totalExperiment  (hours)  timeDoubling 10×=  
Where the growth ratio = 
)A(t
A(t)log
0
10 , where t = time of harvest and t0 = 0 hrs  
                                                          
5 Formaldehydes cross-bind proteins in the sample, while alcohols (e.g. methanol, MeOH) fix cell membranes by 
dissolving lipids and denaturate proteins, forcing the latter to aggregate. 
6 0,4% SRB (w/v) in 1% CH3CO2H (w/v) 
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2.11 Cytostatica sensitivity assays 
 
Cells with constitutive expression of COAS2 and the parental 293 Flp-In cell line were plated 
as indicated earlier in the text. Methotrexate (MTT), Cisplatin (CDDP) and Doxorubicin (dox) 
were added to the growth medium at day 1, and cells were further treated and counted as 
indicated above. The drugs were administred in the following doses: 0,01-100 mM (MTT), 
and 0,01-1000 nM (CDDP and dox). 
 
2.12 The Courtenay-Mills’ soft agar assay 
 
Cells’ ability to grow without anchorage, or their clonogeneicity, is tested using this simple 
growth assay. This ability is correlated with tumourigenicity (Courtenay and Mills, 1978). 
 
Standard protocol 
Two ml blood from one nude rat is mixed with 5 ml phosphate buffered saline (PBS) without 
neither Mg2+ nor Ca2+. Centrifugation at 2800 rpm for 20 minutes is followed by removal of 
the supernatant and intersection, the latter consisting of unwanted leukocytes. After addition 
of 5 ml PBS, and mixing by inversion, the step is repeated once. PBS is added to the initial 
blood volume, and remaining immunogenic factors in the nude rat blood are inactivated at 
42°C for 60 minutes before use. (This solution will provide factors that promote growth of the 
cells in soft agar.) The prepared growth medium must contain 15% inactivated Fetal Calf 
Serum (FCS), 2mM L-Glutamine or equivalent additives, and 2mM penicillin-streptomycine. 
The Fham-12 medium may in some cases be replaced with the standard growth medium if the 
serum amount is adjusted to 15%. Each cell suspension is created in triplicate, and a typical 
range for a chosen cell line would go from a final 5000 cells/ml to 50 cells per millilitre. The 
cells are seeded out in Fham-12 cell growth medium, mixed with erythrocytes (diluted 1:8), 
and sterile 5% Beetor Soft Agar solution (to final 0,5 %). Gentle mixing must be performed 
before the agar solidifies. Incubation takes place in a 5 % CO2/O2-controlled incubator for one 
or two weeks. (The nitrogen ensures 5 % O2 in the incubator at all times.) After one week, 
some tubes are counted, and the remaining lot of cast-in cells receive fresh cell medium if 
prolonged incubation is found necessary. After a fortnight, the jellylike pellet is squashed 
between two gridded plastic surfaces; the grid eases the counting of the tumour-like cell 
colonies. 
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2.13 Flow cytometry and fluorescence 
 
Fluorescence can be defined as the molecular absorption of light energy (photon) at one 
wavelength and its re-emission at another wavelength. Light-absorbing molecules are known 
as chromophores, whilst molecules that both absorb and emit light are known as 
fluorochromes or fluorophores. The process of fluorescence may be divided into three phases, 
i.e. excitation, the transient excited state and emission. The phenomenon can be described as 
follows: The incident monochromatic light excites the sample. If the incoming energy is 
sufficient, some electrons are lifted to a level of higher energy in the sample. The surplus 
energy is passed as transmitted light When the electrons return to their initial energy state, the 
inititally absorbed excitation energy is being released as emission light; photons of a higher 
wavelength. A fluorophore’s extinction coefficient ε characterises its ability to absorb light 
energy, and each fluorophore has excitation and emission maxima related to this variable. The 
(energy) difference between a fluorochrome’s maximal excitation and emission wavelengths 
is known as the Stokes shift. 
 
 
Figure 2.9: The excitation and emission spectra for the Cy3 and Cy5 dyes used in this work. The 
Stokes shift is the difference between the continuous- and dotted line peaks, respectively. 
 
The fluorescence and scattered light from microscopic particles can be quantified and 
analyzed using the flow cytometry method. Both intracellular components and fluorochrome-
tagged endogenous constituents can be visualized and quantified using this technology. 
Fluorescently labelled cells can be sorted and counted with a high degree of sensitivity: a few 
hundred molecules per cell can be detected. Endogenous pyridines and flavins are detected in 
addition to the extrinsic fluorescence that includes all other sorts of fluorochrome-labelled 
particles. In a flow cytometer, the analysed particles (most often cells) are suspended in a 
mobile phase and lead through a funnel-shaped tract, creating a flow that passes the internal 
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system laser(s). Excited by the intense light, each cell creates a brief pulse of emitted light (of 
lower energy thus higher wavelength) which passes beam splitters, mirrors and filters to face 
a photomultiplier tube; (PMT) one tube for each laser. In addition, the cells will spread the 
laser light, and scattered incident light is collected and measured at two angles, namely 
forward (orthogonally, or “forward scatter”), and at low angle (“side scatter”). The scattered 
light provides information on cell size, granularity and structure. All fluorescent signals are 
digitized in the PM tubes, and thus quantified and visualized by the aid of computer software. 
Sorting cells of homogenous nature in a blend of various cells can be done, but sorting of cells 
was not performed and will not be discussed any further. 
 
Figure 2.10: A principle outline of a laser-based flow cytometer. The flow cytometer has sorting 
facilities and opportunity to detect two fluorescent components (PMT2 and PMT3), large angel light 
scattering (PMT1) and light with low angel scattering (forward light scattering detector). Figure from 
(Steen, 1991). 
 
 
2.13.1 Optimizing transient transfection with flow cytometry 
 
The use of green fluorescent protein, or gfp, has greatly improved molecular biotechnology 
(Tsien, 1998). Gfp emits in the green range of visible light when excited with blue light, and 
was first characterised and isolated from the jellyfish Aequorea victoria (Tsien, 1998). The 
enhanced version named egfp (Clontech) has been used in this work. For preliminary tests of 
transfection efficiency, we transiently transfected the EGFP-N1 plasmid from Clontech into 
the Flp-In 293 and Flp-In 293 T-rex cell lines with electroporation and FuGene6, respectively. 
Flow cytometry was used to analyze the percentage of successfully transfected living cells, 
with the DNA-binding dye propidium iodide (PI, see also next section) as a control marker. 
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(PI enters dead cells only, permitting us to remove these by gating for the viable, non-emitting 
cells.) Both dyes were excited with one argon laser at 488 nm, but various filters in the 
FACStar are applied for each dye. Egfp emits at 509 nm (green) and PI at 617 nm (red), 
respectively. 
 
Sample preparation 
 
The electroporation and FuGene6 transfection were performed as described in section 2.9.6. 
Electroporation of the T-Rex cell line was done with two different cell concentrations in 
parallel series, 3,2 and 6,4 x 105 cells/ml.  
 
Transient transfection of the Flp-In 293 cell line with the FuGene6 reagent: 
 
Table 2.7: Optimisation of transfection using the FuGene6 reagent. Initial setup of reagents. 
 
Tube no. 1 2 3 4 5 
DMEM w/o FCS (µl) 97 97 97 94 88
EGFP-N1 DNA (µg) 0,5 1 2 1 2 
FUGENE6 (µL) 3 3 3 6 12
 
 
Quantification of Flp-In induction and egfp-intensity    
 
With the stably egfp-transfected cells, we aimed to measure both percentage of transfected 
cells and to create an induction curve for the tetracycline-inducable clone. Cells were induced 
with tetracycline, and harvested at various time points according to section 2.9.2-3.  
Between two centrifuge runs, the cells were washed once and diluted in PBS to a final 
concentration of 0,5-1,0 million cells/ml. Some samples were fixed in ice-cold 
paraformaldehyde (final 3%) for 60 minutes on ice, spun for 5 minutes at 1000 rpm and 
resuspended and stored as above. Shortly before the run, the suspensions were filtered through 
a 50 µm mesh to obtain a maximum number of single cells for injection. Subsequently, PI was 
added to a final 0,5 µg/µl for detection of dead cells. With the kind aid from fellow student 
Lise Ramberg and Mrs. Kirsti S. Landsverk at the Flow Cytometer Core Facility at the 
Norwegian Radium Hospital, the analysis was performed on the Becton Dickinson 
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FACStarPLUS (FACS = Fluorescence Activated Cell Sorter) flow cytometer and the 
CELLQuest v3.3 software.  
 
2.13.2 Cell cycle analysis 
 
As described in section 1.2, eukaryotic cells follow the cell cycle where the DNA content 
changes between phases. Estimating the cells’ position in the cycle can therefore be made 
using a flow cytometer and a DNA-binding dye. Propidium iodide (PI, excitation maximum at 
536 nm) was the chosen fluorochrome. Acting as an intercalating agent, the dye binds 
stoichiometrically to every 4-5 base pairs. PI also binds to RNA, necessitating treatment with 
ribonucleases to distinguish between DNA and RNA staining. (Ribonuclease A (RNase A) 
specifically attacks single-stranded RNA 3’ to pyrimidine residues and cleaves the phosphate 
linkage to the adjacent nucleotide.) The enzyme works in the absence of cofactors and 
divalent cations.) To deselect or gate dead cells away from the analyzed population, PI can be 
used in companionship with other dyes, as it cannot enter viable cells. However, for cell cycle 
analysis, all dead cells are included, making the assay less sensitive.  
 
Protocol 
Two populations were seeded out at day 1: Cells with transfected COAS2 under promoter 
control, and parental reference cells. After induction of the cells with tetracycline, the cells 
were harvested and counted according to section 2.9.2-3. After one wash with PBS, the pellet 
was very gently vortexed and the cells were ensuite fixed in 1-2 ml of ice cold MeOH. After 1 
minute of incubation, a second 5 minute spin at 1000 rpm followed before they were 
resuspended to a final concentration of 7,5 x 105 cells/ml with a PBS-solution containing 10 
µg/ml propidium iodide and 100 µg/ml RNase A, the latter prepared according to (Sambrook, 
2001). After 1 hour of incubation at 37°C, the sample was analyzed after filtration through a 
50 µm mesh at RT using the same hardware and software as in earlier transfection 
experiments. The FL3 channel was used for DNA measurement as well as doublet 
discriminating module (DDM), with triplicates of each sample type to assess systematic bias. 
Samples were run at medium speed, counting a total of 5000 gated cells in each try. 
 
A second experiment used serum-starved FRT/To/COAS2 clone#3 cells, (fed 2% FCS only 
for 72 hours previous to tetracycline addition), compared to the reference cells grown in 8% 
FCS. Cells were induced and treated exactly as the cells in the former experiment.  
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2.14 Fluorescence confocal microscopy 
 
Traditional light microscopy and fluorescence microscopy cannot produce optical sections 
through a 3-dimensional (3-D) specimen - e.g., an entire cell or a piece of tissue - that, to a 
good approximation, contain information from only one focal plane (Lichtman, 1994). In a 
fluorescence confocal microscope, however, this is possible, as illustrated schematically in 
Fig. 2.11, by moving the focal plane of the instrument step by step through the depth of the 
specimen, a series of optical sections can be recorded (c. f. Lichtman, 1994), seeing where the 
fluorochrome-tagged objects of interest are located in the given sample. Scanning the object 
in the xy- and z-direction (along the optical axis), allows viewing from all sides. 
  
 
Figure 2.11: Illustration of focal XY-planes scattered at three points on the Z-axis. 
 
 
Figure 2.12: Schematic illustration of the confocal principle, courtesy of Leica Microsystems.  
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To image the specimen point by point, a collimated, polarized laser beam is deflected 
stepwise in the x- and y-direction by a scanning unit (not shown) before it is reflected by a 
dichroic mirror (beam splitter) so as to pass through the objective lens of the microscope, and 
focused onto the specimen. The emitted, longer-wavelength fluorescent light (principles of 
excitation and emission are described in section 2.13), collected by the objective lens passes 
through the dichroic mirror (transparent for the longer wavelength), and is focused into a 
small pinhole (i.e., the confocal aperture) to eliminate all the out-of-focus light, i.e., all light 
coming from regions of the specimen above or below the plane of focus. Therefore, the 
confocal microscope does not only provide excellent resolution within the plane of section 
(0.25 mm in x- and y-direction), but also yields similarly good resolution between section 
planes (0.3 mm in z-direction). The in-focus information of each specimen point is recorded 
by a light-sensitive detector (i.e.a photo-multiplier tube) positioned behind the confocal 
aperture, and the analog output signal is digitized and fed into a computer. At the same time, 
the analog photo-multiplier signal can be used to generate an image on a video monitor. To 
obtain a full image, the image point is moved across the specimen by mirror scanners. As for 
a standard fluorescence microscope, the emitted light is filtered through mirrors plus 
beamsplitters and collected in photomultiplier tubes (PMTs). But the difference lies mainly 
within the ability of a confocal microscope to suppress, i.e. lock out all light from structural 
sources not in focus upon image formation, as well as stray light and defocusing blurs. In this 
way, the image of one focal plane through a specimen is created, and by adjustment of the 
numerical aperture plus sensible variations of the focal plane depth, a stack of serial optic 
sections may be created. Such stacks may be summoned to create a composite projection 
image, a procedure that was used in this work with 8 serial pictures per composite image. 
When several fluorochromes and thus several instrument lasers are in use, their respective 
emission/excitation spectra may overlap, a phenomenon called “bleed through” which may be 
corrected upon adjustment of initial laser light strength. “Bleed through” may cause poor 
overall resolution, but was avoided in this work, as we only stained with one 
Rhodamine/TRITC-tagged secondary antibody. 
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Localisation experiments 
 
First, we wanted to stain our COAS2MYC-HIS6-transfected cells with primary Myc or His-
antibodies plus Rhodamine-tagged secondary antibodies. This would enable us to localise 
COAS2 in the 293 cells upon over-expression. 
During her work as a MSc-student, Ms. Birgitte Lygren indicated a possible interaction 
between the proteins filamin type A/C and COAS2. So in a second confocal microscopy 
experiment, we aimed to compare filamin patterns in cells with and without overexpression of 
COAS2. This was done with primary chicken α-goat anti-filamin (SIGMA) and donkey anti-
goat Rhodamin-tagged secondary antibody (#522, a kind gift from Dr. H. Stenmark). Primary 
diluted 1:40, secondary 1:100. We also searched for alterations in the cells’ actin pattern, 
using the actin-binding reagent phalloidin in a 1:750 dilution. This fluorochrome has no need 
for secondary antibody. 
 
2.14.1 Standard protocol for immunofluorescence microscopy of attached cells 
 
Used for both confocal and regular fluorescence microscopes. Modified from a standard 
protocol described by Dr. H. Stenmark. 
Cells are seeded out on 10 mm2 cover glasses 24 hours prior to fixation. Cells in log phase 
growth are washed three times with ice cold PBS before they are covered by freshly made 3% 
paraformaldehyde7 on ice. After 15 minutes, the excess aldehyde groups are quenched using 
50mM NH4Cl for 15 minutes on ice. Incubation on ice for 5 minutes in 0,1-1% Triton X-100 
in PBS permeabilizes the membrane, permitting the antibodies to enter the cells. 20 µl of 
primary antibody solution (5-10 µg/ml) are put onto a small piece of PARAFILM in a 
humidified chamber. The cover glass is then put with cells facing down towards the liquid 
using a pointed forceps. Incubation lasts for 15-40 minutes, and is followed by 3x5 minute 
washes in PBS containing 0,05 % saponin (a detergent originating from the bark of the 
Quillaja tree). The fluorochrome-conjugated secondary antibody incubation and 2x wash are 
                                                          
7 Fixation with paraformaldehyde preserves cell structure better than organic solvents such as MeOH ( Sambrook, J., Russell 
D.W. (2001). Molecular Cloning, A laboratory manual, Cold Spring Harbor Laboratory Press.. Proteins are cross-linked in 
the simple reaction, but it does not allow access of the antibody to the interior of the specimen. This is achieved by non-ionic 
detergent permeabilisation on ice. 
 
 82
performed as listed above, before the glasses are washed 5 minutes in PBS, soaked in water 
and mounted on an object glass with 3 µl of Mowiol (cells facing down.) The sample is now 
ready for inspection after 30 minutes at 37°C to fix the Mowiol-preparation. Cells were 
visualized using a Leica NT confocal microscope at the Department of Biochemistry, the 
Norwegian Radium Hospital. 
 
2.15 Protein expression in bacteria and insect cells 
 
The transition from nucleic acids to peptides and proteins implies a major increase of 
complexity. From a linear amino acid sequence, a three-dimensional peptide or protein will 
form. To investigate whether COAS2 really gave a protein product, we launched into the vast 
field of protein expression and purification. 
 
2.15.1 Prokaryotic COAS2-expression in the Ek/LIC system 
 
The bacterial ligation-independent cloning (LIC) system harbours an IPTG- 
(Isopropylthiogalactoside) inducable promoter, and it is based upon the treatment of a 
linearized vector backbone with T4 DNA polymerase in the presence of only one dNTP, (here 
ATP). The enzyme removes nucleotides from one strand of each specifically designed end 
until it encounters a residue corresponding to the dATP present in the reaction mix. The 
exonuclease activity of the enzyme will be overridden by its polymerase activity, resulting in 
specific non-complementary 13-14 base single stranded overhangs in the Ek/LIC vector. PCR 
products to be inserted are created by building appropriate 5’ extensions into the gene-specific 
primers. The PCR product is further treated with T4 DNA polymerase, and then the 
unidirectional insert and the linearized vector are ligated through annealing. In this work, two 
recombinant prokaryotic pET expression vectors from Novagen were transformed into a 
bacterial BL21(DE3)pLysS strain, which lacks Ion and ompT proteases. The designation 
(DE3) indicates that the host is a lysogen of lDE3, and therefore carries a chromosomal copy 
of the T7 RNA polymerase gene under control of the lacUV5 promoter. pLysS cells carry 
pET-compatible plasmids that encode T7 lysozyme, which is a natural inhibitor of T7 RNA 
polymerase. Cells containing pLysS produce a small amount of T7 lysozyme, used to 
suppress basal expression of T7 RNA polymerase prior to IPTG-assisted induction, and thus 
stabilize pET recombinants encoding target proteins that affect cell growth and viability. 
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Please see the appendix section for plasmid maps. Additional information regarding the LIC 
system and BL21(DE3)pLysS may be obtained at http://www.novagen.com. Fortunately, 
bacterial expression systems create huge amounts of the protein of interest (often 50% of the 
total bacterial protein content), finally taking control of the expression machinery and thus 
killing the cells. In our experiments, we therefore used spectrophotometric analysis to survey 
growth conditions, permitting us to induce COAS2-expression when cells were in exponential 
growth. We used Coomassie Brilliant Blue staining of 12% SDS-PA gels to visualize the 
results. 
 
 
Figure 2.13: Illustration of the ligation independent cloning system, (Novagen).  
Ek = Enterokinase 
 
Cloning procedure outline 
 
pET30EkLIC-COAS2 was cloned by Mr. M. Skårn and the author using LIC 
STARTCOAS2/LIC STOPCOAS2-primers in the Novagen Ek/LIC manual (#TB163 Rev A 
0602) and transformed into BL21(DE3)pLysS as outlined in section 2.1.1. Colonies were 
PCR-screened as described in section 2.3.4. Mr. Jørn Henriksen made the pET3a-COAS2 
construct according to the same LIC manual. After further verification by restriction cutting 
and electrophoresis, freezer stocks were made as outlined in section 2.1.1.  
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Growth and expression conditions in the bacterial systems 
 
A tiny amount of freeze stock was picked with a sterile pipette tip, resuspended and grown in 
5 ml LB for 12-18 hours at 37°C with 1% D-glucose, chloramphenicol (25 µg/ml final), 
kanamycin (25 µg/ml final) or ampicillin (50 µg/ml final). Kan and Amp added for the 
EkLIC30 and pET3a, respectively). The next morning, 1 ml of the culture was washed for 1 
minute at 12000 rpm, and the pellet resuspended in fresh LB before it was transferred to an 
Erlenmeyer flask with 49 ml pre-heated LB with 0,25% D-glucose and Kan or Amp as earlier. 
Cells were grown at 37, 30 and 25°C in separate experiments, and 0,5 ml-aliquots were taken 
during growth. 0,1 ml was immediately harvested at 4000 x g for 20 minutes in previously 
weighed eppendorf tubes, and both supernatant and pellet were separately frozen in a mix of 
dry ice and 70% EtOH, and stored at -20°C. 0,4 ml was assayed for absorbance at 600 nm 
using the Shimadzu UV-1201 spectrophotometer with LB medium as reference. This made it 
possible to closely watch growth rates and to induce expression at a suitable cell density. At 
A600 = 0,6-0,7, IPTG was added. After 3-4 hours of induction, the reaction was halted. In 
some experiments, D-glucose was left out and addition of NaCl/CaCl2 was attempted both 
with and without D-glucose to optimise the folding conditions for the expressed protein. 
 
Preparation of bacterial lysates for protein SDS PAGE 
 
The pellet’s wet weight was measured before it was thawed on ice and resuspended in lysis 
buffer (see appendix for recipe) at 2-5 ml per gram wet weight. Lysozyme was added to 1 
mg/ml, and the blend was kept on ice for 30 minutes before sonication (on ice) was performed 
at 25 W for 6 x 10 seconds with 10 seconds breaks in between. The viscous lysates were 
centrifuged at 10000 x g for 25 minutes at 4°C to pellet the cellular debris. The supernatant 
would now contain total protein. In the case of inclusion body formation, some lysates were 
submitted to a Tween20/EGTA-cleansing cycle: A solution of 0,25 % Tween and 0,1 mM 
EGTA was mixed with the pellet suspension in question, followed by a 13000 rpm spin for 3 
minutes at 4 °C. The supernatant was kept, while the pellet was washed twice more. 
Electrophoresis was performed as described earlier. 
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2.15.2 Protein expression in the RTS 100 cell free system 
 
We also tried the RTS 100 cell free expression system from Roche Applied Science. Using 
both the pET3aCOAS2 and pET30Ek/LICCOAS2 plasmids with the included protocol, we 
were able to obtain egfp control protein, but not to produce sufficient amounts of COAS2 for 
SDS PAGE visualisation with Coomassie Brilliant Blue staining. Please see the supplier’s 
protocol for supplementary information. 
 
2.15.3 Expression of COAS2 in insect cells using the BAC-to-BAC system 
 
In order to express our gene in an insect cell model system, the Bac-to-Bac system was 
chosen. This system relies on the generation of recombinant baculovirus by sit-specific 
transposition in E. coli rather than homologous recombination in insect cells (Jarvis et al., 
1990);(Wickham et al., 1992). A new plasmid vector was created, inserting COAS2 blunt 
ended without start codon into the EheI-digested FastBacHTa vector. DH10Bac bacterial cells 
were later transformed with this recombinant vector to yield a bacmid. After isolation, the 
Sf21 insect cells (Spodoptera frugiperda) were transfected with the bacmid. After 48 hours of 
incubation, recombinant baculovirus could be isolated. The viral stock would finally be used 
to transduce insect cells for protein expression, and protein lysates could ultimately be 
obtained. Please see www.invitrogen.com for further information regarding the Bac-to-Bac 
system. Dr. David J. Warren performed transformations, transfections, transductions and 
culturing of the cells. The author created the recombinant vector and performed the western 
blots required for protein detection.  
 
Cloning procedures  
 
An illustration of this procedure may be found in the appendix section. First, COAS2 was 
amplified from the FRT/To/COAS2 plasmid source using a 20-cycle PCR with Pfu 
proofreading polymerase and the COAS2UpperBac/LowerBac primers. The PCR product was 
gel purified according to section 2.2.4, and 2 µg of the gene-containing eluate submitted to 
end phosphorylation as described in section 2.3.5. The FastBacHTa vector had been digested 
with the enzyme Ehe1, leaving blunt ends. The plasmid was thereafter treated with shrimp 
alkaline phosphatase (SAP) to prevent re-ligation. Dr. David J. Warren of the Norwegian 
Radium Hospital performed the latter two preparations. The vector and insert were ligated in a 
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1:3 vector/insert ratio over night at 14°C as described in section 2.1.6, before the constructs 
were heat-shock transformed into DH5α cells. 20 colonies were screened for the COAS2 gene 
using PCR as described in section 2.3.4. COAS2Upper/LowerBac primers and a DNRTaq 
polymerase were used, and positive clones were grown in 5 ml LB over night with 50 µg/ml 
Ampicillin, and miniprepped as described in section 2.1.2. Having verified sequence and 
direction/correct reading frame, Dr. David J. Warren performed all further steps in the Bac-to-
Bac system. Insect cell lysates were analysed using the western blotting method, see section 
2.16.1. Attempts to enrich the cell lysates for HIS6-COAS2 were made using 
immunoprecipitation (IP) with Protein G agarose (Sigma), see further on. 
 
2.16 Expression of COAS2 in mammalian Flp-In 293 cells 
 
To enable localisation of COAS2 in the 293 cells, we aimed to use confocal microscopy (see 
sections 2.13 and 2.14 for more on CFM). A C-terminal Myc-His6 tag was taken from the 
pcDNA3.1 B(+) Myc-His6 expression plasmid (kindly provided by Hans Christian Åsheim, 
Department of Immunology at the Norwegian Radium Hospital). COAS2 was PCR-amplified 
from the FRT/TO/COAS2 vector with a DaveTaq polymerase and the UpperXbaI/LowerSfuI 
primers, followed by restriction cutting of both pcDNA3.1 vector and PCR product with the 
XbaI and SfuI enzymes. Gel purification was followed by ligation as described in section 
2.1.6, and again transformation into JM109 cells as described in section 2.1.1. 
PCR with the SfuI/XbaI primers was used for screening colonies, and stocks were ultimately 
made after restriction cutting and size verification plus automated dideoxy-sequencing. The 
next PCR step with XhoISTOP and BamHICOAS2 primers and DaveTaq polymerase gave an 
expected ≈ 600 bp product visualised with PAGE. After purification (section 2.3.3), the PCR 
product was digested along with the pcDNA5.1 FRT and FRT/To vectors with XhoI and 
BamHI enzymes (NEB) before gel purification and ligation over night at 16°C. 
Transformation into JM109 cells, PCR screening of the clones with specific primers, 
miniprepping, sequencing and maxiprepping was performed as described earlier.  
Each plasmid was co-transfected with the pOG44 plasmid into their respective 293 cell line in 
a 12:2 ratio of FuGene : DNA (µg). To verify the expression of our gene, we established a 
time series of tetracycline-induced samples. These were submitted to RNA purification with 
Trizol along with one constitutive 293 clone. All samples were further quantified, and 
northern filter was subsequently created. The filter was thus hybridised with a COAS2 cDNA 
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probe. Further protein assays were performed as for the FastBac system, with the α-Myc 
9E10 antibody in addition to the α-His antibodies. 
 
2.16.1 Western blots and antibodies 
 
Western blotting provides a direct method for identifying, monitoring, and determining the 
presence and relative amount of specific proteins in biological samples (Gershoni and Palade, 
1982); (Renart and Sandoval, 1984). In comparison to other blotting techniques, (e.g. 
Southern and northern blotting), proteins are separated in a polyacrylamide gel, and blotted 
either by gravity forces or by the aid of electric force in a blotting apparatus onto either 
nitrocellulose or polyvinylidene fluoride (PVDF) membranes with a poresize of 0,45 µm. The 
filters are blocked towards non-specific hybridisation and further exposed to conjugated 
antibody solutions. Visualisation is possible through enhanced chemoluminescence (ECL) 
after thorough wash cycles. The wash solutions often contain extra detergents such as SDS or 
‘Tween20’ to minimize unspecific binding and thereby ameliorate the results. In a western 
blot, commercially available antibodies are used to detect native or recombinant proteins with 
high specificity. 
 
2.16.2 Chemoluminescence 
 
Emission of light from a substance in an excited state is defined as chemoluminescence if it is 
effected by a chemical reaction. The most known system may be the horseradish peroxidase 
(HRP)/hydrogen peroxide-catalyzed oxidation of luminol under alkaline conditions, which 
was used for visualisation of western blots in this work. The cyclic diacylhydrazide luminol is 
more efficiently oxidated by HRP in the presence of phenols, increasing the light output and 
emission time (also known as “enhanced chemoluminescence”, or ECL). Light produced has 
a maximum emission at 428 nm, which can be detected by a short exposure to blue-light 
sensitive autoradiography film.   
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Figure 2.14: Illustration of the ECL advance system used for visualisation of Western Blots. 
Picture taken from the ECL kit protocol (Amersham Biosciences).  
 
2.16.3 Preparation of mammalian cell lysates 
 
The samples are most often non-purified total protein cell or tissue lysates. The denaturating 
lysate buffers contain cocktails of proteolytic inhibitors, detergents and chaotrophic salts to 
prevent proteolytic activity and hence fragmentation of the protein(s) of interest. It is 
important to keep all solutions on ice while working. In this work, both native (i.e. non-
denaturating), and denaturating conditions have been used to lyse cells and retrieve their 
protein content. Electrophoresis, however, has only been performed under denaturating 
conditions (SDS PAGE with β-mercaptoethanol added to the sample loading buffers).  
 
2.16.4 Protein lysate from mammalian cells in vitro 
 
Cells were harvested as described in section 2.9.2, and the tube containing the pellet was snap 
frozen in liquid N2 and stored at -70°C. Solutions for denaturating conditions were made 
according to guidelines in the Qiagen Expressionist, using 6M Urea as denaturating agent. 
Please see www.qiagen.com for additional information. 
 
Method 1 
The pellet was dissolved in lysisbuffer A8, with added protease inhibitors (Pepstain A, 
Leupeptin Hemisulfate and Aprotinin at a final 0,01 mg/ml; PMSF to 1 mM). As a rule, 0,1 
ml buffer was used per million cells. After 15-120 minutes on ice with occasional vortexing, 
                                                          
8 150 mM NaCl, 50 mM Tris-Cl pH 7.5, 0,1% NP-40 
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the samples were sonicated 3 x 10 seconds at 25 W and spun at 13000 rpm for 15 minutes at 
4°C. The supernatant and pellets were frozen separately at -70°C.  
 
Method 2 
The cell flasks were deprived of medium and held on ice while washed once in ice cold PBS, 
before addition of 500 µl warm lysis solution9. Using a sterile rubber cell scrape, they were 
collected and further transferred by pipette to Eppendorf tubes. Boiled for 5 minutes at 100°C 
and again cooled on ice. The genomic DNA is sheared by mechanical rupture, resuspending 
the solution 4-5 times through a Microlane3 (0,5 x 16 mm) syringe tip. The solution is further 
centrifuged at 4°C for 7 minutes at 13000 rpm, and the supernatant is kept and an aliquote 
taken for total protein content analysis. After quantification, a protease inhibitor cocktail can 
eventually be added in a 1:100 dilution before the samples are snap frozen in liquid N2 and 
transferred to -70°C. 
 
2.16.5 Measurement of protein content (BRADFORD) 
 
The total protein concentration was measured using the Bradford assay as first described by 
M. Bradford (1976). The standard microtiter plate protocol was followed, using a Wallac 
microplate reader at 595 nm along with bovine gamma immunoglobulin (IgG) as standard. 
 
2.16.6 Dot Blot protocol 
 
Serial dilutions of standards (and later samples) were used for antibody optimisation, 
diluted in lysis buffer and applied with a pipette onto dry pieces of nitrocellulose paper (BIO-
RAD), and air-dried for 30 minutes. Further incubations and ECL visualisations proceeded as 
for tank blotted filters, see further on. We used primary antibody concentrations ranging from 
0,1-1,0 µg/ml. 
 
 
 
                                                          
9 1%SDS, 1 mM sodium orthovanadate, (Na3VO4), 1 mM Tris-Cl pH 7.5 
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Protein SDS-PAGE  
 
Our expected expression products had molecular weights of 18-25 kDa, and we chose 12% 
PA-gels for the SDS PAGE, which was performed as described in 2.2.3 with a dual color 
MW-standard from BIO-RAD. The 6x loading buffer contained 25% β-mercaptoethanol to 
prevent reformation of disulfide bridges. Samples were diluted to 20 µl in lysisbuffer, added 
loading buffer and denatured at 95°C for 5 minutes. Following a brief centrifugal spin to 
pellet debris, the samples were loaded onto the gel, which was cast as described in section 
2.2.2 and 2.2.3, using the recipe from table 2.5. Electrophoresis was performed with a 1 x 
glycine/Tris western running buffer (appendix B), and the voltage was set to 30 mA for 15 
minutes followed by 50 mA to end.   
 
Western blot protocol (tank transfer) 
The gels were transferred to a western blotting buffer (either Bjerrum-Scäfer-Nilsen, (BSN), 
or blotting buffer A, please see appendix for recipes), as the Mini-ProteanII blotting equipment 
(BIO-RAD) was assembled. When PVDF filters were used, they were soaked in MeOH for 1 
minute, subsequently rinsed in doubly distilled water and 1 x blotting buffer. This was 
necessary due to its hydrophobic nature. Nitrocellulose filters were directly soaked in buffer 
before the blotting equipment was assembled as illustrated here. 
 
 
 
Figure 2.15: Illustration of a blotting apparatus for western blotting. 
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All blots were run at 4°C, with magnetic stir-circulation of the buffer and cooled with ice to 
keep the equipment from over-heating. The tank transfer was performed overnight at 30 V or 
400mA for 60-70 minutes. Filters could be stained with Amidoblack for 5 minutes and 
destained with the Amidoblack wash solution for 2x10 minutes at this point. The filters were 
washed in ddH2O to clear the inhibiting methanol. All blocking and incubations with different 
primary antibodies were performed according to the supplier’s directives. 
 
The following primary antibodies were used, all at 0,5 µg/ml final concentration:  
In PBS/PBST with 0,5% dry milk: monoclonal mouse-α-human α-Myc 9E10 (kindly provided 
by Dr. David J. Warren), monoclonal mouse-α-human α-His6 and monoclonal mouse-α-
human α-HisHRP (Roche Applied Science). In TBS/TBST10 with 3%BSA: monoclonal mouse-
α-human α-pentaHis (Qiagen). The Roche antibodies proved to be dysfunctional, not being 
able to bind positive controls under native conditions (results not shown). After a 3 x 10 min 
wash in either PBS/PBST, or TBS/TBST, the filter was exposed for 60-120 minutes to the 
secondary HRP-conjugated antibody from DAPI, diluted 1:5000 in PBS + 5% dry milk (w/v) 
or TBS + 5% dry milk (w/v). This was followed by 3 new 10 min PBST/TBST wash cycles, 
where the final wash was with distilled water only, before ECL-visualisation according to the 
supplier’s protocol. The films were exposed from 10-600 seconds and developed as described 
earlier. The ECL kits were from Pierce (SuperSignal West Pico), and Amersham Biosciences. 
Solution recipes can be found in the appendix section B.  
 
2.17 Immunoprecipitation of epitope-tagged COAS2 
 
Immunoprecipitation (IP) is a procedure by which peptides or proteins that react specifically 
with an antibody are removed from solution and examined for quantity or physical 
characteristics (molecular weight, isoelectric point, et cetera) (Harlow, 1988); (Sambrook, 
2001). Antibody-antigen complexes are removed from solution by addition of an insoluble 
form of an antibody binding protein such as Protein A, Protein G or second antibody. 
Analysis of the immunoprecipitate is usually by electrophoresis although other techniques can 
be used (Sambrook, 2001). The choice of immobilized antibody binding protein depends upon 
the species that the antibody was raised in. In this work, we applied Protein G, since it binds 
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strongly to IgG from cow, goat, sheep, cow, horse, rabbit and guinea pig and to mouse IgG1 
and IgG3. Protein G can also bind bovine serum albumin (BSA). Thus, BSA was added to 
buffers used with Protein G. To detect the mouse IgG1-antibodies used in this work, we used 
three different protocols from Qiagen and Invitrogen (www.qiagen.com, 
www.invitrogen.com). Experiments were conducted with HIS6- tagged COAS2 from insect 
cells. These were initially detected using penta-HIS antibodies, which again was bound by the 
Protein G reagent. SDS-PAGE was applied for sample analysis. Please see the supplier’s 
websites for further information regarding immunoprecipitation. 
                                                                                                                                                                                     
10 T = 0,05% (v/v) Tween20 
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3 RESULTS 
 
Cyclophilins have been extensively investigated over the past 20 years, resulting in findings 
that may be of value for the COAS2 protein. It has 84% amino acid homology to peptidyl-
prolyl isomerase A (PPIA), a protein with diverse functions. PPIA has been reported to be 
important during developmental stages of many human malignancies (e.g. HIV-infection of 
host cells and cancer development), whilst COAS2 has been found amplified and over-
expressed in a subset of human cancers (Bukrinsky, 2002; Meza-Zepeda et al., 2002). To 
characterise this potential oncogene, we initially performed analysis of the nucleotide- and 
amino acid sequence, followed by diverse methods examining potential cancer-related effects 
of cells over-expressing COAS2 (e.g. cellular growth, cell cycle regulation and COAS2-
mediated cellular resistance to chemotherapeutic agents). In parallel, we expressed the gene 
product in three model systems for production of a monoclonal antibody towards COAS2. 
  
3.1 Sequence analysis of COAS2 
 
It has been shown that PPIA harbours a proteoglycan-binding site at its C-terminus (Saphire 
et al., 1999). A Blast2 search verifies the existence of such a sequence in the translated 
COAS2 mRNA, where the 148RNSKTSKK155 site differs in one amino acid only between the 
two: (150GÆ150S in COAS2). In addition to this, the pI of COAS2 has been estimated in 
silico to be 9.3, compared to the CypA pI of 7.8. Furthermore, a hydropathy plot of COAS2 
versus that of Cyp A made using the Vector NTi software gives very different total 
hydropathy values (Hi-values) for these two proteins.  
The search name “COAS2” in the NCBI Entrez protein database presently holds the accession 
number NP_839944 with REFSEQ-accession number NM_178230. Dr. Shinji Tanaka 
submitted an identical sequence to the NCBI in May 2002, in parallel with the COAS2-
sequence submitted by Dr. Leonardo A. Meza-Zepeda. Dr. Tanaka reported the transcript as 
over-expressed in and thus related to liver cancer, and the sequence was termed “Cyclophilin-
LC”. Later findings at the DNA and protein levels have been limited. In 2003, Mr. Andrzej 
Galat summarised the findings of class A-cyclophilins; a subgroup to which COAS2 belongs. 
In the human genome, the author reported the existence of 18 paralogues of the 18 kDa CypA 
in silico, whereof two have been identified and mapped to a chromosomal location (Galat, 
2003). This number has increased to a total of 78 probable 
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http://pseudogene.org/human/index.html), whereof three locus-mapped pseudogenes, (named 
PPIA1-3 (Willenbrink et al., 1995). The human CypA gene holds three alternatively spliced 
variants encoding two distinct isoforms that have been observed. A good number of the 
remaining paralogues could represent processed pseudogenes or mutated genes of some sort. 
However, most accession codes given in Galats paper have already been removed as a result 
of standard genome annotation processing, making further analysis difficult. In addition (until 
proven otherwise), an accession number does not necessarily represent a fully functioning 
gene that codes for a unique RNA or protein product(s).  
 
To illustrate this point, potentially incorrect computer-based analysis indicates the existence 
of a long COAS2 sequence found through computer-assisted genome-wide mapping and 
annotation (“GNOMON” at the NCBI). Only expression of the 495 nt mRNA has so far been 
confirmed using human tissue samples, even though GNOMON suggests that a larger mRNA 
of 217 aa with accession number XM_352323 should exist alongside COAS2.  
 
The 660 bp RefSeq NM_178230 COAS2 sequence (which harbours the 495 bp coding 
sequence), has a 75 bp leader sequence containing no significant repeated sequence plus one 
additional upstream start codon. The Kozak sequence of COAS2 is 5’ CTATCAGCC 3’  
 The 1652 bp RefSeq NM_021130 PPIA sequence has a 72 bp leader sequence containing 
containing no significant repeated sequences nor additional upstream start codons, displaying 
a 5’CTAGTAGCC 3’ Kozak sequence. The relevance of these leader sequences will be given 
further attention in the discussion module. 
 
3.2 Artificial expression studies  
 
The cyclophilin family of proteins exert diverse functions in vivo, and little could therefore be 
hypothesised about the novel family member COAS2. However, its high amplification levels 
in a subset of tumours indicated that it could be a novel proto-oncogene. Many proto-
oncogenes are known regulators of growth (hereunder cell cycle regulation). Proto-oncogenes 
are thought to apoptosis and to cancer therapies. To examine effects of over-expressed 
COAS2 on characteristic cancer traits (growth regulation, chemotherapy resistance, cell cycle 
regulation and more), we decided to create stably transfected cell lines. Because FRT-
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containing 293 cells were available, they were used for these studies although the cell type 
was not optimal for experiments related to mesenchymal oncogenesis. 
In the egfp model system, the pEGFP-N1 plasmid was transfected into the 293 cells using the 
ratios depicted in table 2.6. Results indicated that electroporation under these conditions was 
less efficient than FuGene6. The results also showed that a 6:1 (µl/µg) ratio of FuGene6: 
DNA was the most efficient, with a maximum of 38,5 % living cells expressing egfp. This 
single experiment does not, however, eliminate experimental errors, and the relative 
percentages should therefore be merely viewed as estimates. Figure 3.1 shows the percentage 
of cells expressing egfp as a function of FuGene6:DNA ratio used for the transfection. The 
numbers were calculated using mean intensities for the fluorescent viable cells. 
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Figure 3.1: Percentage of living 293 Flp-In cells expressing pEGFP-N1 after transfection with 
FuGene6. Egfp-expression was screened by flow cytometry on transiently transfected cells. 
 
The electroporation series, however, were not entirely adequate examples since the amounts 
of cells were 1/6th of the recommended 4 x 106/ml in the standard protocols. For the two 
experiment series, we found that the optimal electroporator voltage setting was 54 V/mm, 
where 21% of the plated cells were successfully transfected (see figure 3.2).  
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Figure 3.2: pEGFP-N1 electroporation experiment of 293 cells. The x-axis has dual values, acting as 
% of living cells for the leftmost curve, and as % of transfected (living) cells for the second dataset. 
See text for further explanation.  
 
In a parallel experiment, parental cell lines in antibiotic-free growth medium were plated in 35 
mm culture dishes for cytotoxicity assays, in a range from 1 x 105 to 3 x 105 cells per dish. 
six µl FuGene6 was added to 94 µl of serum free Dulbecco’s Modified Eagle Medium 
(DMEM), followed by incubation for 15 minutes at room temperature and even dispersion of 
the blend into the growth medium of the plated cells. After 48 hours, the cells showed no 
apparent sign of growth inhibition or stress compared to the mock control (results not shown). 
Since the FuGene6 reagent caused no cytotoxic side effect, and demanded only an average of 
2x105 cells per 35 mm dish for a single transfection (compared to 4 x 106 cells per ml in a 
standard electroporation experiment), we decided to keep working with FuGene6. 
 
3.2.1 Testing the Tet-promoter system with EGFP-transfectants 
 
Flow cytometry analysis of tetracycline-induced T-rex Flp-In 293 egfp transfectants was 
performed with parental T-Rex 293 cell line as negative control. The time points at 5, 24 and 
96 hours were used to design the following curve (cells grown and harvested by Miss Lise 
Ramberg). The average intensity of green light was used, and its fold increase of intensity was 
calculated relative to the negative control. After tetracycline addition, the light intensity was 
found increased more than 1000-fold. 
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Figure 3.3: Increased intensity of green light upon tetracycline addition to 293 T-Rex cells transfected 
with egfp. Curve designed by Lise Ramberg.  
 
The TetOn promoter did show signs of “leakage”, as some of the uninduced egfp-transfected 
cells emitted green light when excited with blue light in an inverted fluorescence microscope. 
To investigate whether this originated from tetracycline present in the fetal calf serum (FCS) 
in use, a cell culture was grown in triplicate for 22 days in growth medium with 8% 
tetracycline-free calf serum from PAA. Flow cytometry was used for comparison of cells 
grown in the respective media. With standard FCS, we measured the amount of cells 
expressing egfp to 0,4% of the total. The new FCS merely lowered this value to 0,3% (results 
not shown), which may indicate that a permanent promoter leakage existed independently of 
serum tetracycline. We confirmed induction of egfp in the same clone by fluorescence 
microscopy (results not shown). 
 
3.2.2 Creation of Flp-In cell lines and assay for antibiotic-sensitivity 
 
In the Flp-In system, selection of positive clones is driven by addition of antibiotics to the 
growth media. Proper function and ideal working concentration of the antibiotic in use had 
thus to be evaluated before any transfection experiment could be launched. We therefore 
performed toxicity assays for Zeocin, Blasticidin and Hygromycin. One exception was made, 
where LOX-cells were chosen for Zeocin-testing, since our 293 parental cell lines were 
Zeocin-resistant. However, Zeocin does not have a traditional antibiotic “mode of operation” 
where cells round up and detach from the cell flask, but a slower progress where 293-cells 
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treated with Zeocin gain necrotic features with vague contours and blurred edges. The cells 
were therefore submitted to Zeocin-sensitivity testing with 1-1000 µg/ml Zeocin. After 2 
weeks of selection, the apparently ideal concentrations were found to be 500 µg/ml Zeocin for 
sensitivity assays (five times the concentration recommended for culturing the parental cell 
lines), and 150 µg/ml Hygromycin for clone selection purposes. In a third experiment, both 
LOX-cells and 293 Flp-In parental cells grown in DMEM with 15 µg/ml Blasticidin were all 
dead after one week of treatment. This concentration was used to culture Flp-In T-Rex 293 
cells and its descendants.  
 
               
 
  
 
Figure 3.4: Zeocin killing 293 cells. Left: After 7 days of selection, right: single cell after 12 days of 
selection.  
 
3.2.3 Stable transfection in the Flp-In system 
 
FuGene6-transfection was used for the creation of all cell lines. After 24 hours of incubation, 
selection was initiated with medium containing Hygromycin (Flp-In 293 constitutive 
expression), and Hygromycin/Blasticidin (T-Rex 293 tetracycline-inducible expression). After 
9-12 days, cell clones were picked and transferred using a 200-1000 µl pipette. Remaining 
cells were pooled after 17-20 days of selection. The clones were further mycoplasma-tested 
and assayed for Zeocin-sensitivity and finally stored as described in 2.9.4. 
 
293 cells transfected with COAS2 
 
Of 15 picked FRT/TO/COAS2-clones, only one was Zeocin-sensitive, compared to three out 
of the total eight for the constitutive clones. The reason why these clones showed resistance to 
7 days
12 days
 99
both Hygromycin and Zeocin was examined in a Southern blot analysis using DNA from 
parental cell lines and transfectants, see section 2.8. 
 
293 cells transfected with COAS2MycHis6 
 
The two MYC-HIS6-tagged COAS2-clones showed a higher degree of Zeocin-sensitivity. In 
the case of tetracycline-inducible clones, only the pooled backup samples collected in the 
final phase of cell clone isolation and expansion were resistant to Zeocin. The single 
expanded constitutive MYC-HIS6 clone was Zeocin-resistant.  
 
293 cells transfected with egfp 
 
The Zeocin-sensitivity assay was not performed for the egfp-transfectants, although it may 
pinpoint a reason for promoter leakage (see further on). 12 clones were selected for each cell 
line; six with constitutive expression, and six with inducible expression. All clones were 
analyzed for egfp-expression using a Zeiss inverted fluorescence microscope with a FITC 
filter. 
 
293 cells transfected with COAS2/egfp and egfp/COAS2 fusion constructs 
 
Mr. M. Skårn created two fusion constructs where the coding sequence of the egfp reporter 
gene was cloned N- and C-terminally of COAS2 ORF, respectively. After cloning and 
purification of the recombinant plasmid, the sequences were verified. The constructs were 
subsequently transfected, followed by selection of positive clones according to section 2.9.6. 
Only two clones of 20 were found to be Zeocin-sensitive. All clones were further submitted to 
tetracycline induction (added to 0,1 µg/ml and 1µg/ml for comparison of egfp fluorescence 
intensity). 
 
In parallel, Mr. M. Skårn transfected the egfp fusion constructs transiently into the Flp-In 
cells, i.e. without co-transfection of the Flp Recombinase-expressing pOG44 plasmid.  
As positive controls, the FRT/TO/egfp clone #1 (stable transfectants) and the pEGFP-N1 
(transient transfection) plasmids were chosen.  
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3.3 Southern blot-assay of the Flp-In system 
 
To assay the isogenicity and interclonal difference of the cell line, a Southern blot was 
utilised. The number of FRT integration sites in parental and clone could be connected to 
antibiotic resistance and sensitivity in the given clones. Since Zeocin-sensitive and Zeocin-
resistant clones were found for both Flp-In systems, we therefore included both types of 
clones in this experiment, (constitutive and inducible expression). The hygromycin-gene of 
pcDNA5 plasmid-origin should produce a single band in all transfectant samples, and yield no 
band in the parental controls. The expected single band occurred in all samples for the lacZ-
Zeo probe, indicating that both parental cell lines plus transfected downstream products had 
one copy only per locus of this gene. This was a prerequisite for cell line isogenicity. If the 
DNA was properly quantified but the band intensities showed signs of divergence, this could 
hypothetically be an indication that several copies had been integrated. The different 
intensities in the blots shown in figure 3.5 are nevertheless most likely due to concentration 
variations, (as shown in figure 3.6). 
 
 
   
 
 
Figure 3.5: Southern blot of COAS2-transfected Flp-In 293 cells. Each lane harbours 7 µg HindIII-
digested genomic DNA. Left: lacZ-Zeo-probe, and right: Hygromycin-probe. In both assays from left: 
1kb MW-ladder, Constitutive #1, Constitutive #3, Flp-In parental, Inducible #12, Inducible #3, T-Rex 
parental. Some lacZZeo was left after on the filter even though the filter was stripped after the first 
hybridisation. This is indicated the figure (right). A Cyclin D1-probe was applied as loading control. 
 
The blot was quantified using a fragment of the cyclin D1 gene, kindly provided by Ms. Åse 
Bratland. Laser densitometry was applied on the blot, as shown in figure 3.6. 
Hygromycin 
lacZZeo lacZZeo 
Cyclin D1 
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Figure 3.6: Quantified Southern blot from figure 3.4. 
 
The levels of T-Rex parental cell line were very high compared to the other samples, 
explaining the strong band shown in figure 3.4 (lacZeo probe). 
 
3.4 Verification of COAS2-expression in the Flp-In system 
 
To investigate whether COAS2 was properly expressed upon tetracycline addition, a time 
series was established as described in sections 2.7 and 2.9. It should be considered, however, 
that tetracycline has a half-life of 24 hours, and must therefore be replenished every 48 hours 
to provide sufficient levels at all time points in the series. Six micrograms of total RNA was 
used for Northern analysis, along with equal amounts from the constitutive clone #1. 
The antibiotic resistance assays indicated that both the constitutive clone#1 and the inducable 
clone #12 were resistant to both antibiotics. The clone #3 was therefore used in all further 
experiments, except for the microarray experiments, where clones #3 and #12 were included 
to address potential dye incorporation differences. 
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Figure 3.7: Northern blot of COAS2-transfected 293 cells. Top: tetracycline-induction of COAS2-
transcription in tetracycline-inducable cell clones #3 and #12. Bottom: 18S r RNA loading control. 
 
As indicated in the band at t = 0 hours, endogenously expressed cyclophilins may be present 
in the samples. Using the 18s rRNA and a laser densitometer, the northern blot was 
quantified: (Figure 3.8) 
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Figure 3.8: The expression levels of COAS2 are slightly clone-dependent. Tetracycline has a half-life 
of 24 hours, and was only added anew after 48 hours. Black: Parental cells and OHS, a cell line over-
expressing COAS2. Grey: Time series of clone #12 with over-expressed COAS2. Turquoise: Time 
series of clone #3 with over-expressed COAS2. 
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3.5 Expression of COAS2- MYC9E10-HIS6 in the Flp-In system 
 
COAS2, C-terminally tagged with MYC-HIS6 was cloned into two different pcDNA5-
plasmids, and further transfected with FuGene6 into the Flp-In cell lines as described earlier. 
A time series was made for northern blot verification of proper system function. RNA was 
prepared and the northern run as outlined in the methods section. The cDNA probe used for 
the COAS2-cell line material was applied to a filter containing ten micrograms of total RNA. 
 
 
 
 
 
 
Figure 3.9: Northern blot illustrating the expression of COAS2-MYC-HIS6 mRNA in the tetracycline-
induced samples compared to the negative control. The Const#1 is the clone with constitutive 
expression of COAS2. OHS is a cell line established at the Department of Tumor Biology from a 
primary osteosarcoma from femur. Equal levels of expression in both the Const#1 and the negative 
control sample (0 hours) cannot be explained without further experiments, please see further on. Fresh 
growth medium with tetracycline was added after 48 hours. Numbers from 0-95 signifies timepoint of 
sample harvest (hours after tetracycline addition). See figure 3.9 for additional details. 
 
As indicated in the band at t = 0 hours, endogenously expressed cyclophilins may be present 
in the samples. To determine what the band represents, we must hybridise the filter with a 
probe containing the Myc9E10-His6-sequence only. If a negative control, e.g. a parental 293 
RNA sample is included; hybridisation of the Myc9E10-His6 probe will probably determine 
the wild type identity of these bands. The low levels of expression in the Const#1-sample will 
also be addressed through a second experiment. The filter was hybridised with a control probe 
(18s rRNA), and quantified using a laser densitometer (Figure 3.9). 
   OHS Const#1        0      8     22    50    76    95hrs  
COAS2 
 
 
 
18S rRNA 
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Figure 3.10: Diagram depicting expression ratios when quantified with a 18S rRNA control probe. 
Const#1 = cell clone with constitutive expression of COAS2. OHS is a cell line with amplification of 
COAS2. See figure 3.8 for additional details. 
 
Although the existence of the Myc-His6 tail was only verified for the plasmid DNA sequence, 
the northern filter strongly indicated a positive induction of our ORF when hybridised with a 
COAS2-probe. (We must hybridise the filter with a probe containing the Myc9E10-His6-
sequence only to address the existence of the tag.) We therefore proceeded to the protein 
visualisation step without further delay. Total protein lysates were prepared as outlined in the 
methods section, giving us two sample sets that were examined for COAS2-MYC-HIS6 
expression using SDS-PAGE. We never detected the protein, despite countless efforts of 
optimisation, using phosphate-and Tris-buffered saline of various concentrations, different 
antibodies and antisera, plus two different types of ECL-kits. For both α-Myc9E10 and α-
His5 antibodies, the positive controls gave strong, clear signals (results not shown). Possible 
explanations are hypothesized in the discussion section. 
 
3.6 Growth rate and cytotoxicity experiments 
 
3.6.1 Monolayer growth assays 
 
In addition to the soft agar experiments, two in vitro growth rate experiments were performed 
using SulphoRhodamine B staining in order to calculate an approximate doubling time for 
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two COAS2-transfected cell lines (the constitutive clone#1 and the tetracycline-inducable 
clone#3), and the parental Flp-In 293. The first experiment would give an estimate of cell 
growth, and thus the ideal range of dilutions to plate. Data was hence obtained in the second 
experiment. Using data from the 3000 cells per well-series and the formula depicted in section 
2.10, we were able to estimate as follows: 
 
Table 3.1: Determination of cell doubling time in the COAS2-transfected clones using the SRB 
colorimetric assay. 
 
Cell line Abs540 (t = 0) Abs540 (t = 4) Doubling time 
Flp-In 293 0,145 0,764 40.0 hours 
Constitutive clone#1 0,175 1,044 37.25 hours 
Tetracyline-induced clone#3 0,132 0,742 38.50 hours 
Clone#3, negative control 0,106 0,576 39.3 hours 
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Figure 3.11: Growth curves for COAS2-transfected clone and parental cell line, respectively. The 
mid-range of 3000 cells per well was used to estimate doubling times. 
 
Determination of growth rate for the 293 transfectants indicated that COAS2 had a small 
effect on growth rate when compared to a negative control.  
 
3.6.2 Soft agar growth assays 
 
With kind assistance from Mr. Meng Yu Wang, an initial experiment compared soft agar 
growth of the constitutive COAS2-clone #1 and the parental Flp-In 293 cell line. The first soft 
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agar experiment indicated a difference in clonogeneicity; the ability to form tumour-like cell 
colonies from single cells when grown without anchorage (attachment to a surface). The 
second experiment confirmed the first, even though minor internal differences for the 
constitutive clone data indicate that the number of initial cells differed in the two separate 
experiments. The data from the second experiment is shown, where triplicate mean values 
have been applied for each sample 
.
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Figure 3.12: Soft agar assay of cells over-expressing COAS2. The clone with constitutive expression 
forms more cell clones than its parental cell line, as indicated. Black = constitutive clone 1, and purple 
= 293 Flp-In parental cell line. Shown is one of two parallel experiments. Numbers are means of 
triplicate values. 
 
3.6.3 In vivo growth assays 
 
However, it is quite possible that COAS2 affects tumour growth in vivo, as indicated by the 
soft agar assay and monolayer results. We thus generated tumours from four 293 cell line 
transplants, by injecting cell suspensions subcutaneously in immunodeficient mice (athymic 
Balb-c/(nu/nu), bred at the Norwegian Radium Hospital). These xenografts were later 
propagated and their growth rates assayed over a time period of three months. Mr. Christoph 
Müller generated independent growth curves. The experiments were performed in triplicate, 
according to a protocol by (Kistner et al., 1996). 
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Figure 3.13: Model depicting growth rates for 293 cell grafts in nude immunodeficient mice. The 
tetracycline-inducable cell line FRT/To/COAS2/3 in green  , with the control tumours shown in red 
∇. The constitiutive clone FRT/COAS2/1 (pink  ), and the parental Flp-In 293 control (from passage 
2) in blue  .  
 
The growth curves of the xenografts indicate that over-expressed COAS2 has a potential effect 
on tumour growth. In the tetracycline-inducible tumours, the Flp-In system harbouring the 
TetOn promoter may have been disturbed after a long period without antibiotic selection. 
Interestingly, the experiments show that both negative control and tetracycline-induced cells 
from the T-Rex 293 origin grow faster than both parental 293 and clone with constitutive 
expression of COAS2.  
 
Total RNA from the tumours will be isolated and compared to cell line material using micro 
array analysis in the near future. Unfortunately, this was not possible within the timeframe of 
this work. 
 
3.6.4 Cytostatica-sensitivity assays 
 
A newly discovered oncogene may be of great worth, as its gene product may be sensitive to 
existing and new cancer therapies. To assay whether COAS2 could confer resistance to cancer 
drug treatment, Mr. C. Müller performed cytotoxicity experiments in triplicate with the stably 
COAS2-transfected clone#1 (constitutive expression), and reference parental 293 cell line. All 
samples were incubated with cytostatica for either four hours or 72 hours in triplicate 
experiments. The chosen cancer drugs cisplatin, doxorubicin (0,01-1000 nm) and 
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methothrexate (0,01-100 mM) gave similar results in this system, as sample and reference 
responded almost identically in all three experiments. Data from these experiments were 
summarised by Mr. C. Müller, and kindly reprinted here. 
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Figure 3.14: SRB growth inhibition assays. From top: Parental Flp-In 293 versus clone #1 with 
constitutive COAS2-expression, treated with cisplatin, methothrexate and doxorubicin, respectively. 
There were no significant growth differences between the cell lines in either experiment, indicating 
that over-expression of COAS2 in these cells may not confer resistance to these anticancer drugs upon 
treatment. Graphs and data are courtesy of Mr. C. Müller. 
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In all three assays, the relative growth rates were equally affected for parental and clone, 
respectively. This indicates that the over-expressed COAS2 gene product does not contribute 
to resistance to any of these drugs, at least not in 293 cells. The levels of COAS2 in these 
samples before and after treatment should ideally be verified in a repeated experiment. 
 
3.7 Flow cytometry analysis of cell cycle ratios in COAS2-transfected cells 
 
To investigate wether over expressed COAS2 had an effect on the cell cycle, we performed 
flow cytometry on methanol-fixed COAS2-transfected cells stained with the DNA-binding 
dye propidiumiodide. The 293 cells were prepared as described in section 2.13, with 
triplicates for all sample types. The experiment was repeated twice, and the graphs were 
visually compared. Thus quantitative data for the G1, M and G2 phases are not available, but 
will be upon repetition of the experiment using lower amounts of FCS in the cell growth 
medium. An interesting observation was made in the experiment using 2 % FCS; the 
existence of a small peak prior to the G1-peak in the negative controls only (indicated with an 
ellipsoid in figure 3.18 D). This could be background noise, or dead (possibly through 
apoptotis) cells stained with propidiumiodide. Please see discussion for further comments on 
this subject. 
The cell lines fed with 2 % FCS grew more slowly than those with 8 % FCS, as expected. 
However, the 2 % did not fully inhibit cellular growth, nor did the samples grown in 2% FCS 
show any major difference to the 8 %-samples regarding possible COAS2-influence on the 
cell cycle display. (The tetracycline-induced cells showed similar G1-S-G2-patterns as the 
reference cells.) Although 2 % FCS caused lowered growth, an actual effect of COAS2 on 
cell cycle distribution may not be seen unless the experiment is repeated with 0,5-1 % FCS for 
more pronounced growth reduction. This was however not possible within the timeframe of 
this work. 
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Figure 3.15: Cell cycle distributions of 293 Flp-In cells over-expressing COAS2. Y-axis: 5000 
counted cells, x-axis: total fluorescence intensity (propidiumiodide excitation).  Data from two unique 
experiments are shown. A: Standard conditions (8 % FCS), sample with over-expressed COAS2.  
B: Standard conditions, uninduced control. C: Cells fed with 2 % FCS, sample with over-expressed 
COAS2, and D: Cells fed 2 % FCS, uninduced control.  
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3.8 cDNA microarray-results 
 
cDNA microarray analysis of stably transfected cells was applied in this work to create a 
transcription profile of cells over-expressing COAS2. Upon over-expression in 293 cells, the 
microarray procedure could potentially reveal signal pathways affected by ectopically 
expressed COAS2, giving information about the functional role of this cyclophilin. 
 
Two series of cDNA slide prints were applied to the total RNA in question, and hybridisations 
have been performed at various temperatures, as manual and machine-assisted hybridisations. 
Initially, cDNA arrays were chosen for two different time series with three timepoints each 
(5,11 and 25 hours, respectively). This would give a notion of biological variation, as the 
series originated from two different clones. As reference in these series, non-induced samples 
harvested at the corresponding time points were used. Existence of COAS2 mRNA had been 
verified in both clones, but one was resistant to both Hygromycin and Zeocin after isolation, 
whilst the other was only Hygromycin-resistant (#12 and #3, respectively, see figure 3.10). 
The RNA quality of the 25 hour sample from clone #12 was however not adequate, forcibly 
reducing the number of time points to five. In addition to the time series, the parental cell line 
was run as reference when analysing clone#1 (with constitutive COAS2-expression), an assay 
that theoretically should give the two series an endpoint for comparison (where a high level of 
COAS2 had been expressed for a long time). To determine the efficiency of dye incorporation 
and eventual downstream effects thereto, a single dye swap experiment was used for the 
sample set of constitutive expression. The dyes were equally incorporated in both sample and 
reference, hence not affecting the expression ratios for most transcripts. However, full 
accuracy only can be assessed after internal array-array normalisation, which was not 
accomplished in BASE. 
 
The results are presented as sample/reference ratios of a subset of the upregulated genes, as 
well as total intensity values. COAS2 was not present in the cDNA arrays. All the sequences 
of genes included (except the cyclophilins) have been verified. 
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Table 3.2: Ratios from cDNA microarray time series experiments. C = constitutive expression of 
COAS2. Ratio cutoff = 2; X = absent (flagged spot), L = spot with expression ratio of less than 2 in 
the experiment. Cl = cell line. Ratios stem from parallel or triplicate experiments except for the 6 and 
12 hour samples.  
Gene symbol Gene name Sample/reference ratio (Cy5/Cy3) 
Cl: #3  #12      #3     #12       #3  
  5        6         11       12        25        C 
COL1A2 Collagen type 1 alpha 2 L 4.4 L 4.6 L 2.2 
GJA5 Gap junction protein, alpha 5, (connexin 40) 4.5 4.2 L 3.0 2.2 4.1 
HMP19 Hypothalamus golgi apparatus expressed 19 kDa protein 4.1 4.6 L 3.1 L 3.4 
IL7R Interleukin 7 receptor 3.1 3.0 2.3 4.0 2.1 2.8 
L-Sox5 SRY-box 5,transcript variant 2 2.6 2.9 3.0 5.9 3.8 4.1 
MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 2.9 3.0 X 3.4 3.5 X 
MGLL Monoglyceride lipase X 4.7 2.6 4.9 2.1 L 
MST1R Macrophage stimulating 1 receptor X X L 4.7 3.6 2.5 
MYL3 Myosin, light polypeptide 3 2.1 3.9 L 3.2 L 4.5 
Sox6 SRY-box 6 3.6 5.2 2.1 6.2 X 3.7 
PPIC Peptidyl-prolyl isomerase C 1.0 1.0 0.6 1.1 1.2 1.0 
PPIF Peptidyl-prolyl isomerase F 1.1 0.8 1.0 0.9 1.1 1.1 
PPIA Peptidyl-prolyl isomerase A 1.0 0.9 1.4 1.3 1.1 1.4 
 
The 6 and 12 hour time points stem from the clone #12, whereas the three other time points 
originate from clone#3. The data for L-Sox5 illustrates a problem that may be caused by this 
fact: In the 12 hour-sample, the ratio value is twice that of the 11 hour sample, suggesting 
considerable clonal variation. However, northern blotting did demonstrate that levels of 
COAS2 expression in clone #12 are higher than those of clone#3. The high level of COAS2 in 
clone#12 could contribute to the higher levels of several putative downstream genes observed 
here.  
 
Table 3.3: Intensities taken from two separate experiments for the L-Sox5 and Sox6 genes. 
Background levels have been subtracted; intensities stem from normalised data. 
Gene 
symbol 
Gene  
name 
Intensity  
11 hour 
sample 
Intensity  
11 hour 
control 
 
Ratio 
Intensity  
12 hour 
sample 
Intensity 
12 hour 
control 
 
Ratio 
Sox6 SRY-box 6 1521 504 3,0 3966 668 5,9 
L-Sox5 SRY-box 5, transcript 
var. 2 
805 383 2,1 2890 464 6,2 
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The interclonal variation were not adjusted for, (that is normalised array by array), 
normalising parallels and excluding spots that do not exist in 80% of the data set. Such a 
method is not available in BASE, but in external programs, creating a file that cannot be 
reverted for later data comparison in BASE. Importantly, most of the spots are ignored 
because of similar levels throughout the experiment. It should be mentioned that in-house 
printed cDNA arrays have been reported to have some errors. The most interesting clones in 
this context were sequenced (but not COAS2), and certain errors were found. The cause of 
these faults may have been in the clone collections or arisen during probe preparation. 
 
In most assays, myosin light chain 1 (MYL1), interleukin 6 receptor (IL6R), tumour necrosis 
factor ligand superfamily member 11 (TNFSF11), and antigen CD37 were present as 
moderately upregulated genes. These probes were however not sequenced. The MGLL and 
HMP19 protein products were not examined further in this work. The collagen type one alpha 
two (COL1A2), was not present in more than half of the samples, but was included here 
because of its connection to the Sox family of transcription factors. 
The cDNA arrays indicated two HMG-box-containing transcription factors L-SOX5 and 
SOX6 as the most highly upregulated in many of the samples. (Sequencing identified the L-
Sox5 and Sox6-probes to be of murine origin, added by a user. M. musculus Sox6 and L-Sox5 
have 89 and 93% base pair homology to H. sapiens genes, respectively.) These two group D 
Sox proteins have been shown to form homo-or heterodimers through their coiled-coil 
domains and recognize pairs of HMG-binding sites (Lefebvre et al., 1998). Together with 
Sox9, the L-Sox5 and Sox6 proteins have been reported to regulate the expression of collagen 
type two alpha one (COL2A1) during chondrogenesis (Lefebvre et al., 1998). The COL2A1 
was printed on the microarrays, but was not found to be significantly upregulated. 
Expression of L-Sox5, Sox6 and COL2A1 in our samples was examined using the northern 
blotting method. Clones for H. sapiens L-SOX5, -6 and -9 were purchased from the Deutsches 
Ressourcenzentrum für Genomforschung (RZPD) in Germany, and the corresponding SOX5, 
SOX6 and SOX9-probes were generated as described in section 2.6.4. The COL2A1 probe had 
earlier been shown to have sufficient sensitivity in Southern blots, and was kindly provided by 
Dr. Leonardo Meza-Zepeda. Through database searches, mRNA levels in mammals of the 
respective SOX genes were found to be low, in the range of 5-20 transcripts per million in a 
mammalian cell, whilst the collagen is only expressed at high levels during early stages of 
chondrogenesis. No bands could actually be seen when hybridised towards a RNA filter 
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containing Flp-In cell line material with over-expressed COAS2 (Filter shown in figure 3.6).   
 
The absence of bands could potentially be due to poor incorporation of α-32P dCTP; therefore, 
the sensitivity of the SOX-probes were examined in a Southern blot: All three SOX-probes 
were hybridised to a filter containing genomic DNA from H. sapiens placenta and four cell 
lines whereof two were of human and two of murine origin. When the Southern filter was 
hybridised with SOX6, a single band occurred for all samples (results not shown), with the 
exception of two bands for the BALB-c murine cell line. L-SOX5 produced signals for murine 
samples only, whereas SOX9 did not hybridise at all to the filter. However, since the L-SOX5-
probe only detected murine DNA when hybridised to a Southern filter, this could mean, of 
course, that the probe actually was from M. musculus, rather than H sapiens. It might be 
explained by human error during probe preparation either at the site of purchase 
(Ressourcenzentrum für Genomforschung (RZPD), Germany), or by the author. 
At the time, the conclusion was however that the SOX probes were difficultly labelled with γ-
32P. Nevertheless, (with only the COL2A1 and SOX6-probes found to be adequately sensitive), 
we were not able to verify cDNA microarray results using northern blotting. 
 
3.9 Intracellular localisation experiments using egfp fusion proteins 
 
Mr. M. Skårn transiently transfected U2OS cells with pcDNA5FRT/TO/egfp/COAS2 and 
pcDNA5FRT/TO/COAS2/egfp. Both experiments displayed COAS2 fusion proteins (figure 
3.16). The fluorescence was relatively weak compared to the pEGFP-N1 control, but it was 
similar for both fusion constructs. Located to the cell membrane and the cytoplasma, the 
speckled pattern obtained in earlier experiments by Ms. Lygren was not reproduced.  
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Figure 3.16: U2OS cells transiently transfected with COAS2/egfp and egfp/COAS2. Pictures were 
taken 17 hours after transfection. Left: COAS2/egfp, middle: egfp/COAS2, and right: pEGFP-N1 
control. Pictures courtesy of Mr. M. Skårn. 
 
However, when the same constructs were used to create stably transfected Flp-In 293 T-Rex 
cells, the cells showed no expression of fusion construct (no visible fluorescence above the 
autofluorescence from the 293 cells). Analysis of the stable transfectants using northern and 
western blotting will be performed, but it is outside the timeframe of this work.  
 
3.9.1 Intracellular localisation experiments using COAS2-MYC-HIS6 
 
Intracellular identification of COAS2-MYC-HIS6 was attempted using confocal microscopy 
on fixed cells stained with a Rhodamine-tagged secondary antibody, in addition to two 
separate experiments that addressed filamin and actin expression in fixed cells with over-
expressed COAS2. The cells were prepared according to the standard protocol outlined in 
section 2.14.1, using in total three different primary antibodies, towards MYC, His6 and 
filamin(s). 
 
With the His5- and Myc9E10 antibodies, attempts were made to localise the tagged COAS2 
protein. The antibodies were initially applied in a range from 0,5-5 µg/ml, with the secondary 
Rhodamine-tagged antibody in a 1:100 dilution. Only the HIS5 antibody produced a signal. 
This signal was localised to the nucleus (excluding the nucleolus), as visualized by adding 3 
µl Vectashield mounting medium with DAPI-stain of the same cells. (DAPI stains genomic 
DNA and emits blue light in contrast to the red-emitting Rhodamine.) However, the signal 
arose in control 293 Flp-In parental cells too, indicating that this was a background artefact. 
The MYC9E10-signal was very weak, (at levels equal to control cells, whose levels were 
those of background signal only), and uniformly spread. Of course, endogenous MYC should 
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ideally have been detected if expressed in the 293 cells. The concentrations of primary 
antibodies were altered, using 5-10 µg/ml with secondary antibody concentrations as in earlier 
experiments. However, this did not produce a significant change: we were not able to detect 
the tagged protein.  
 
 
Figure 3.17: Cells with over-expression of COAS2-MYC-HIS6 show a nucleus-specific (excluding 
the nucleolus) signal when stained with α-His5 antibody. Secondary antibody was Rhodamine-tagged. 
Depicted is a merged photo taken after 16 hours of induction. 
 
     
     
 
Figure 3.18: Staining of MYC-His-tagged COAS2 protein in the Flp-In system with a Rhodamine-
tagged secondary antibody. Top row: Rhodamine/DAPI-stained 293 cells pictured with a DAPI filter, 
bottom row: identical cells pictured with a Rhodamine filter. Left: constitutive expression, center: 
parental Flp-In 293 negative control, right: tetracycline induced expression of COAS2-MYC-His after 
18 hours.  
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3.9.2 Filamin-staining of 293 cells 
 
We wanted to visualise the filamin proteins in cells with over-expression of COAS2 to 
examine whether this ectopic expression could cause a different pattern of filamin 
organisation or filamin expression. We stained for actin, using phalloidin, an actin-binding 
reagent, and filamin, using a goat anti-chicken filamin antibody (whole serum). No evident 
alteration was seen, as shown in figures 3.19 and 3.20. 
 
 
 
 
 
 
 
Figure 3.19: COAS2-transfected Flp-In cells stained with goat anti chicken filamin antibody (cross-
reactive towards human filamins). Left: over-expressed COAS2, right: negative control.  
 
    
 
Figure 3.20: COAS2-transfected Flp-In cells stained with phalloidin, an actin-binding reagent. Left: 
over-expressed COAS2, right: negative control.  
 
A specific antibody would facilitate studies of the COAS2 protein. The localisation 
experiments will thus be repeated upon generation of an antibody towards COAS2. 
 
 
 
 118
3.10 Protein expression in bacteria 
 
To produce a monoclonal antibody, a relatively large amount of purified protein is necessary. 
These amounts are most easily acquired using bacterial expression systems, which give good 
yield, but lack post-translational processing cellular mechanisms found in mammalian cells. 
Therefore, expression of a mammalian protein in bacterial cells is not a straightforward 
procedure, since proteins formed will not be fully processed and thus may cause the formation 
of inclusion bodies. We chose the BL21(DE3)pLysS cells partly because of their genotype 
and the tight transcription control mediated by the pLysS function. In this system, the rate of 
transcription could thus possibly be controlled so as to delimit the formation of inclusion 
bodies. Two different pET plasmids were used with these cells, to give two differently tagged 
COAS2 proteins upon expression. The pET30EkLIC plasmid would give a COAS2 protein 
with S-tag and His6-tag, whilst the pET3a plasmid only produced a T7-tagged COAS2.  
All three tags could be used for purification of the recombinant protein, using 
immunoprecipitation or immunoblotting with appropriate commercibly available antibodies.  
The expression of COAS2 in BL21(DE3)pLysS cells was visualized with SDS PAGE and 
Coomassie staining as described in the methods section. The first gel indicated a product in 
the pellet fraction of the sample at all time points.  
        
 
 
 
 
Figure 3.21: SDS-PAGE of time points during COAS2/S-tag-HIS6 expression in BL21pLysS cells. 
The 23 kDa protein is found solely in the pellet fraction (migrating as a somewhat larger protein, see 
figure). 
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No soluble COAS2/S-tag-HIS6 was formed. Later experiments therefore included additives in 
the LB in addition to a lowered growth temperature (30 °C) to overcome this problem. A 
construct producing cyclophilin A, however, produced the expected soluble protein in parallel 
cultures. We tried LB with added salt (0,02 mM CaCl2, 4 mM NaCl), glucose-rich, (0,06-
0,015 M), and glucose-free LB, and lysis with an acidic lysis buffer (NaAc, pH 5.2), to 
solubilize our protein. Seeing no formation of soluble protein, we repeated the assay at room 
temperature with the same conditions. After two experiments, the pellet suspension was 
rinsed with a blend of EGTA and Tween to extract soluble COAS2 as described in section 
2.15.1, but the attempt was not successful, as judged from a Coomassie-stained SDS-
polyacrylamide gel: (figure 3.22) 
 
 
 
 
 
 
 
Figure 3.22: SDS-PAGE of time points during COAS2/S-tag-HIS6-expression at 26°C in BL21pLysS 
cells. The protein remains in the pellet fraction after Tween-assisted purification.  
 
The pET3a/COAS2 construct was applied for production of a T7-tagged COAS2, but even 
here, only insoluble protein was formed despite altered growth conditions and subsequent 
purification attempts (results not shown). Our collaborators in the group of Dr. Schiene-
Fischer at the Max Planck Institute in Halle, Germany, came to the same conclusions. COAS2 
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forms insoluble protein in these bacterial systems, and may not be refolded or extracted using 
detergent washes from the aggregates formed in the pellet fraction. 
 
3.10.1 Protein expression in the RTS100 system 
 
The RTS100 cell free protein translation kit from Roche was used for attempted in vitro 
expression of COAS2. If positive results were achieved, the larger RTS500 system would be 
the next step, increasing the amount of produced soluble protein. In the RTS100 cell free 
system, the existence of the egfp control protein was easily verified in UV light, but with 
more difficulty in a SDS-PA gel. Attempts were made to up-concentrate the His6-tagged egfp 
protein using Ni2+-agarose columns were not successful. Several proteins were sought 
expressed using the RTS100 system, including COAS2-T7, COAS2-S-tag-His6 and S100A4-
His6 (courtesy of Dr. G. Mælandsmo). In all cases, enough protein was not produced for 
Coomassie Brilliant-Blue staining. Since the protein lysates created “smears” where COAS2 
and other products were difficultly located, we finally attempted to solubilise present protein 
using a detergent-based procedure described by the supplier: (figure 3.23) 
      
 
 
Figure 3.23: SDS-PAGE showing expression levels of COAS2 in the RTS100 cell free system after 
EGTA-Tween20-purification. The weak egfp positive control proteins (28 kDa) are indicated with an 
ellipsoid. Lanes number 1,3,5,8,10, 12 and 14 contain non-purified protein lysates. Even numbers 
contain MW-standards (lanes 6 and 14), purified COAS2-T7 (lanes 2 and 4), purified COAS2-S-tag-
HIS6 (lanes 7 and 9), and egfp controls (lanes 10-13). 
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Sufficient amounts of protein (for Coomassie Brilliant Blue-staining) were not produced.  
The pET vectors from Novagen were applied in this assay. We later learned that their 
backbone was not ideally suited for the RTS system, in contrast to the pIVEX plasmids from 
Roche. However, we were subsequently offered to express protein for monoclonal antibody 
production in eukaryotic cells, and thus decided to change expression system from bacteria to 
insect cells. 
 
3.10.2 Protein expression in insect cells with the Bac-to-Bac system 
 
As the Bac-to-Bac® system was readily established and managed by Dr. David J. Warren, we 
opted for COAS2-expression in this system, which is based upon baculovirus transduction of 
insect cells with concomitant protein production. The necessary primary transfer vector was 
generously offered to us, and the cloning procedure followed the flow chart displayed earlier 
in this section. Dr. Warren gave us seven different insect cell lysates after harvest and 
separation of pellet and supernatant. A band of correct size was detected as indicated in figure 
3.22, but COAS2 was seemingly present at low levels in the supernatant fraction. Usually, the 
pellet contains cell wall material and aggregated insoluble protein. Based upon former 
knowledge with bacterial expression of COAS2, our protein might be present (in high 
amounts) in this fraction. We did, however, only obtain the supernatant for visualization and 
quantification of the gene product, and do therefore not know whether more COAS2 was 
present as insoluble protein in the pellet fraction (potentially as Russell bodies or aggresomes 
in the insect cells).  
 
Dot blots were performed as outlined in section 2.16.6. Based upon dot blot results, we used 
0,5 µg/ml final antibody concentrations for our western assays (the standard varies from 0,1-
1,0 µg/ml for most antibodies). In parallel, lysates containing a small HIS6-tagged protein 
named CA125 were used as control. Both inserts shared the pFastBacHTa vector backbone. 
We quantified the total protein content with Bradford reagents, and loaded a range of 2 to 20 
µl with 6 x loading buffer onto a 5% + 12% PA gel. The gel was run, blotted and developed 
according to the methods section, and finally visualized using chemoluminescence. 
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Figure 3.24: Western blot of insect cell lysates, indicating the 21 kDa recombinant COAS2 and the 24 
kDa CA125 control protein. The α-His5 antibody (Qiagen) also bound MW-standard proteins in 
addition to several unknown probably His-containing proteins in the total cell lysate. 
 
The HIS6-COAS2 protein showed low, yet even levels of expression in all samples. The 
CA125 control had higher levels of expression: only 2-3 µl was needed in comparison to 10-
12 µl of COAS2-lysate in the above picture. This ratio was later confirmed in parallel blots 
(not shown). However, the pellet fraction was not examined for existence of the HIS6-tagged 
COAS2 protein, where some protein might be present. The lysates have been shipped to our 
collaborating group at the Max Planck Institute in Halle, Germany, where purification 
experiments will be performed.  
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4 Discussion  
 
Throughout this work, attempts have been made to characterise the novel cyclophilin coded 
by Chromosome One Amplified Sequence 2 (COAS2). Amplified and over-expressed in a 
subset of human tumours of mesenchymal origin, COAS2 holds great interest as a putative 
oncogene (Meza-Zepeda et al., 2002). An oncogene can potentially promote cellular growth 
through deregulation of signal pathways, possibly affecting the cell cycle regulation (Hartwell 
et al., 1994; Enzinger, 1995; Hesketh, 1997; Ford and Pardee, 1999). In addition, it could, as 
seen for the homologue PPIA in collaboration with other proteins, confer resistance to 
chemotherapeutic agents (Hesketh, 1997; Hirai et al., 1999; Kawazu et al., 1999). 
  
As mentioned earlier, COAS2 is a member of cyclophilin family of peptidyl-prolyl cis-trans 
isomerases (PPIases) (Meza-Zepeda et al., 2002). Their enzymatic activity is thought to be a 
rate-limiting step during protein folding and may modulate the activity of other proteins and 
their susceptibility to e.g. phosporylation by bending their peptidyl-prolyl bonds, thus 
changing their structure (Fischer et al., 1984; Etzkorn et al., 1994; Shaw, 2002). Because all 
amino acids necessary for this activity are preserved in COAS2, it is thus possible that 
COAS2 can exert such PPI-activity. 
 
However, because cyclophilins are abundantly expressed and exert diverse functions (Fischer 
and Schmid, 1990; Schiene-Fischer and Yu, 2001; Bukrinsky, 2002; Shaw, 2002), many 
possible functional roles could be foreseen for COAS2. To investigate some possible 
oncogenic function(s), cell growth and cell cycle regulation experiments were performed 
using stably transfected cell lines with over-expression of COAS2. In parallel, production of 
the COAS2 protein in model systems for monoclonal antibody production was attempted. 
Furthermore, we aimed to generate a transcription profile of 293 cells over-expressing 
COAS2 using cDNA microarray analysis, as this could possibly link the gene to known 
regulatory cellular pathways. Characterisation of the mammalian cell clones, confirming the 
proper insertion and expression of the gene product were performed using molecular biology 
techniques. Later, the project evolved to include confocal microscopy-based localisation 
studies using cell lines stably transfected with epitope-tagged COAS2.  
Of course, the adapted model systems are not ideal for the characterisation of a gene found 
amplified and over-expressed in sarcomas and breast cancer. They were a priori selected due 
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to ease of manipulation during the time schedule set for this work (traditionally 12-18 
months). As mentioned earlier, members of Ola Myklebost’s group are currently attempting 
to establish mesenchymal stem cell line models. These will be of major importance to future 
research on human sarcomas, including the cellular function(s) of COAS2. 
 
4.1 In silico analysis of the COAS2 sequence 
 
DNA sequence analysis may often indicate the structure and possible function of the gene 
product. Hence, domain searches at several online databases have been applied in this work to 
acquire information regarding COAS2. As mentioned, COAS2 has great amino acid homology 
to several cyclophilins, with a maximum of 84% amino acid identity to PPIA (Meza-Zepeda 
et al., 2002). In earlier work done on COAS2 sequence, Ms. Lygren and Dr. Meza-Zepeda 
generated hydropathy plots and an mRNA expression profile of the cyclophilin in a panel of 
tumors and some normal tissues. Later, Dr. S. Tanaka reported it to be upregulated in liver 
cancer (direct submission to the NCBI database), and termed the gene ‘cyclophilin-LC’.  
Additional mRNA or protein data has until the time of writing not not been published. The 
early findings indicate that the gene product may exert a similar function as CypA, having 
conserved the amino acids required for PPI acitivity (Meza-Zepeda et al., 2002). Upon 
examination of the translated mRNA, the high occurrence of acidic amino acids in COAS2 
explains the computed pI of 9.3 compared to the 7.7 of PPIA, but this has not yet been 
associated with any functional differences. Furthermore, the glycosaminoglycan (GAG) 
binding sites at amino acids #148-155 of both proteins differ in one amino acid only, an 
aspect which may indicate that the COAS2 gene product also binds GAG-containing proteins, 
but perhaps slightly different polycarbohydrates than those of PPIA, whose GAG-site has 
been shown to bind to heparins (Saphire et al., 1999). COAS2 and PPIA may therefore be 
expressed during different conditions or at different locations, targeting interaction partners 
via non-identical hydrophobic or hydrophilic parameters. COAS2 does not; however, seem to 
possess other known interaction domains, neither N- nor C-terminally.  
 
Cyclophilin A has many pseudogenes (www.pseudogene.org), and it cannot be excluded that 
the COAS2 gene could be a pseudogene of CypA. Pseudogenes may be generated by 
retrotransposition (Haendler and Hofer, 1990; Zhang et al., 2004), i.e. reverse transcription of 
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a mRNA transcript with subsequent re-integration of the cDNA into the genome. Since 
COAS2 does not have any introns, as opposed to CypA, it may have been generated by 
retrotransposition. Such copies of genes are termed processed pseudogenes, and when 
generated by this mechanism, such “retrocopies” of genes may, due to redundancy, 
accumulate random mutations over the course of evolution, and either acquire new functions, 
or become processed pseudogenes (Haendler and Hofer, 1990; Zhang et al., 2004).  
Of course, a requirement for a gene to be termed as a pseudogene is that no protein is 
produced (Zhang et al., 2004). However, the selection of over-expressed, amplified COAS2 in 
tumours, the absence of nonsense mutations and the conservation of the active site argue 
against this being a pseudogene. In a retrotransposed pseudogene, the promoter sequence may 
be unefficient or absent (Haendler and Hofer, 1990; Zhang et al., 2004). Again, the fact that 
COAS2 is over-expressed and amplified in tumours indicates that an active promoter does 
exist; alternatively that COAS2 could be over-expressed and amplified in a subset of tumours 
as a result of aberrant promoter regulation. 
 
Database annotations suggest that COAS2 may exist as a longer transcript, where the 5’ end is 
prolonged in respect to the 495 bp gene used in this work. However, the annotations are 
purely based on sequence analysis and theoretical predictions, and may be incorrect, possibly 
related to the existence of genomic upstream start codons (for more on database annotation, 
please see http://www.ncbi.nlm.nih.gov/Web/Newsltr/FallWinter03/builds.html). 
 
Such upstream codons create minicistronic sequences, a common trait thought to have 
regulatory functions in the human genome (Kozak, 1987). Regardless of computer-based 
errors, examination of the NM_178230 660 bp sequence reveals a 5’leader sequence of 75 bp 
harbouring one upstream ATG with a cytosin at –3. This indicates that this upstream coding 
sequence may function as a regulatory minicistron for the COAS2 gene (Kozak, 1987). 
Furthermore, if expressed, this small coding sequence should theoretically pose no problem 
for in vitro synthesis (e.g. leaky scanning, resulting in ribosome throw-off) (Kozak, 1987).  
Interestingly, the Kozak-sequences upstream of the start codons in COAS2 and PPIA are  
5’ CTATCAGCC 3’ and 5’ CTAGTAGCC 3’, respectively. These are quite different when 
compared to the consensus sequence (GCC) GCCRCCATGG (where R = A or G), which 
often is recommended in system manuals for molecular cloning procedures. But they are 
relatively similar to each other, indicating that COAS2 mRNA could be translated, however 
possibly at lower levels than that of PPIA due to the the lack of stabilising guanidines (Kozak, 
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1987) at positions -6 and -9 in the COAS2 Kozak sequence. Indeed, the highly expressed 
PPIA has a stabilising G at –6. 
 
In conclusion, examinations of DNA, mRNA and amino acid sequences indicate that the 
COAS2 protein has a pI of 9.3, and a C-terminal proteoglycan-binding sequence with 87,5 % 
conserved amino acids compared to that of PPIA. In addition, earlier evidence suggests that 
all the amino acids necessary for PPI enzymatic activity in PPIA are preserved in COAS2.  
Moreover, divergence of the two sequences through evolution or retrotransposition may have 
created a more polar and hydrophilic cyclophilin CypA-homologue such as COAS2, with 
complementary functions in- or outside the eukaryote cell. Furthermore, COAS2 is amplified 
and over-expressed in a subset of human tumours of mesenchymal origin, indicating that it is 
not a processed pseudogene. Finally, the existence of the COAS2 protein has not yet been 
reported, but comparisons of PPIA and COAS2 show that the –10 to +1 upstream sequence of 
PPIA has been preserved, suggesting that the COAS2 mRNA is translated in human cells. 
Based on the sequence analysis, it may be advisable to include the 5’ sequences reported in 
new constructs, and perhaps also to change the Kozak sequence to that of PPIA, which works 
well in our hands. 
 
4.2 Creation and characterisation of stably transfected Flp-In cell lines  
 
COAS2 had earlier been studied using transient expression only (Meza-Zepeda et al., 2002). A 
cell line with a stably integrated single copy of a gene of interest (GOI) downstream of a 
controllable Tet-promoter as described by (O'Gorman et al., 1991) and (Yao et al., 1998), 
would be a better tool than transient transfection methods for functional gene characterisation. 
First, this system would imply better control of expressed protein, in contrast to the 
uncontrolled expression levels directed by strong promoters when transient transfection is 
applied. Second, intracellular aggregation of proteins and possible downstream artefacts, as 
experienced in the previous studies, could thus putatively be avoided (Sauer, 1994; Yao et al., 
1998). A system where stable transfectants are created would thus reduce the number of 
potential problems (Sauer, 1994). In this work, the Flp-In system was applied to create such 
cell lines; a system based on antibiotic selection of positive clones harbouring the GOI, 
integrated at a specific site (Craig, 1988; Sauer, 1994).  
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Although COAS2 is a member of a protein family with numerous and diverse functions, its 
possible effects on cancer-related mechanisms of growth and cell cycle regulation were 
prioritised in this work due to the proposed oncogenic role. Microarray analysis (of cells over-
expressing COAS2) could however give clues to downstream effects and link the protein to 
any type of signal pathway.  
 
Upon creation of the Flp-In cell lines used in this work, the reading frame of the integration 
site was altered towards expression of a Hygromycin-resistance molecule after integration of 
the GOI. This should ideally fully halt the transcription of the fusion gene lacZZeo, inevitably 
making the cells sensitive to Zeocin, and resistant to Hygromycin (Craig, 1988; Sauer, 1994). 
Very few clones did exhibit Zeocin-sensitivity when tested, a fact that still has not been 
explained. Interestingly, the levels of COAS2 were shown to differ between Zeocin-resistant 
and Zeocin-sensitive clones, as indicated in figure 3.7. To rule out that this could be due to 
different amounts of integrated COAS2, we determined the copy numbers using a Southern 
blot, as seen in figure 3.5. When insertion occurs at the single FRT site, it should do so only 
once, but an option may be either duplicate insertion, i.e. the insertion of the GOI-containing 
plasmid twice or more in an existing FRT site, insertion of one or more copies at other 
location(s), or (in theory) multiple copies of FRT sites. However, when examined, both 
parental and COAS2-transfected cell lines seemed to have one copy of the lacZ-Zeo fusion 
gene in their genome, and only the transfected cells had one copy of the Hygromycin gene, as 
expected after integration of only one copy of COAS2.  
 
The supplier of the Flp-In system offers a third test for selection of positive clones, but this 
has not been used in this work. This test benefits from the parental cell line-expression of the 
E. coli lacZZeo gene, the lacZ moiety coding for the enzyme β-galactosidase. This enzyme of 
bacterial origin can utilize the synthetic substrate X-gal to yield blue-stained cells (Mensa-
Wilmot and Englund, 1992). In positive clones, the transcription of the lacZ gene is disrupted, 
and the cells will therefore not stain blue when fed X-gal to the cell growth medium (blue-
white selection method known from E. coli). To apply this method for initial clonal screening 
instead of screening for Zeocin-sensitivity may be advisable for future purposes, since it is 
less time consuming. This could improve the selection of positive clones.  
 
Interestingly, expression levels of COAS2 in the transfected Flp-In cell lines have been shown 
to vary between Zeocin-sensitive and Zeocin-resistant clones. However, promoter release by 
 128
tetracycline addition to the cell growth medium generates an induction of COAS2-expression 
in all cases, as seen in figures 3.7 and 3.9, and it thus does not seem that Zeocin screening is a 
reliable assay for integration. 
 
For further characterization of the FRT site in the cell line genome before and after 
transfection, one could perform a repeated Southern experiment where a second restriction 
enzyme is used, in addition to quantification of mRNA (with RT-PCR or titration curves of 
COAS2 mRNA levels using northern blots), and protein (with western blotting upon 
generation of an antibody towards COAS2). At the moment, further information on eventual 
interclonal differences is thus limited.  
 
4.3 Cell growth assays 
 
Oncogenic activity may be related to mediation of cell proliferation, (Hesketh, 1997), and 
effects of cyclophilins on cell growth have been reported (Andersen et al., 2003). In addition, 
the Pin1 protein, a member of the immunophilin family of proteins, has been shown to be a 
cell cycle regulator (Wulf et al., 2002). 
Accordingly, the putative effects of over-expressed COAS2 on cell growth were therefore 
addressed in this work through the use of several in vitro and in vivo growth assays.  
 
It is also known that the class A cyclophilins bind the immunosuppressive drug cyclosporin A 
(CsA) (Fischer et al., 1989). Interestingly, the multidrug resistance pump P-glycoprotein 
(PGP) has been shown to be noncompetitively inhibited by CsA (Wigler, 1999). In repeated 
experiments with PGP and cyclosporins, the influence of cellular cyclophilin has been 
indicated (Fakata et al., 1998; Kawazu et al., 1999; Tiberghien et al., 2000). This suggests a 
possible role for COAS2 as mediatior of drug resistance, however depending upon the nature 
of the applied cytostatic. Thus, the ability of COAS2 to confer resistance to three types of 
cytostatica in this model system was examined. 
 
In vitro growth rate, determined as a part of the cytostatics testing, showed that cells over-
expressing COAS2 grow slightly faster than their parental cell lines (figure 3.11). Moreover, 
the two soft agar assays indicated a moderate but reproducible increased growth potential for 
the COAS2-transfected cells with constitutive expression when compared to the parental Flp-
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In 293 cell line. For in vivo confirmation, cells were subsequently injected subcutaneously 
into nude mice, and the following xenograft growth experiments performed by Mr. Christoph 
Müller supported the soft agar data (figure 3.13). Furthermore, as expected from a putative 
oncogene, over-expression of COAS2 in these stable cell lines does not induce apoptosis. 
Over-expression of COAS2 did not; however, seem to exert a large effect on cell growth of 
293 Flp-In cells, although the results in all systems were coherent, suggesting a positive 
effect. Further analysis is nevertheless needed to confirm that these results are not just due to 
clonal variation. It should be noted that even a moderate growth advantage might be selected 
for in a tumour over years of development, and could even be increased under certain in vivo 
conditions. 
 
We used flow cytometry to investigate effects on cell cycle distribution in cells with over-
expressed COAS2. However, such effects are often masked when using over-expression of 
proteins in in vitro assays. They may only be seen under conditions of low cell growth, or 
only towards a certain background of defects (e.g. in “knockout” or “knockdown” cells). 
Therefore, experiments should ideally be performed under conditions of reduced growth (e.g. 
low fetal calf serum (FCS) concentration in cell growth medium), or with colchicine-
synchronised cells. We thus compared the cell cycle distribution of Flp-In 293 cells with and 
without over-expression of COAS2, with different levels of (FCS) in the cell growth medium. 
From our series of experiments, the COAS2 protein apparently does not seem to have a gross 
effect on cell cycle regulation, neither when cells were grown in 2 % FCS nor in 8 % FCS. 
Interestingly, a small peak occurred in control samples without over-expression of COAS2 
(figure 3.15 D). It is possible that these cells are apoptotic cells, and that over-expressed 
COAS2 counteracts this apoptosis, since this was not observed in samples with over-
expressed COAS2. Furthermore, this would have significance for cell growth in cells with 
over-expressed COAS2; the lack of apoptosis could explain the moderately increased growth 
seen in the model cell lines used in this work. Moreover, a continued negative regulation of 
apoptosis will affect tumourigenesis, strengthening the role of COAS2 as amplified and over-
expressed in a subset of human cancers. This possible inhibition of apoptosis was however 
insufficient to counteract the cytostatic drugs analysed in other experiments (see further on). 
Consequently, future experiments where the serum levels are kept below 1 % in addition to 
synchronisation experiments and measurement of apoptosis may give more conclusive results 
to a possible role of COAS2 in cell cycle regulation. Preliminary results suggest that COAS2 
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does not affect cell cycle regulation when overexpressed in the model system used in this 
work. This is of course when over-expressed alone; its regulatory function may be depending 
on other interaction partners not present in our cell system. 
 
4.4 Resistance to cytostatics 
 
Investigations of cytostatic response using SRB colorimetric assays showed that, regardless of 
their type, the applied cytostatica caused both controls and samples to react equally, as shown 
in figure 3.14. The COAS2 gene product may thus not confer resistance to cisplatin, 
methotrexate nor doxorubicin, at least not in this system. However, the importance having the 
correct model system should be emphasized; important experiments will be repeated when a 
mesenchymal model cell line has been established. 
 
4.5 Transcription analysis of cells over-expressing COAS2 
 
Being able to monitor expression changes in a large set of samples is the major advantage of 
microarray analysis  (Ball et al., 2002; Miller et al., 2002; Quackenbush, 2002). The 
microarray technology is now an established method for transcription analysis. In Norway, 
the activity is guided by the Norwegian Microarray Consortium (NMC), a national 
collaboration between universities in Oslo, Bergen and Trondheim. 15k spotted cDNA arrays 
from the NMC have been used in this work to identify possible effects on the transcriptome 
by our cyclophilin.  
 
Although it is unlikely that COAS2 participates directly in transcription regulation, perturbing 
the cell by COAS2 over-expression might affect its transcriptional profile, indirectly linking 
the COAS2 protein to signal pathways. Therefore, we used microarray analysis on stably 
transfected cell lines where over-expression of COAS2 was achieved from a controllable 
TetOn-promoter (Craig, 1988). Time points were selected to examine possible primary (early) 
and secondary (late) effects of over-expression. The high expression of a COAS2 transcript 
upon tetracycline induction was illustrated in figures 3.7 and 3.8. The COAS2 cDNA was not 
present on the arrays, as opposed to other cyclophilins (PPIA, PPIC and PPIF), to whom 
COAS2 displays a high degree of amino acid homology. The other cyclophilins were not 
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found to be highly upregulated (maximum sample/reference ratio of 1.4 for the PPIA, as 
shown in table 3.2). This suggests that the stringency of our experiments was sufficient, 
minimising the degree of cross-hybridisation from other cyclophilin cDNAs, further 
strengthening the obtained results. 
 
Upon examination of the data, two Sry-box (SOX) transcription factors were found to be 
upregulated in the cell line material, as seen in table 3.2. These two were interesting because 
the SOX family of proteins are involved in many stages of cell differentiation, as controllers 
of embryonal neurogenesis, (Muhr, J. et al, in press), chondrogenesis and osteogenesis (Zhao 
et al., 1997; de Crombrugghe et al., 2000; de Crombrugghe et al., 2001; Lefebvre et al., 2001). 
This could represent a link between COAS2, which has been found to display high mRNA 
levels in osteosarcoma samples with amplification (Meza-Zepeda et al, 2002), and chondro- 
and osteogenesis. In fact, 1q amplification has been connected to ossifications and 
osteosarcomatous differentiations in earlier work done on well-differentiated liposarcomas 
(WDLPS) (Forus et al., 2001b). 
 
Together with a known modulator of mammalian osteogenesis and chondrogenesis, Sox9, the 
L-Sox5 and Sox6 have been shown to regulate collagen type two alpha one (col2a1),(Zhao et 
al., 1997; Lefebvre et al., 1998; Smits et al., 2001). However, COL2A1 was present on the 
cDNA arrays, but only found weakly upregulated in one sample, and the control hybridisation 
performed using northern analysis supported the microarray data.  
 
On the other hand, among the upregulated genes in our data was the collagen type 1 alpha 2, 
which normally is present at later stages of bone differentiation (Lefebvre et al., 2001). This 
was expressed at detectable levels in few samples, and has not been further investigated. 
However, the connection between COAS2 and cartilage- and bone-expressed proteins is 
nevertheless very interesting, and will be examined further. 
  
Verification of high expression of L-SOX5, SOX6 and SOX9 was attempted using northern 
blotting (SOX9 despite the fact that no SOX9 cDNAs were present on the cDNA array slides). 
This was, however, not successful, probably because the levels were below the detection 
limits of the respective probes.  
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Verification using northern was finally abandoned as oligonucleotide arrays became available, 
arguing that results from the oligonucleotide arrays presumably would be able to confirm 
cDNA array data. However, we ran out of RNA, making repeats of the cDNA array 
experiments with oligonucleotide arrays difficult. Evidently, all interesting genes must be 
examined for expression and thus confirmed as high- or upregulated using northern (or 
potentially western blotting), or rather real time reverse transcriptase PCR upon repetition of 
the experiment. Without experimental confirmation, the link between COAS2 and the above 
genes thus remains interesting, but not confirmed at the time of writing.  
 
4.6 Cell biological studies 
 
Localisation of a protein may give valuable clues to its function (Jarvik and Telmer, 1998). 
The cyclophilin family, subclass A, to which COAS2 belongs, are ubiquitously expressed in 
human tissues (Bukrinsky, 2002; Galat, 2003). PPIA, to which COAS2 shares 84 % amino 
acid similarity, is preferentially located in the cytoplasma (Shaw, 2002), but has also been 
shown to be present outside the cell membrane when active during HIV-virion formation 
(Saphire et al., 1999). In addition, localisation of the endogenous protein demands a highly 
specific antibody, but this is not yet available. We could only therefore do in vitro 
experiments using epitope-tagged COAS2 in this work. 
 
Thus, three tags were applied to COAS2 through molecular cloning, either egfp or MYC-HIS6. 
All constructs were transfected into the Flp-In system to establish stable integrants under 
tetracycline-controlled TetOn promoters (O'Gorman et al., 1991).  
 
The egfp protein will fluoresce when excited under blue light, and is therefore an ideal target 
protein, making fixation and thus destruction of intracellular networks unnecessary (Tsien, 
1998). Live imaging using confocal microscopy was planned for the egfp fusion proteins, 
whilst the MYC-HIS6-tag was intended for use in fixed-cell imaging and possible pulldown 
experiments.  
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4.6.1 Localisation of the COAS2-MYC-HIS6 protein 
 
COAS2 mRNA was identified in all samples using northern blot analysis (figures 3.9 and 
3.10), and the sequences were all verified by sequencing. However, when interpreting the 
levels of COAS2 over-expression (figure 3.7 and 3.9), it was noted that in samples with no 
over-expressed COAS2, a band was present. This could be due to endogenously expressed 
COAS2 in the samples. To more precisely investigate the level of expression of the uninduced 
transgene, probes containing the MYC-HIS6 tag only may be hybridised to the northern filter 
shown in figure 3.9.  
  
Detection of COAS2-MYC-HIS6 was thus subsequently attempted using western blotting. 
However, using antibodies towards both tags, proteins were not detected in the cell lysates 
under neither denaturating nor native conditions despite the fact that both antibodies could 
detect respective control MYC and HIS6-proteins, regardless whether the tag was located N- 
or C-terminally. This phenomenon remains unexplained, because if the (MYC-HIS6) tag was 
properly translated and the (COAS2-MYC-HIS6) protein incorrectly post-translationally 
processed or folded, one would still be able to identify the protein in a western blot with 
properly-functioning antibodies towards the tags (Harlow, 1988). Nevertheless, several 
possible explanations exist; perhaps the cause could be the lack of laboratory skill or 
knowledge, i.e. that the protein is present at very low levels, but we were not able to fully 
optimise our detection system. Alternatively, the mRNA may be incompletely processed post-
transcriptionally, regulating or fully inhibiting translation.  
 
Attempts were however further made to localise COAS2-MYC-HIS6 with confocal 
fluorescence microscopy. As shown in figures 3.17 and 3.18, the obtained signals were not 
specific for COAS2, as a nuclear staining excluding the nucleoli was seen for all samples, 
including the negative control. Due to the low signal intensity of the His5 antibody, and the 
absence of a signal when stained with the MYC antibody, we were therefore not able to 
localise the MYC-HIS6-tagged COAS2 protein in the cells.  
 
Here too, several explanations may exist. Optimisation of the system was attempted, and extra 
precautions were taken during the experiments to avoid bleaching of the Rhodamine-
conjugated antibody. As mentioned earlier, positive induction of COAS2 mRNA upon 
tetracycline addition was verified (figure 3.9). Nevertheless, without proven existence of the 
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full length tagged mRNA, western blot- and localisation results will remain unexplained. We 
must therefore hybridise the northern filter depicted in figure 3.9 with a MYC-HIS6-probe. If 
detected, the (COAS2-MYC-HIS6) mRNA should theoretically be translated into a 
recombinant protein that might be seen on an optimised western blot (Harlow, 1988). 
However, results indicate that COAS2-MYC-HIS6 may not be translated correctly, eventually 
misfolded or aggregated. It can be difficult to assign this to either aggresome- or Russell body 
formation, since there are no easy ways of identifying these molecular complexes in the cell 
(Kopito and Sitia, 2000). With electron microscopy, aggregating structures could possibly be 
seen intracellularly. This was however not possible within the timeframe of this work.  
 
4.6.2 Localisation of COAS2 using egfp fusion proteins 
 
In transient localisation experiments performed by Ms. Lygren, COAS2 in fusion with egfp 
showed a speckled pattern of intracellular localization in fibroblasts, neither localised to 
nucleus, endosomes nor lysosomes (Lygren, 2002). This phenomenon could represent a 
translational error or an artefact of unknown origin. Moreover, Ms. Lygren reported a low 
level of cells with (<1%) of speckled fluorescence, whereas the levels of fluorescence were 
noticeably higher in the 40 % of cells transiently transfected with egfp only. This could 
possibly be a result of interactions between the COAS2-egfp fusion protein and the 
cytoplasmic proteasomes, recruiting the fusion protein for degradation (see further on).  
A second explanation may be COAS2-induced misfolding of egfp. Alternatively, COAS2 
may have an isomerase activity that prevents proper egfp folding, thereby inactivating the 
fusion protein’s ability to fluoresce.  
 
A possible connection between the cytoplasmic protein degradation complexes known as 
proteasomes and COAS2 has been reported (Lygren, 2002). Links between COAS2 and the 
proteasome subunit alpha seven as well as the filamin A and C proteins and COAS2 were 
established by Ms. Lygren using the yeast-two hybrid method. The proteasomes can be 
stained using specific antibodies, but will only give an even fluorescence located to the 
cytoplasmic region of the cells (Dr. H. Stenmark, personal communication). 
 
To further investigate Ms. Lygren’s results, Mr. M. Skårn transiently transfected U2OS cells 
with egfp-tagged COAS2 (figure 3.16). The transiently transfected cells produced a pattern of 
egfp fluorescence only weakly reminiscent of the speckled pattern seen in Ms. Lygren’s 
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transfected fibroblasts (results not shown). The levels of fluorescence were low when 
compared to the pEGFP-N1-transfected control, but stained perinuclear substructures looking 
more like intracellular membranes than the previously observed speckles. Furthermore, the 
transfected cells displayed even fluorescence (of both COAS2-egfp and egfp-COAS2) also in 
the cell membrane, a result not seen in earlier experiments. One possibility could be that this 
is due to binding via the GAG-domain to the cell surface. 
 
Flp-In cell lines with stably integrated egfp-tagged proteins were created. Interestingly, the 
transfectants expressing the same egfp/COAS2 or COAS2/egfp constructs did not fluoresce 
above background levels. This could indicate that the lower, more physiological levels of 
expression aimed for in this work, created insufficient protein for detection. (The positive 
control, a cell line over-expressing the egfp protein only, fluoresced brightly when 
examinated.) It is known that cellular autofluorescence can mask low levels of fluorescent 
protein (Lichtman, 1994), and we will not therefore exclude a low expression of COAS2-egfp 
or egfp-COAS2 in these cells. 
 
In light of these results, the egfp fusion proteins expressed from the Flp-In 293 cells are thus 
most likely functional, as suggested by the transient experiments, but the levels produced 
from a single copy integrated transgene may be insufficient for detection by fluorescence 
microscopy.  
 
4.6.3 Altered filamin structures 
 
In light of the yeast two-hybrid results where an interaction between COAS2 and filamins 
were reported, we tried to examine changes of cellular filamin- and actin structure upon over-
expression of COAS2, using confocal fluorescence microscopy. (Actin filaments are cross-
linked in e.g. a muscle cell by the filamin proteins; the proteins are thus interdependent.) 
However, the filamin structures were no different with or without over-expressed COAS2 in 
the COAS2-transfected clone #3. Neither were the actin structures particularly altered as 
displayed by the levels of the actin-binding reagent phalloidin (figures 3.19-20).  
Consequently, although only duplicate experiments were performed, over-expressed COAS2 
does not seem to have an effect of neither actin- nor filamin structure nor filamin- or actin 
organisation in this system. 
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4.7 Protein expression in bacteria and insect cells 
 
The existence of an endogenous COAS2 protein can be addressed with the use of a highly 
specific antibody towards COAS2.  
 
Moreover, the results found through the use of cell line material must be confirmed with 
protein data. Purified COAS2 will therefore be used for monoclonal antibody formation in 
addition to other downstream experiments. Being a member of the cyclophilin family of 
proteins, which displays great internal sequence similarity (Willenbrink et al., 1995; Galat, 
2003), may cause some problems. However, the high pI of COAS2 compared to that of the 
other cyclophilins suggests that the more polar amino acid sequence of COAS2 could induce 
an antibody with a high degree of specificity.  
 
The attempts of protein expression in BL21pLysS cells were halted due to formation of 
insoluble protein (figures 3.21 and 3.22), as affirmed by our more expert collaborators at the 
Max Planck Institut für Enzymologie in Halle, Germany. Their refolding experiments 
produced an incorrectly folded COAS2 protein without enzymatic activity in solution, and 
they were unable to refold it (results not shown). Considering that neither important co- and 
post-translational modifications nor disulfide bridge formation occur in bacterial cells (Kopito 
and Sitia, 2000; Sambrook, 2001), it is very likely that insoluble protein aggregates were 
formed because of incorrect folding or modification errors upon IPTG-assisted induction of 
protein expression. Even though the formation of aggressomes and inclusion bodies in eu- and 
prokaryotic model systems is known, its cause has not at present been fully determined 
(Kopito and Sitia, 2000). However, to address whether inclusion bodies or aggressomes are 
formed in the cells upon over-expression, staining procedures or electron microscopy must be 
applied. This was outside the scope of this work.  
 
In most cases, protein researchers find the change of model system to be a better adaptation 
than refolding experiments (Dr. D. J. Warren, personal communication). Consequently, the 
production of COAS2 in a eukaryotic model system would be better for all downstream 
purposes, also because recombinant protein from E. coli would most likely harbour 
lipopolysaccharide contamination, which again could profoundly affect some cellular 
responses (Sambrook, 2001; Simpson, 2003). Insect cells harbour most of the necessary 
transcription and translation machinery needed for immaculate synthesis of mammalian 
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proteins in vitro (Jarvis et al., 1990; Wickham et al., 1992), and was chosen for further 
attempts at COAS2-production. 
 
The viral-based Bac-to-Bac system used for COAS2-expression caused expectations to rise 
when western blotting identified a band of proper size in the first cell lysates to be analysed 
(figure 3.24). However, the levels of protein were low, as described in section 3.10.2. 
Moreover, it should be mentioned that the fraction containing cell debris and possible protein 
aggregates was not kept and analysed. Attempts were made in order to up-concentrate the 
His-tagged protein, using immunoprecipitation with Protein G agarose (results not shown). 
The experiments were repeated several times, under different conditions taken from three 
different protocols, but the attempts were not successful. Some lysate was therefore 
subsequently shipped to Germany for analysis, where members of Dr Schiene-Fischer’s group 
will attempt to purify the recombinant protein.  
 
4.8 Future aims 
 
To raise a monoclonal antibody towards COAS2, the COAS2 ORF will either be subcloned 
into the pET43.1 Nus-tag plasmid for expression in BL21pLysS bacterial cells, or 
preferentially prepared for protein expression in a yeast (P. pastoris) system (in collaboration 
with Dr. David J. Warren).  
 
Further validation is needed for our COAS2-MYC-HIS6 construct. Western and northern 
blotting will be applied to address the expression of COAS2-MYC-HIS6 and COAS2/egfp 
fusion proteins at mRNA and protein levels. In addition, the existing transfected Flp-In 293 
cells expressing COAS2- and epitope-tagged COAS2 may be studied further with confocal 
microscopy and markers for various cellular substructures for all experiments, or with 
electron microscopy to see if the proteins are membrane-associated, or form aggregates upon 
over-expression.  
For all experiments, a mesenchymal cell type will be used, most likely from stroma-derived 
MSC tert 20 (Simonsen et al., 2002), which is currently used in our lab. 
Transcriptional profiling (microarray) experiments should be repeated with oligonucleotide 
arrays, with 4-6 time points for increased clarity. Positive transcripts need, of course, to be 
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validated, e.g. with quantitative reverse transcriptase PCR. Further characterisation of the 
promoter sequence of COAS2 will shed light on its pattern of translation in vivo, e.g. by using 
luciferase constructs of COAS2.  
 
Further analyses of the interaction partners detected by yeast two-hybrid analysis will be 
important. This might be accomplished with immunoprecipitation assays using both candidate 
interaction partners, or by validating the interactions in relevant cells using e.g. peroxisome-
directing tags (Nilsen et al., 2004). In addition, the effect of a proteasome inhibitor “cocktail” 
on expression rates of COAS2 in the Flp-In clones will hopefully be elucidating. 
 
Finally, possible effects of over-expressed COAS2 on cell cycle regulation will be examined 
using cells grown in conditions of low (<1%) fetal calf serum, following a procedure that has 
been described earlier in this work. The possible effect(s) of COAS2 on cell death in this 
system will be further investigated. 
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Appendix A: Glossary 
 
 
actin An abundant 43-kd protein that polymerizes to form cytoskeletal filaments. 
 
active site The region of an enzyme that binds substrates and catalyses an enzymatic reaction. 
   
allele One copy of a gene. 
 
amino acid Monomeric building blocks of proteins, consisting of a carbon atom bound to a carboxyl group, an amino 
group, a hydrogen atom, and a distinctive side chain. 
 
amplicon A chromosomal region amplified in certain subtypes of cancer  
 
anaphase The phase of mitosis during which sister chromatids separate and move to opposite poles of the spindle. 
 
APC; anaphase-promoting complex A ubiquitin ligase that triggers progression from metaphase to anaphase by 
signaling the degradation of cyclin B and cohesins. 
 
anaplastic A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells. 
 
angiogenesis The formation of new blood vessels. 
 
antibody A protein produced by B lymphocytes that binds to an antigen, (foreign molecule), via its epitope. 
 
antigen A molecule against which an antibody is directed. 
 
apoptosis An active process of programmed cell death, characterised by cleavage of chromosomal DNA, chromatin 
condensation, and fragmentation of both the nucleus and the cell. 
 
autocrine signaling A type of cell signaling in which a cell produces a growth factor to which it also responds. 
  
autoradiography The detection of radioisotopically labeled molecules by exposure to X-ray film. 
 
bacteriophage A bacterial virus. 
 
base-excision repair A mechanism of DNA repair in which single damaged bases are removed from a DNA molecule. 
  
benign tumour A tumour that remains confined to its site of origin. 
 
blastula an early embryonic form produced by cleavage of a fertilised ovum and usually consisting of a single layer of 
cells surrounding a fluid-filled spherical cavity. 
 
calmodulin A calcium-binding protein. 
 
cancer stem cell A cancerous cell with either aquired ability of self-renewal, or a mutated stem cell acting as a cancer 
cell precursor. Thought to mediate growth with or without the aid of more differentiated cells in a tumour. Identified 
per January 2004 in glioma and leukaemia. 
capillary electrophoresis The separation of biomolecules in a buffer-filled narrow capillary by application of an 
electric field, such as in isoelectric focusing, IEF. (Separation by electrophoresis is based on solute velocity differences 
in an electric field. The velocity of an ion is a function of its electrophoretic mobility and the applied voltage.)  
carcinogen A cancer-inducing agent. 
 
carcinoma A cancer that arises in epithelial cells, of endo- or ectodermal origin. 
 
cardiac hypertrophy Enlargement of either one or both heart ventricles. This increase in ventricular mass is attributed 
to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. 
Common cause of death in industrialized countries worldwide. 
 
Cdk inhibitor (CKI) A family of proteins that bind Cdks and inhibit their activity. 
 
 147
Cdks Cyclin dependent protein kinases that control the cell cycle of eukaryotes.  
 
cell cycle Regulated series of events occurring in the eukaryotic cell between cell divisions. 
 
chaotropic Pertaining to chaotropism, often ions with chaotropic ability. 
  
chaotropism (Greek: Chaos = disorder, confusion; trope = a turning) The property of certain substances, usually 
ions (e.g., SCN-, ClO4-, guanidinium), to disrupt the structure of water and thereby promote the solubility of nonpolar 
substances in polar solvents (e.g. water), the unfolding of proteins, the elution from or movement through a 
chromatographic medium of an otherwise tightly bound substance, etc. 
 
chaperone A protein that facilitates the correct folding or assembly of other proteins. 
 
chaperonin A family of heat-shock proteins that assist during protein folding by keeping amino acid chains 
outstretched until proper folding is assisted by chaperones. 
 
clonogeneicity The ability of a single cell to form clonal expansions, thus grow to form tumours in vitro. 
 
collagen The major structural protein of the extracellular matrix. 
  
complementary DNA (cDNA) A DNA molecule that is complementary to a mRNA molecule, synthesized in vitro by 
reverse transcriptase. 
 
cosmid A vector that contains bacteriophage  sequences, antibiotic resistance sequences, and an origin of replication. 
It can accommodate large DNA inserts of up to 45 kb. 
  
cyclins A family of proteins that regulate the activity of Cdks and control progression through the cell cycle. 
 
cyclophilins A protein family with peptidyl-prolyl-isomerase activity, involved in protein folding and diverse 
regulatory processes. Belongs to the immunophilin superfamily of proteins. 
 
double minutes Characteristic chromosomal arrangement of amplified regions in both murine and human tumours. 
 
ectoderm The outer germ layer; gives rise to tissues that include the skin and nervous system. 
 
embryogenesis Generation of an embryo from a fertilised egg. 
 
endoderm The inner germ layer; gives rise to internal organs. 
 
endoplasmic reticulum (ER) An extensive network of membrane-enclosed tubules and sacs involved in protein 
sorting and processing as well as in lipid synthesis. 
  
enzymes Proteins or RNAs that catalyze biological reactions. 
 
erythrocytes Red blood cells. 
 
exon A segment of a gene that contains a coding sequence. 
 
exonuclease An enzyme that hydrolyzes DNA molecules in either the 5´ to 3´ or 3´ to 5´ direction, beginning at the 
ends of the linear molecules in contrast to endonucleases. 
 
expression vector A vector used to direct expression of a cloned DNA fragment in a host cell, e.g. plasmid. 
 
extinction coefficient or molar absorption coefficient Unit describing the molar cross-section for absorption of light. 
The greater the cross-section of the absorbing molecule, the greater its ability to block the passage of the incident 
radiation. Its dimensions are 1/(concentration x length), and it is normally expressed in litres per mole per centimetre 
(L mol-1 cm-1). 
 
extracellular matrix Secreted proteins and polysaccharides that fill spaces between cells and bind cells and tissues 
together. 
 
fibroblast A cell type found in connective tissue. 
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filamins Structural protein connecting actin filaments in eukaryotic cells, stabilizing the meshwork and greatly 
increasing the viscosity of the surrounding medium. 
 
fluorophore A molecule that may be linked to a non-fluorescent molecule for detection purposes through fluorescence 
techniques. 
 
G0 A quiescent state in which cells remain metabolically active but do not proliferate. 
 
G1 phase The phase of the cell cycle between the end of mitosis and the beginning of DNA synthesis. 
 
G2 phase The phase of the cell cycle between the end of S phase and the beginning of mitosis. 
  
gene A segment of DNA that encodes a polypeptide chain or a RNA molecule. 
 
gene amplification An increase in the number of copies of a gene resulting from the increased replication of a region 
of DNA. 
 
giant marker, ring and rod chromosomes Chromosomal rearrangements containing amplified regions characteristic 
of well-differentiated liposarcomas (WDLPS). 
 
glycosaminoglycan (GAG) Glycosaminoglycans are polysaccharides (e.g. chondroitin sulfate, dermatan sulfate, 
heparan sulfate, heparin and keratan sulfate), made of repeating disaccharides (usually 40-100 times), which consist of 
uronic acid (or galactose) and hexosamines. See proteoglycans. 
  
green fluorescent protein (GFP) A protein from the jellyfish A. .victoria that is commonly used as a marker for 
fluorescence microscopy. 
 
growth factors Polypeptides that control animal cell growth and differentiation. 
 
heat-shock proteins A highly conserved group of chaperone proteins expressed in cells exposed to elevated 
temperatures or other forms of environmental stress. 
 
histocytes Or macrophages, cells with endocytic ability. Part of the immune system in vivo. 
  
homeostasis The maintenance of a dynamic steady state by regulatory mechanisms that compensate for changes in 
external circumstances. 
hyperlipidemia A general term for elevated concentrations of any or all of the lipids in the plasma, such as 
cholesterol, triglycerides and lipoproteins. 
hyperplasia Too much growth of cells or tissue in a specific area, exemplified by increased growth in the lining of the 
prostate, causing benign prostatic hyperplasia. 
 
hypoxia Metabolic condition in which the supply of oxygen is severely limited 
 
in situ hybridization The use of radioactive or fluorescent probes to detect RNA or DNA sequences in cell extracts, 
chromosomes, or intact cells. 
 
intercalating dye A planar molecule that is inserted between two successive bases in a nucleic acid, such as ethidium 
bromide, EtBr. 
in vitro translation Protein synthesis in a cell-free extract. (Confer the RTS system described in this work.) 
 
interphase The period of the cell cycle between mitoses, which includes G1, S, and G2 phases. 
 
intracellular signal transduction A chain of reactions that transmits chemical signals from the cell surface to their 
intracellular targets, see the SOS-RAS-RAF-MAP kinase pathway. 
 
intron Noncoding sequence that interrupts exons in a gene. 
 
karyotype Chromosomal content of an eukaryotic cell, displayed in terms of its appearance at metaphase in a 
karyogram. 
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Lambert-Beer law log (I0/I) = εcl Incident light intensity (I0) divided by transmitted light intensity (I) equals the 
molar extinction coefficient (ε) in the medium times the concentration (c) of the absorbing species times the cuvette’s 
path length (l). This law collects the basics for spectrophotometric quantification of biomolecules in a sample, where a 
fixed path length causes a proportional relationship between the absorbance A (= log(I0/I)) and the concentration of the 
absorbing solute c. Empirically deduced law. 
 
leucine zipper A protein dimerization domain containing repeated leucine residues; found in many transcription 
factors, often as basic leucine zippers, bLH. 
 
leukemia Cancer arising from the precursors of circulating blood cells. 
 
liposome A small spherical vesicle composed of a phospholipid bilayer, which forms spontaneously when 
phospholipids are suspended in an aqueous buffer. 
 
lymphocyte A blood cell that functions in the immune response. B lymphocytes produce antibodies and T 
lymphocytes are responsible for cell mediated immunity. 
 
M phase The mitotic phase of the cell cycle. 
  
malignant tumour A tumour that invades normal tissue and spreads throughout the body. 
 
MAP kinases A family of mitogen-activated protein-serine/threonine kinases that are ubiquitous regulators of cell 
growth and differentiation. 
 
matrix The inner mitochondrial space. 
 
mesoderm The middle germ layer; gives rise to connective tissues and the hematopoietic system. 
 
methylation Addition of methyl (-CH3) groups to positions on DNA strands. Functions mainly as a negative regulator 
of transcription in eukaryotes, through methylation of CpG islands upstream of actively transcribed genes.  
 
messenger RNA (mRNA) A RNA molecule that serves as a template for protein synthesis. 
 
metaphase The phase of mitosis during which the chromosomes are aligned on a metaphase plate in the center of the 
cell. 
 
metastasis Spread of cancer cells through the blood or lymphatic system to other organ sites. 
 
mismatch repair Repair system that removes mismatched bases from newly synthesized DNA strands.  
  
monoclonal antibody An antibody produced by a clonal line of B lymphocytes. 
 
mutation Genetic alteration. 
 
myoblast A skeletal muscle cell precursor. 
myosin A protein that interacts with actin, functions as a molecular motor. 
 
neoplasia Abnormal and uncontrolled cell growth 
  
neurite extension Extension of a neuronal cell, the term neurite may signify both dendrite and axon. 
 
nucleoside A purine or pyrimidine base linked to a sugar (ribose or deoxyribose). 
 
nucleotide A phosphorylated nucleoside. 
 
nucleotide excision repair A mechanism of DNA repair in which oligonucleotides containing damaged bases are 
removed from a DNA molecule. 
 
oligonucleotide Short polymer of only a few nucleotides. 
 
oncogene Gene capable of inducing one or more characteristics of cancer cells. 
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palindrome Segment of duplex DNA in which the base sequences of the two strands exhibit twofold rotational 
symmetry about an axis. 
 
peptidyl prolyl isomerase An enzyme that facilitates protein folding by catalyzing the cis-trans isomerization of 
prolyl peptide bonds. 
 
phalloidin A drug that binds to actin filaments and prevents their disassembly. 
   
phosphorylation The addition of a phosphate group to a molecule. 
 
plasmid A small, circular DNA molecule capable of independent replication in a host cell. See vector. 
 
polylinker A short, often synthetic fragment of DNA containing recognition sequences for several restriction 
endonucleases 
  
polymerase chain reaction (PCR) A method for amplifying a region of DNA by repeated cycles of DNA synthesis in 
vitro. 
  
processed pseudogene A pseudogene that has arisen by reverse transcription of mRNA. 
  
prokaryotic cells Cells lacking a nuclear envelope, cytoplasmic organelles, and a cytoskeleton (primarily bacteria). 
 
promoter A DNA sequence to which RNA polymerase binds to initiate transcription. 
 
proofreading The selective removal of mismatched bases by DNA polymerase. 
 
proteasome A large 20S protease complex that degrades proteins tagged by ubiquitin. 
 
protein kinase An enzyme that phosphorylates proteins by transferring a phosphate group from ATP, see also 
phosphorylation. 
 
protein phosphatase An enzyme that reverses the action of protein kinases by removing phosphate groups from 
phosphorylated proteins.  
 
proteoglycan A protein containing one or more covalently linked and usually sulfated glycosaminoglycan. Aggrecan, 
for example, is the major proteoglycan component in articular cartilage. 
 
proteolysis Degradation of polypeptide chains. 
 
proto-oncogene A normal cell gene that can be converted into an oncogene. 
 
pseudogene A nonfunctional gene copy. 
  
Raf A protein-serine/threonine kinase (encoded by the RAF oncogene) that is activated by Ras and leads to activation 
of MAP kinase. 
  
Ras A family of small GTP binding proteins (encoded by the RAS oncogenes) that couple growth factor receptors to 
intracellular targets, including the Raf protein-serine/threonine kinase and the MAP kinase pathway. 
 
RB A transcriptional regulatory protein encoded by the tumour suppressor gene RB1 that was identified by the genetic 
analysis of hereditary retinoblastoma, a cancer that causes retinal tumours at young age. 
 
recombinant molecule A DNA insert joined to a vector. 
  
repressor A regulatory molecule that blocks transcription. Example: The Tet-repressor molecule expressed in the Flp-
In system used in this work. 
 
restriction endonuclease An enzyme that cleaves DNA internally at a specific sequence, often at palindromic repeats. 
 
restriction point A regulatory point in animal cell cycles that occurs late in G1. After this point, a cell is committed to 
entering S and undergoing one cell division cycle. 
   
reverse transcriptase A DNA polymerase that uses an RNA template to generate complementary DNA, (cDNA). 
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ribosomal RNA (rRNA) The RNA component of ribosomes, in humans the 5S, 18S and 28S fractions together 
constitute the total rRNA. 
 
ribosomes Particles composed of RNA and proteins that are the sites of protein synthesis. 
  
Rotamase An immunophilin, enzyme with peptidylprolyl isomerase activity. 
 
Rous sarcoma virus (RSV) An acutely transforming retrovirus, in which the first oncogene was identified. 
  
S phase The phase of the cell cycle during which DNA replication occurs. 
 
sarcoma Cancer of cells of connective tissue. 
 
sarcosyl N-lauroyl-sarcosine, anionic detergent used for RNA isolation and RNA stabilization in solution. 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) A commonly used method to separate proteins by gel 
electrophoresis on the basis of size. 
 
SH2 domain A protein domain of approximately 100 amino acids that binds phosphotyrosine-containing peptides. See 
the SOS-RAS-RAF-MAP kinase pathway. 
 
signal sequence A hydrophobic sequence at the amino terminus of a polypeptide chain that targets it for secretion or 
organelle inclusion after modification in the endoplasmatic reticulum, (the latter for eukaryotic cells only). 
 
smooth muscle Muscles surrounding internal organs. Contraction of smooth muscle controls the diameter of blood 
vessels and propels food along the gastrointestinal tract, amongst other functions. 
 
SOS-RAS-RAF-MAP kinase Pathway signal cascade where ligand binding to a receptor is carried via several 
cytoplasmic proteins to SOS-RAS-RAF and ultimately forms a MAP kinase dimer that translocates to the nucleus 
where it activates transcription of cell cycle- and differentiation-specific proteins. Oncogenic activation of the Ras or 
both Ras and Raf protein(s) is common in many cancer types. 
  
Src A nonreceptor protein-tyrosine kinase encoded by the oncogene (src) of Rous sarcoma virus. 
 
stem cell A cell that divides to produce daughter cells that can either differentiate or remain as stem cells. Most stem 
cells divide asymmetrically to give one stem cell with self renewal potential equal to the parent cell, and one stem cell 
intended for differentiation. 
 
striated muscle Cross striations is a characteristic trait in differentiated muscles associated with contractile ability of 
mature (skeletal, heart and smooth) muscle cells. 
 
stromal cells Cells forming supporting connective tissue of an organ. 
 
substrate A molecule acted upon by an enzyme. 
 
supernumerary rings Chromosomal arrangement trait characteristic of well-differentiated liposarcomas (WDLPS). 
These rings contain amplified regions of DNA. 
 
Svedberg (S) Unit of measure of the rate at which a particle sediments in a centrifugal field. 
 
Synovial sarcoma Relatively rare type of soft tissue sarcoma most common at knee. 
 
Synovial membrane A layer of connective tissue that lines the cavities of joints, tendon sheaths, bursae (fluid-filled 
sacs between tendons and bones), and the cavity (hollow enclosed area) that separates the bones of a freely movable 
joint, such as the knee or elbow. The synovial membrane makes synovial fluid, which has a lubricating function.  
 
T-lymphocyte activation Activation of one type of white blood cell that attacks virus-infected cells, foreign cells, and 
cancer cells. T cells also produce a number of substances that regulate the immune response.  
 
telomerase A reverse transcriptase that synthesizes telomeric repeat sequences at the ends of chromosomes from its 
own RNA template. 
 
telomeres or chromosome ends or telomere caps; Repeats of simple-sequence telomeric (TEL) DNA that maintain 
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the ends of linear chromosomes, counteracting the tendency of a chromosome to be shortened during each round of 
replication. See telomerase. The caps are complexes of protein and DNA. 
 
teratoma A type of germ cell tumour that may contain several different types of tissues, such as hair, muscle, and 
bone. Teratomas occur most often in the ovaries in women, the testicles in men, and the tailbone in children. Not all 
teratomas are malignant. 
 
transcription factor A protein that indirectly or directly regulates the activity of RNA polymerase. 
 
transcription The synthesis of an RNA molecule from a DNA template. 
  
transfection Transient or stable introduction of foreign DNA or RNA into eukaryotic cells. 
 
transformation of bacteria The introduction of foreign DNA or RNA into bacterial cells 
 
transforming growth factor  (TGF-) A polypeptide growth factor that generally inhibits animal cell proliferation. 
  
translation The synthesis of a polypeptide chain from a mRNA template. 
 
tumour Any abnormal proliferation of cells. 
 
tumour necrosis factor (TNF) A polypeptide growth factor that induces programmed cell death. 
 
tumour suppressor gene A gene whose inactivation leads to tumour development. 
 
tumour virus A virus capable of causing cancer in animals or humans. 
 
ubiquitin A highly conserved protein that acts as a marker to target other cellular proteins for rapid degradation. 
  
vector A DNA molecule used to direct the replication of a cloned DNA fragment in a host cell. 
  
yeast artificial chromosome (YAC) A vector that can replicate as a chromosome in yeast cells and can accommodate 
very large DNA inserts (hundreds of kb). 
 
zygote A fertilized egg. 
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Appendix B: Cloning procedures  
 
In this work, four plasmid constructs in total were made by the author, of which two shared a 
common insert. Three cloning procedures are illustrated below. Standard molecular biology 
methods were applied, and these have been described in the previous sections.  
 
The pFastBACHTa/COAS2 plasmid was created as outlined in figure A1, with 1) PCR with 
the COAS2Upper- and LowerBac primers to create a blunt-ended product which was 
phosphorylated using T4 kinase and ATP. In 2), the FastBACHTa plasmid was 
dephosphorylated after digestion with the EheI restriction enzyme, and following T4 ligase-
mediated ligation at 14°C over night, the construct was heat-shock transformed into DH5α 
cells, and positive clones were further screened and treated as outlined in the methods section 
to yield a purified recombinant plasmid. Dr. D. J. Warren further used this in the Bac-to-Bac 
system for COAS2 production in insect cells. 
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Figure A.1: Illustration of the cloning procedure for the pFastBACHTa/COAS2 plasmid. 
 
The pcDNA5FRT/COAS2MYCHIS6 and pcDNA5FRT/To/COAS2-MycHIS6 plasmids were 
created as outlined in figures A2-3, with (1) PCR with the SfuILower- and XbaIUpper 
primers to create a product with overhangs that was gel purified, verified by agarose gel 
electrophoresis and digested using the SfuI and XbaI restriction enzymes (2). The pcDNA3.1 
plasmid was also digested with these enzymes, and ligation using T4 ligase over night at 16°C 
gave a construct that subsequently was heat-shock transformed into JM109 cells (3). Positive 
clones were further screened and treated as outlined in the methods section to yield a purified 
recombinant plasmid. The COAS2MYC-HIS6 was PCR-amplified using the COAS2BamHI 
and HisTagCOAS2StopXhoI primers, gel purified and verified for proper size using agarose 
gel electrophoresis (4). Both PCR product and the pcDNA5FRT and pcDNA5FRT/To 
plasmids were digested using BamHI and XhoI restriction enzymes (5), further ligated and 
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heat-shock transformed into JM109 cells as indicated for the pcDNA3.1COAS2MYCHIS6 B 
recombinant plasmid (6). Positive clones were further screened and treated as outlined in the 
methods section to yield two purified recombinant plasmids. These would be used for the 
creation of stably transfected Flp-In cell lines.  
 
 
Figure A.2: Illustration of the cloning procedure for the pcDNA3.1MYCHIS6/COAS2 plasmid. 
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Figure A.3: Illustration of the cloning procedure for the pcDNA5FRT- and FRT/To/COAS2 plasmids. 
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Appendix C: Materials and equipments 
 
Chemicals 
 
Product Supplier 
[γ-32P]-dATP, 3000 Ci/mmol Amersham Pharmacia Biotech 
[α-32P]-dCTP, 3000 Ci/mmol Amersham Pharmacia Biotech 
Ammonium acetate (NH4Ac) Merck 
Ammonium persulfate BIO-RAD, cat. no 161-0700 
Ampicillin Bristol-Meyers Squibb 
Agarose Gibco BRL, Life Technologies 
Aprotinin  Sigma, cat. no A4529 
Array slidehyb#3  Ambion, 8863 
Bacto-agar Difco Laboratories 
β-mercaptoethanol Sigma 
Blasticidin S Invitrogen, 46-1120, lot no 1188354 
Blot Qualified Bovine Serum Albumin Promega, W384A 
Bromophenol blue Merck 
Bovine serum albumin (BSA), 10 x New England BioLabs 
Chloroform Merck 
Coomassie Brilliant Blue Sigma, B-0630 
Cot-1 DNA Invitrogen 
Cy3, NHS-ester leaving group Amersham Biosciences, PA 23001 
Cy5, NHS-ester leaving group Amersham Biosciences, PA 25001 
Diethylpyrocarbonate (DEPC) Sigma Chemical 
dNTPs Amersham Pharmacia Biotech 
dNTPs-C Amersham Pharmacia Biotech 
Dithiotreitol (DTT) Gibco BRL, Life Technologies 
Dimethyl sulphate oxide, DMSO  Sigma, D2650 
Dry milk powder (Molico) Nestlé 
Dulbecco’s Modified Eagle Medium BioWhittaker, BE 12-614F 
18 S oligo Amersham Pharmacia Biotech 
Ethylene diamine tetra acetate (EDTA) Merck 
Ethidium bromide (EtBr) Sigma Chemicals 
Ethanol, 75%, 95%, abs. EtOH Arcus  
Ficoll 400 Pharmacia, 170400-02 
Foetal calf serum, FCS PAA, A15-043 
Formaldehyde, 37% Merck 
Formamide Merck 
FuGene6 Transfection reagent, 0,4 ml Roche Biosciences, 1815091, lot.no 93051021/93117823 
Glucose D+ Merck 
Glutamax 1 100x  Invitrogen, 35050-038 
Glycine Merck, IC32046601 
Glyserol Merck 
Hydrochloric acid, HCl Merck 
HEPES Sigma, N9136 
Hygromycin B Invitrogen, lot no A6694 
IPTG Gibco BRL, Life Technologies 
Isopropanol Arcus products 
Imidazole Merck 
Kanamycin Pedersen & Sønn A/S 
Leupeptin Hemisulfate, Sigma, L2884 
Magnesium chloride (MgCl2) Merck 
Magnesium dichloride (MgCl2), 25mM  Perkin Elmer 
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Mowiol Calbiochem 
NaH2PO4⋅H2O Merck 
NaOH Merck 
Nonidet P-40  USB corporation, 19628 
Orange G  Sigma 01625 
Penicillin Invitrogen 
Penicillin-Streptomycin for cell culture BioWhittaker, DE17-602E 
Pepstain A  Sigma P4265 
PMSF Sigma, P7626 
Poly d(A)40-60  Amersham Pharmacia Biotech 
Potassium acetate (Kac) Merck 
Potassium chloride (KCl) Merck 
Protein G agarose Sigma 
RNAseZAP  Sigma R-2020  
Saponin (extract from the Quillaja tree) Sigma  
Sephadex G50 Medium Amersham Pharmacia Biotech 
Sodium acetate (NaAc) Serva 
Sodium chloride (NaCl) Merck 
Sodium dodecyl sulfate (SDS) Bio Rad Laboratories 
Sucrose  Sigma, S-0389 
Tris-(hydroxymethyl)-aminomethane base Merck, 1083822500 
Trizol reagent Invitrogen, 15596-018  
Trypsin/EDTA Bio-Whittaker 
Tween20 Merck, S3830084 
Vectashield Mounting medium with DAPI Vector laboratories Inc. H-1200 Lot 1213 
Xylene orange Sigma  
Zeocin 100mg/ml Invitrogen, lot.no 3000038 
 
Instruments 
 
Product Supplier 
Automatic pipettes Finnpipette 
Centrifuges:   
                  Tabletop: Mikro 20 Hettich Zentrifugen 
                                  Biofuge Pico Heraeus Intruments 
                  Floor: Megafuge 1.0 Heraeus Sepatech 
                                  Sorvall RC 5C Plus Sorvall 
Electrophoration:      BTX Pulse Generator BTX 
                                  Cuvettes Plus 4 mm BTX 
Electroporesis:          Power PAC 300 BioRad 
     Gene Pulser II apparature  BioRad 
Flow cytometer         FACSCalibur Becton Dickinson 
Homogeniser:            Ultra Turrax T8 IKA labortechnik 
Humidified incubator  FormaScientific 
Hybond N+ nylon membrane Amersham Pharmacia Biotech 
Hybridization oven Hybaid 
Hypercassette Amersham Life Science 
Incubator (37 oC) Fermaks 
Microscope:               Axiovert S100 Zeiss 
                                   LEICA DM RE confocal microscope  LEICA 
Microarray scanner  Agilent 
Nitrocellulose filter membrane, 0,45 µm  BIO-RAD 
PCR machine:            GeneAmp PCR System 9700/2400 PE Applied Biosystems 
     Programmable Thermal Controller MJ Reseach, Inc 
pH-meter, PHM 80 Portable  Radometer Copenhagen 
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Platform Rocker str6 Bibby Stuart 
Immobilon-P Polyvinylidene fluoride protein filter, 0,45µm  Millipore, Cat.no IVPH 00010 
Sequencing:  MegaBACE 500 Amersham Biosciences 
Shaker Gallenkamp Orbital 
Spectrophotometric: Gene Quant II Pharmacia Biotech 
                                  UV1201 UV-VIS spectrophotometer Bergman 
Tubes:                       Eppendorf tubes 1.5 ml Eppendorf 
    MicroAmp strips Perkin Elmer 
   GeneAmp PCR tubes 0.5 ml, 0.2 ml Perkin Elmer 
   10 ml polypropylene Falcon tubes NUNC 
   15 ml polypropylene tubes Sarstedt 
   50 ml polypropylene tubes Sarstedt 
   30 ml centrifuge tubes w/lids Sarstedt 
Ultrasonic homogenizer 4710  Cole-Parmer 
Ultraviolet Illumination GelDoc 1000 BioRad  
UV-crosslinker GS Gene linker BioRad  
Vortex MS2 Minishaker IKA Tamro lab 
Weights:                    Sartorius 300,00g Kebo-Bredal A/S 
   SauterAR1014 Nerliens Kemisk-tekniske selskaper 
X-OMAT UV film Kodak 
 
Primers 
Name of primer Sequence, 5’Æ3’ 
M13 Forward CAC ACA GGA AAC AGC TAT G 
M13 Reverse GTT GTA AAA CGA CGG CCA GTG 
T7 TAA TAC GAC TCA CTA TAG GG 
T3 CAA TTA ACC CTC ACT AAA GG 
Sp6 ATT TAG GTG ACA CTA TAG 
COAS2BamHI CGG GAT CCC GAC CAT GGT CAA CTC CGT CGT C 
HisTagCOAS2StopXhoI CCG CTC GAG CGG TTA TCA ATG GTG ATG GTG ATG AT 
COAS2XbaIUpper GCT CTA GAG CAT GGT CAA CTC CGT CGT CTT T 
COAS2SfUILower TTT TTG TTC GAA TCC GAA TTG TCC ACA GTC AGC AAT G 
COAS2UpperBAC GTC AAC TCC GTC GTC TTT TTT G 
COAS2LowerBAC TCA TTA GAA TTG TCC ACA GTC AGC 
LICCOAS2Start GAC GAC GAC AAG ATG GTC AAC TCC GTC GTC 
LICCOAS2Stop GAG GAG AAG CCC GGT TCA TTA GAA TTG TCC ACA GTC AGC AAT 
 
Enzymes and buffers 
 
All enzymes and buffers were from New England Biolabs (NEB) unless otherwise stated. “+BSA” 
signifies the addition of bovine serum albumin to 0,1 mg/ml.   
 
Enzyme Buffer Supplier 
Restriction enzymes   
AflIII 3+BSA  
BamHI Neb buffer for BamHI + BSA  
EcoRI Neb buffer for EcoRI + BSA  
EcoRV 3+BSA  
HindIII 2  
KpnI 1  
NotI 3  
SacI 1  
SfuI/BstBI 4  
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XbaI 2+BSA  
XhoI 2  
   
Thermostable enzymes   
“DaveTaq”, produced at DNR, 5 U/µl In-house PCR buffer without MgCl2 David J. Warren 
“DNRTaq”, produced at DNR, 5 U/µl In-house PCR buffer without MgCl2 David J. Warren 
Pfu, produced at DNR, 4 U/µl In-house Thermopolymerase buffer David J. Warren 
   
Various enzymes:   
DNA polymerase I (Klenow)   
PlatinumTaq 5 U/µl PCR Buffer w/o MgCl2 Invitrogen, 10966-026 
T4 DNA ligase  NEB buffer for T4 ligase  
T4 Polynucleotide Kinase (PNK) NEB buffer for T4 PNK  
 
NEB Buffer composition  
 
BSA dilution buffer (100x): (20 mM, KPO4, 50 mM NaCl, 0,1 mM EDTA, 5% (v/v) glycerol)  
NEB#1: (10 mM Bis Tris Propane HCl, 10 mM MgCl2, 1 mM DTT) 
NEB#2: (50 mM NaCL, 10 mM Tris-HCl,10 mM MgCl2, 1 mM DTT) 
NEB#3: (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT) 
NEB#4: (50 mM KCH3CO2, 20 mM Tris-CH3CO2, 10 mM Mg(CH3CO2)2, 1 mM DTT) 
BamHI-buffer: (150 mM NaCL, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT) 
EcoRI-buffer: (50 mM NaCL, 100 mM Tris-HCl, 10 mM MgCl2, 0,025% (v/v) Triton-X-100) 
T4 PNK buffer: (70 mM Tris-HCl (pH 7,6), 10 mM MgCl2, 5 mM DTT, add ATP to 1 mM) 
T4 ligase-buffer: (50 mM Tris-HCl pH 7,5, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 µg/ml BSA) 
 
Commercial kits 
 
Kit Supplier 
DYEnamicTM ET dye terminator cycle sequencing kit 
(MegaBACE) 
Amersham Pharmacia Biotech, US81090 
Fairplay Micro Array labeling kit, 30 reactions Stratagene 
Jetquick Plasmid Midiprep Spin Kit Genomed, 210050 
Jetquick Plasmid Miniprep Spin Kit 50 Genomed, 200050 
Mycoplasma detection kit ATCC, 90-1001K 
QIAquick PCR purification Kit Qiagen, 28106 
QIAquick Gel Extration Kit Qiagen, 28704 
Qiagen EndoFree plasmid maxiprep kit Qiagen, 12362 
ECL kit Amersham Biosciences, RPN2209 
SuperSignalWestPico ECL kit Pierce, 34078  
RTS100 protein expression kit Roche Biosciences, 3186418 
Wizard SV PCR purification kit Promega, 9281 
Microcon YM-30 column Amicon 
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Antibodies 
 
Antibody Supplier Dilution (range) 
Goat anti-chicken filamin, whole serum Sigma, F2762  
Lot. no 3944818 
1:40, PBS11 
Mouse anti-PentaHis, IgG1 Qiagen, 34660  
Lot. no 11549390 
0,1-2,0 µg/ml in PBS12  
Secondary antibody rabbit-α-mouse DAPI, P0161 1:5000 in 5% dry milk (w/v) 
Rhodamine/TRITC goat anti-mouse IgG 
(H+L) 
Jackson Immunoresearch, 
115-025-146, Lot. no 57054 
1:100 in PBS10 
Anti-His6  Roche Biosciences, 1922416, 
lot. no 85272825, 
0,1-2,0 µg/ml in TBS13  
Mouse anti-His6-HRP  Roche Biosciences, 1965085 As the non-HRP conjugated 
Mouse anti-Myc9E10 Mr. David J. Warren  0,1-2,0 µg/ml in TBS12 
Rhodamine donkey anti-goat #522 Jackson Immunoresearch 1:100 in PBS10 
 
Plasmids and markers 
 
Plasmid Supplier Selection 
pET3a and pET30EkLIC Novagen Ampicillin, Kanamycin 
PCMVsport6 and PFastBACHTa Invitrogen Ampicillin, Ampicillin/Geniticin 
pcDNA3.1MycHis B (+) Invitrogen Ampicillin/Neomycin 
pcDNA5FRT and FRT/To Invitrogen Ampicillin/Hygromycin 
POG44 and pFRTlacZeo Invitrogen Ampicillin 
PT7T3DpacI, pOTB7 and pBS KS+ Stratagene Ampicillin, Chloramphenicol and Chloramphenicol  
PEGFP-N1 Clontech Kanamycin 
 
Molecular weight markers Supplier 
φx 174/HaeIII Invitrogen 
λ DNA/HindIII NEB, digest made in-house 
λ DNA/BstEII NEB, digest made in-house 
100 bp ladder NEB, N3231S 
1 kb ladder NEB, N3232S 
2 log ladder NEB, N3200L 
 
 
Mammalian cell lines 
 
• 293 Human embryonic kidney (HEK) Flp-In, Flp-In T-rex.  
These cells have been adenovirus-transfected. The parental 293 HEK has ATCC number CRL 
1573. The Flp-In system has been established in these cells (Invitrogen). 
 
• OHS; Cell line established at the Department of Tumor Biology from primary tumour from 
femur.  
 
                                                          
11 0,05% saponin (w/v) 
12 3% BSA (w/v) 
13 with 1-5% dry milk (w/v) 
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Bacterial strains 
 
• E. coli DH5α - genotype: F- φ80dlacZ∆M15 ∆(lacZYA-argF) U169 deoR recA1 endA1 
hsdR17(rK-, mK+) phoA supE44 λ- thi-1 gyrA96 relA1 
 
• E. coli JM109 - genotype: endA1, recA1, gyrA96, thi, hsdR17(rK-, mK+), relA1, supE44, 
∆(lac-proAB), [F’, traD36, proAB, lacIq Z∆M15] 
 
• E. coli BL21(DE3)pLysS - genotype: F- ompT hsdSB (rB- mB- ) gal dcm (CamR ) 
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Appendix D: Media and solutions 
 
Media 
 
LB medium (Luria-Bertani Medium) 
 
10 g bacto-tryptone 
5 g yeast extract 
10 g NaCl 
1 l dH2O 
Adjust the pH to 7.0 with 5 M NaOH,  
sterilise by autoclaving. 
 
For LB-plates add 15 g/l Bacto Agar before 
autoclaving. Antibiotics are added after autoclaving 
when the medium holds 60 oC or less. Ampicillin: 
50 mg/ml, Kanamycin: 10 mg/ml, 
Chloramphenicol: 50 mg/ml.  
 
SOC-medium 
 
20 g bacto-trypton 
5.0 g yeast extract 
0.5 g NaCl 
800 ml dH2O 
1 ml 2.5 M KCl 
Adjust the pH to 7.0 with 5 M NaOH, sterilize by 
autoclaving. When cool, add 5 ml 2 M MgCl2 and 
20 ml 1 M solution of glucose 
Dulbecco’s Modified Eagle Medium (DMEM) 
for the Flp-In 293 cell line 
 
DMEM 
8% Fetal Calf Serum 
2mM PenStrep 
2 x Glutamax 
100 µg/ml Zeocin 
DMEM for the Flp-In 293 T-Rex cell line 
DMEM with additives as devised for the Flp-In 293 
cell line 
15 µg/ml Blasticidin 
 
DMEM for Flp-In 293 transfected with gene of 
interest (positive transfectants) 
 
DMEM with additives as devised for the parental 
cell lines without Zeocin, nor Blasticidin 
0,15 µg/ml Hygromycin B 
 
DMEM for Flp-In 293-T-Rex transfected with 
gene of interest (positive transfectants) 
 
DMEM as devised for the transfected cell lines 
15 µg/ml Blasticidin 
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Solutions 
 
Agarose gel, 1 % 
 
50 ml 1 x TAE buffer 
0.5 g agarose 
Boil to dissolve the agarose 
Cool to 60ºC, then add 1-2 µl ethidiumbromide (10 
mg/ml), swirl to mix and pour into casting tray. 
 
Amidoblack staining solution for protein 
 
1 g Naphtol Blue Black 
450 ml MeOH 
100 ml acetic acid 
ddH2O to 1 litre 
 
Amidoblack wash solution 
 
900 ml MeOH 
20 ml acetic acid 
80 ml ddH2O 
 
Ammonium chloride, NH4Cl in PBS, 50 mM 
 
133 mg NH4Cl  
PBS to 100 ml 
Filter-sterilize the solution by filtration through a 
0.2 µm filter. 
 
Bjerrum-Schäfer-Nilsen 1 x blotting-buffer for 
Western 
 
5,8 g Tris-amino hydroxymethane 
2,9 g glycine 
ddH2O to 1 litre 
 
Blotting-buffer “A” for Western with Methanol 
 
25 mM Tris pH8.3 
192 mM glycine 
20% (v/v) MeOH 
ddH2O  
Add MeOH as final ingredient. 
 
50 mM CaCl2:Glyserol (85:15) 
 
85 ml 50 mM CaCl2 
15 ml 99 % glycerol 
 
Church hybridization solution (RNA) 
 
500 mM Sodium phosphate pH 7.2, 7 % SDS, 1 
mM EDTA  
250 ml 1 M Sodium phosphate pH 7.2 
175 ml 20 % SDS 
1 ml 0.5 M EDTA 
DEPC-dH2O to 500 ml 
 
Church wash solution (RNA) 
 
40 mM Sodium phosphate pH 7.2, 1 % SDS 
40 ml 1 M Sodium phosphate pH 7.2  
50 ml 20 % SDS 
DEPC-dH2O to 1000 ml 
For DNA: Church hybridization solutions as for 
RNA except ddH2O. 
 
Coomassie Brilliant Blue staining solution for 
protein 
 
1 g Coomassie Brilliant Blue 
500 ml MeOH  
100 ml glacial acetic acid 
ddH2O to 1 litre 
 
Coomassie Brilliant Blue fix/wash solution 
 
400 ml MeOH 
100 ml glacial acetic acid 
ddH2O to 1 litre 
 
DEPC treated water 
 
0,1% DEPC 
ddH2O 
Let the solution stand for 1 hour after DEPC-
addition, then autoclave. Shake container while still 
hot for final inactivation of excess reagent. It is 
important to be sure that DEPC has been 
inactivated as it will modify RNA and inactivate 
enzymes such as reverse transcriptases and kinases.  
 
Dithiothreitol, DTT, 1 M 
 
3.09 g dithiothreitol  
20 ml 10 mM sodium acetate pH 5.2 
Sterilize by filtration, aliquot and store at –20 oC 
 
DNAse I-buffer 
 
10 mM Tris-Cl pH 7.5 
150 mM NaCl 
1 mM MgCl2 
DNAse I 
DNAse I may be diluted in this buffer in a 
concentration range from 50 to 500 ng/ml. 
  
EDTA, 0.5 M pH 8.0 
 
186.1 g disodium EDTA⋅2H2O 
dH2O 
Dissolve EDTA in 800 ml water, then stir 
vigorously on a magnetic stirrer. Adjust the pH to 
8.0 with NaOH, finally add dH2O to 1000 ml and 
autoclave 
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Etidiumbromide, EtBr, 10 mg/ml 
 
1 g ethidium bromide  
dH2O to 100 ml 
Stir on a magnetic stirrer until the dye has 
dissolved. Aliquot. Store at 4 oC, dark. 
 
Gel loading dye #1, 6x, for DNA 
 
0.25 % (w/v) bromphenol blue 
0.25 % (w/v) xylene cyanol FF 
30 % (v/v) glycerol in water 
 
Gel loading dye #2, 6x FEBX, for DNA 
 
15% Ficoll 400 
0,25 % Orange G Sigma cat 01625 
 
Gel loading dye, 1,3x, for RNA 
 
20 mM NaH2PO4 pH 6.6 
66 % formamide 
8,6 % formaldehyde 
0,07 % xylene-orange 
0,7 µg/ml EtBr  
ddH2O 
Mix in a ventilated area, preferably under a safety 
hood. Aliquot and store at -70°C. 
 
Gel loading buffer, 2x, for protein 
 
2 ml sH2O 
1 ml 1 M Tris-Cl pH 6.8 
4 ml 50 % glycerol 
1 ml 2 % Brom-phenol blue (BFB) 
2ml 20% SDS (w/v) 
 
Heat SDS at 37ºC for 15 minutes in Tris and water 
to dissolve. Mix, aliquot and store at -20ºC. 
 
Gel loading buffer, 6x, for protein 
 
15 % SDS,  
50 % glycerol  
0,3 M Tris-Cl pH6.8  
25 % beta-mercaptoethanol  
Brom-phenol blue (BFB) 
Heat SDS at 37ºC for 15 minutes in Tris and water 
to dissolve. Mix, aliquot and store at -20ºC. 
 
Isopropyl-beta-D-thiogalactopyranoside, 
(IPTG), 100 mM 
 
238 mg IPTG 
10 ml dH2O 
Sterilize by filtering through a 0,45 µm filter. 
 
Lysisbuffer for purification of E.coli under 
native conditions 
 
As described in the QiaExpressionist-protocol 
collection: 
 
50 mM NaH2PO4 
300mM NaCl 
10mM imidazole 
Adjust to pH 8.0 with NaOH. 
 
Lysozyme, 10 mg/ml 
 
Dissolve to 10 mg/ml in 10mM Tris-Cl pH 8.0 
immediately before use. 
Verify pH≥8.0 to ensure proper lysozyme activity 
in solution. 
 
Magnesium chloride MgCl2, 1 M  
 
203 g MgCl2⋅6H2O 
dH2O to 1000 ml 
 
NT-stop solution for gel filtration 
 
20 mg/ml blue dextran, 1 % SDS, 40 mM EDTA 
600 µl 25 mg/ml blue dextran 
50 µl 10 % SDS  
50 µl 0.5 M EDTA 
 
OLBo-buffer, 5 x 
 
250 µl 1 M Tris-HCl pH 7.6 
25 µl 1 M MgCl2 
500 ml 2 M HEPES pH 6.6 
3.5 µl β-mercaptoethanol 
220 µl dH2O 
 
Paraformaldehyde, 4 % 
 
4 g paraformaldehyde 
10 ml dH2O 
Heat to 60oC, add 2-6 droplets 1 M NaOH until the 
solution becomes clear, then cool. Sterilize by 
filtration. Add PBS to 100 ml, adjust pH to 7.4. 
Store at 4°C, dark for 14 days maximum. 
 
Phosphate-buffer saline (PBS), 1 x 
 
2.7 mM KCl, 1.4 mM KH2PO4, 137 mM NaCl, 4.3 
mM Na2PO4  
200 mg KCl 
200 mg KH2PO4 
8.0 g NaCl 
1.15 g Na2PO4⋅7H2O 
800 ml dH2O 
Adjust pH to 7.2 with 1 M NaOH 
dH2O to 1000 ml 
Sterilize by filtration through a 0,2-0,45 µm filter. 
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Potassium acetate (KAc), 5 M 
 
491 g KAc 
dH2O to 1000 ml, autoclave. 
 
RNAse A, 5 mg/ml 
 
50 mg RNase A 
10 ml 10 mM NaAc pH 5.2 
Incubate 5 minutes at 100 oC, then cool to RT.  
Adjust pH to 7.4 with 1 M HCl, aliquote and store 
at -20 degrees. 
 
Sodium Acetate, NaAc, 3 M pH 5.2 
 
408 g NaAc⋅3H2O 
800 ml dH2O 
Adjust pH with glacial acetic acid 
dH2O to 1000 ml, autoclave. 
 
Sodium hydroxide, NaOH, 10 M 
 
400 g NaOH 
dH2O to 1000 ml, dissolve gently due to heat 
generation, preferentially in glass equipment.  
Filter-sterilise. 
 
Sodium phosphate, 1 M pH 7.2 
 
134 g Na2HPO4⋅7H2O 
800 ml dH2O 
Adjust pH with 85 % H3PO4 
dH2O to 1000 ml, autoclave. 
 
Sodium phosphate, 0.2 mM pH 6.6 
 
27.6 g NaH2PO4⋅H2O 
800 ml DEPC-H2O 
Adjust pH with 10 M NaOH, add DEPC-H2O to 
1000 ml and finally autoclave. 
 
 
 
 
 
Standard saline citrate, SSC, 20 x 
 
3 M NaCl, 0.3 M sodium citrate 
175 g NaCl 
88.2 g Na3citrate⋅2H2O 
800 ml DEPC-dH2O 
Adjust pH to 7.0 with 1 M HCl 
dH2O to 1000 ml, autoclave. 
 
TAE-buffer, 50 x 
 
40 mM Tris-acetate, 1 mM EDTA 
242 g Tris (hydroxymethyl aminomethane) base 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA pH 8.0 
dH2O to 1000 ml 
Mix water, Tris and acetic acid in a safety hood. 
Finally add EDTA to adjust pH, then autoclave. 
 
TBE-buffer, 10 x 
 
45 mM Tris-borate, 1 mM EDTA 
108 g Tris (hydroxymethyl aminomethane) base 
55 g boric acid 
40 ml 0.5 M EDTA pH 8.0 
Add EDTA as final ingredient to adjust pH, 
autoclave. 
 
TE-buffer 1x 
 
10 mM 1 M Tris-HCl pH 8.0, 1 mM EDTA 
10 ml 1 M Tris-HCl pH 8.0 
2 ml 0.5 M EDTA 
dH2O to 1000 ml, autoclave. 
 
Tris-buffered saline, TBS for western blotting 
 
10 mM Tris-Cl, pH 7.5 
150 mM NaCl 
 
Western running buffer 1 x 
 
3,02 g Tris (hydroxymethyl aminomethane) base 
14,4 g glycine 
5 ml 20% SDS 
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Appendix E: Plasmid maps 
 
 
        pcDNA5/FRT/TO          pcDNA5/FRT 
                                                 
 
 
 
   
                   pOG44              pcDNA3.1/myc-His A,B,C 
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pFastBacHT A     pFRT/lacZeo 
  
 
 
 
 
pEGFP-N1 
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pET-30 Ek/LIC 
 
 
pET-3a 
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                   pCMV-SPORT6           pBluescript KS+ 
 
 
pOTB7 
 
pT7T3D-PacI             
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APPENDIX F: Internet sites 
 
In addition to URLs given here, many links to interesting websites can be found at http://folk.uio.no/leonardm, 
http://test.radium.no/myklebost, http://folk.uio.no/mskarn, and http://research.radium.no/institute 
 
http://www.atcc.org The global bioresource center. 
http://cgap.nci.nih.gov   The cancer genome anatomy project. 
http://www.nih.gov/news/stemcell/scireport Stem Cell info from NIH, USA. 
http://stemcells.nih.gov/infoCenter/stemCellBasics.asp An introduction to stem cells. 
http://www.molmine.com Software solutions for microarray data analysis. 
http://alba.uio.no/base The BASE microarray software environment  
http://www.bioinfo.no The FUGE bioinformatics platform homepage. 
http://www.enzyme-halle.mpg.de Protein folding and PPI-material. 
http://www.biocarta.com Models of eukaryotic signal pathways available online. 
http://us.expasy.org The Expert Protein Analysis System proteomics server.
http://www.rcsb.org/pdb The Protein Data Bank 
http://www.pubcrawler.ie Updates the contents of Medline and GenBank. 
 
 
 
Database accession numbers 
 
 
Database Accession number 
NCBI Nucleotide and protein ID COAS2:  GI:4826471; NP_839944  
L-SOX5: GI:23308714 
SOX6:     GI:13435017 
SOX9:     GI:4557852 
REFSEQ-accession number COAS2:  NM_178230 
L-SOX5: NM_152989 
(ExPaSy) pfam (protein family) COAS2:  160 
LocusLink  COAS2:  164022 
COL2A1:1280 
UniGene COAS2:  Hs.523569 
 
 
 
